{
    "drugSuccessPredictions": [
      {
        "drugId": "27572",
        "displayName": "lenalidomide",
        "drugPrograms": [
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "02-Dec-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Dec-2019",
            "endDate": "30-Dec-2025",
            "statusDate": "02-Dec-2019",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "02-Dec-2019",
                "endDate": "27-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Apr-2024",
                "predictedDateU50": "30-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Aug-2017",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3243",
              "name": "POEMS syndrome"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Aug-2017",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "161",
              "name": "Hodgkins disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2007",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2007",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "185",
              "name": "Immune disorder"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Sep-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "12-Sep-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "311",
              "name": "T-cell lymphoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2017",
            "endDate": "10-Oct-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jul-2017",
                "endDate": "25-Nov-2024",
                "successPercentage": "33%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Nov-2024",
                "endDate": "17-Aug-2027",
                "successPercentage": "39%",
                "predictedDateL50": "14-Feb-2024",
                "predictedDateU50": "29-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2027",
                "endDate": "21-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "22-Jun-2026",
                "predictedDateU50": "22-Jan-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Apr-2028",
                "predictedDateU50": "10-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2013",
            "endDate": "",
            "statusDate": "02-Dec-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2013",
                "endDate": "02-Dec-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Dec-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2006",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2006",
                "endDate": "30-Nov-2013",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2013",
                "endDate": "31-Jan-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jan-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2005",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2005",
                "endDate": "01-Apr-2010",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Apr-2010",
                "endDate": "31-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Mar-2016",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "15-Mar-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1743",
              "name": "Lymphoplasmacytic lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2009",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Mar-2009",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Priority Review",
            "startDate": "02-Dec-2019",
            "endDate": "",
            "statusDate": "02-Dec-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "02-Dec-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Feb-2019",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "26-Feb-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Dec-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Dec-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Dec-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Dec-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Dec-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "NL",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2005",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2005",
                "endDate": "02-Sep-2010",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Sep-2010",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "1754",
              "name": "Cutaneous T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Jan-2018",
            "endDate": "08-Jun-2028",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "24-Jan-2018",
                "endDate": "08-Nov-2024",
                "successPercentage": "20%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Nov-2024",
                "endDate": "20-Jun-2027",
                "successPercentage": "29%",
                "predictedDateL50": "18-Mar-2024",
                "predictedDateU50": "14-Jun-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jun-2027",
                "endDate": "23-Apr-2028",
                "successPercentage": "89%",
                "predictedDateL50": "03-May-2026",
                "predictedDateU50": "10-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jan-2028",
                "predictedDateU50": "08-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Apr-2011",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Apr-2011",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "3243",
              "name": "POEMS syndrome"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2014",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Mar-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "3243",
              "name": "POEMS syndrome"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2012",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jul-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2014",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Jun-2014",
                "endDate": "29-Mar-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "29-Mar-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "4339",
              "name": "Plasma cell dyscrasia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Aug-2017",
            "endDate": "18-Oct-2027",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "02-Aug-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "43%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "08-Sep-2026",
                "successPercentage": "44%",
                "predictedDateL50": "14-Mar-2023",
                "predictedDateU50": "21-Jul-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Sep-2026",
                "endDate": "05-Sep-2027",
                "successPercentage": "94%",
                "predictedDateL50": "13-Jul-2025",
                "predictedDateU50": "21-Feb-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-May-2027",
                "predictedDateU50": "18-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive results of phase II study ( 2016-003105-33; EMN12/HO129) of carfilzomib and lenalidomide in 25 patients were presented. Best response was &gt;/= partial response (PR) in 80%, &gt;/= very good (VG) PR in 68% and &gt;/= complete response (CR) in 36%. The median progression free survival was 13.8 months and overall survival was 24.8 months. In the pre-maintenance best response (n = 25), overall response rate (ORR) was 80%, VGPR was 68%, CR was 32% and minimal residual disease (MRD) was 8%. In the overall best response (n = 25), ORR was 80%, VGPR was 68%, CR was 36% and MRD was 12% [ <ulink linkID=\"2796181\" linkType=\"Reference\">  2796181 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15065",
              "name": "Bristol-Myers Squibb Co"
            },
            "indication": {
              "id": "4682",
              "name": "Histiocytosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2015",
            "endDate": "",
            "statusDate": "20-Nov-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15331",
              "name": "Celgene Corporation"
            },
            "indication": {
              "id": "259",
              "name": "Peripheral neuropathy"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Apr-2021",
            "endDate": "25-Oct-2030",
            "statusDate": "22-Apr-2021",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "6.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "22-Apr-2021",
                "endDate": "09-Jun-2024",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "09-Jun-2024",
                "endDate": "07-Feb-2027",
                "successPercentage": "21%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "05-Oct-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Feb-2027",
                "endDate": "06-Nov-2029",
                "successPercentage": "33%",
                "predictedDateL50": "11-Nov-2025",
                "predictedDateU50": "02-Sep-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Nov-2029",
                "endDate": "12-Sep-2030",
                "successPercentage": "95%",
                "predictedDateL50": "10-Sep-2028",
                "predictedDateU50": "21-Apr-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Sep-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jun-2030",
                "predictedDateU50": "25-Oct-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15331",
              "name": "Celgene Corporation"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2015",
            "endDate": "",
            "statusDate": "30-Jun-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "35991",
        "displayName": "plinabulin",
        "drugPrograms": [
          {
            "company": {
              "id": "1076232",
              "name": "Dalian Wanchunbulin Pharmaceuticals Ltd"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2016",
            "endDate": "",
            "statusDate": "21-Jul-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Jul-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1076232",
              "name": "Dalian Wanchunbulin Pharmaceuticals Ltd"
            },
            "indication": {
              "id": "3795",
              "name": "Febrile neutropenia"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy, Priority Review",
            "startDate": "25-Oct-2017",
            "endDate": "07-Dec-2025",
            "statusDate": "30-Mar-2020",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Oct-2017",
                "endDate": "30-Mar-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Mar-2020",
                "endDate": "26-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Mar-2024",
                "predictedDateU50": "07-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, data reported from the phase II/III trial (NCT03102606) demonstrated patients treated with plinabulin had less bone pain while being equally protected against severe neutropenia compared to patients treated with pegfilgrastim. Patients maintained median absolute neutrophil counts within normal range, whereas pegfilgrastim caused higher than normal median absolute neutrophil counts [<ulink linkType=\"Reference\" linkID=\"2048443\">2048443</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, the company initiated the rolling submission of NDA, for chemotherapy-induced neutropenia to China's National Medical Products Administration (NMPA) [<ulink linkType=\"Reference\" linkID=\"2260449\">2260449</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "03-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, the NMPA granted Breakthrough Therapy designation to the drug for treatment of febrile neutropenia in China [<ulink linkType=\"Reference\" linkID=\"2315011\">2315011</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "16-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In  November 2020, an implied trial approval was granted for  severe neutropenia in patients with solid tumors receiving myelosuppressive docetaxel monotherapy in China [<ulink linkType=\"Reference\" linkID=\"2352357\">2352357</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "12-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the product was granted for Priority Review in China  <ulink linkID=\"2457482\" linkType=\"Reference\">  [2457482 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2023",
            "endDate": "21-May-2028",
            "statusDate": "01-Mar-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Mar-2023",
                "endDate": "03-Mar-2025",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Mar-2025",
                "endDate": "16-Jul-2027",
                "successPercentage": "48%",
                "predictedDateL50": "16-May-2024",
                "predictedDateU50": "15-Jul-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Jul-2027",
                "endDate": "21-Apr-2028",
                "successPercentage": "92%",
                "predictedDateL50": "07-Jul-2026",
                "predictedDateU50": "03-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Jan-2028",
                "predictedDateU50": "21-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Sep-2018",
            "endDate": "14-Dec-2026",
            "statusDate": "06-Sep-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Sep-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "31-Jan-2026",
                "successPercentage": "31%",
                "predictedDateL50": "16-Apr-2023",
                "predictedDateU50": "13-Apr-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jan-2026",
                "endDate": "14-Nov-2026",
                "successPercentage": "91%",
                "predictedDateL50": "16-Feb-2025",
                "predictedDateU50": "06-Jun-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Nov-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Aug-2026",
                "predictedDateU50": "14-Dec-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "04-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, data from phase I portion of the phase I/II trial (  <ulink linkID=\"345011\" linkType=\"Protocol\">  NCT03575793 </ulink> ) were presented [  <ulink linkID=\"2468354\" linkType=\"Reference\">  2468354  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2022, data from phase II trial (NCT03575793) were expected in the second half of 2022 [ <ulink linkID=\"2590492\" linkType=\"Reference\">  2590492 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Sep-2022",
                "milestoneExtendedDate": "30-Sep-2022",
                "notes": "In September 2018, an investigator-initiated, phase I/II trial in patients with recurrent SCLC was initiated in the US. At that time, the trial was expected to complete in September 2022 [<ulink linkType=\"Reference\" linkID=\"2079916\">2079916</ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "National Science and Technology Major Project",
            "startDate": "28-Jun-2016",
            "endDate": "14-Jan-2025",
            "statusDate": "28-Jun-2016",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Jun-2016",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "05-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "07-Oct-2023",
                "predictedDateU50": "09-Jan-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Aug-2024",
                "predictedDateU50": "14-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "National Science and Technology Major Project",
                "status": "Granted",
                "milestoneDate": "04-Dec-2017",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In April 2019, an NDA filing for the combination of plinabulin with docetaxel for the second or third line treatment of NSCLC (study 103) was expected in 2019 in China [<ulink linkType=\"Reference\" linkID=\"2144818\">2144818</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In April 2019, an NDA filing for the combination of plinabulin with docetaxel for the second or third line treatment of NSCLC (study 103) was expected in fourth quarter of 2019 in China [<ulink linkType=\"Reference\" linkID=\"2146846\">2146846</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In April 2019, data from a second pre-specified interim analysis from 293 patients in phase III trial of NSCLC were expected in the fourth quarter of 2019 [<ulink linkType=\"Reference\" linkID=\"2146846\">2146846</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Mar-2020",
                "notes": "In July 2019, an NDA filing in China for NSCLC and CIN was expected in the  fourth quarter of 2019 or first quarter of 2020 [<ulink linkType=\"Reference\" linkID=\"2172055\">2172055</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, final data readout from a phase III trial (NCT02504489;  DUBLIN-3) was expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2230122\">2230122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, an NDA filing for the combination of plinabulin with docetaxel for the second or third line treatment of NSCLC (study 103) was expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2230122\">2230122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "By September 2020, rolling NDA submission for NSCLC was expected in the first half of 2021 [<ulink linkType=\"Reference\" linkID=\"2314803\">2314803</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In September 2020, topline date from phase III trial (NCT02504489; DUBLIN-3) in patients with NSCLC were expected in the first half of 2021 [<ulink linkType=\"Reference\" linkID=\"2314803\">2314803</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In June 2021, data from phase III trial (NCT02504489; DUBLIN-3) in patients with NSCLC were expected in the mid of 2021 [  <ulink linkID=\"2478618\" linkType=\"Reference\">  2478618  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021, data from phase III trial (NCT02504489; DUBLIN-3) in patients with NSCLC were expected in the second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2420622\">2420622</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "04-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, the positive topline data from a phase III trial (NCT02504489; DUBLIN-3) in advanced non-small cell lung cancer were reported. The study met primary and secondary endpoints [ <ulink linkID=\"2504681\" linkType=\"Reference\">  2504681 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "04-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, the positive topline data from a phase III trial (NCT02504489; DUBLIN-3) in advanced non-small cell lung cancer were reported. The study met primary and secondary endpoints [ <ulink linkID=\"2504681\" linkType=\"Reference\">  2504681 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2021, NDA submission was expected in the second half of 2022 [ <ulink linkID=\"2590492\" linkType=\"Reference\">  2590492 </ulink> ]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In April 2023,  NDA submission to NMPA for plinabulin for the treatment of NSCLC was expected by mid-2023 [ <ulink linkID=\"2899807\" linkType=\"Reference\">  2899807 </ulink>] </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Feb-2009",
            "endDate": "12-Oct-2024",
            "statusDate": "16-Jul-2015",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "88%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Feb-2009",
                "endDate": "16-Jul-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jul-2015",
                "endDate": "10-Dec-2023",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "10-Sep-2024",
                "successPercentage": "94%",
                "predictedDateL50": "13-May-2023",
                "predictedDateU50": "24-Feb-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Jun-2024",
                "predictedDateU50": "12-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Mar-2020",
                "notes": "In July 2019, second interim data from phase III trial (Study 103) were expected in the fourth quarter of 2019 or first quarter of 2020 [<ulink linkType=\"Reference\" linkID=\"2172055\">2172055</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In April 2019, an NDA filing for the combination of plinabulin with docetaxel for the second or third line treatment of NSCLC (study 103) was expected in 2020 in the US [<ulink linkType=\"Reference\" linkID=\"2144818\">2144818</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, final data readout from a phase III trial (NCT02504489;  DUBLIN-3) was expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2230122\">2230122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Aug-2020",
                "milestoneExtendedDate": "31-Jan-2021",
                "notes": "By September 2020, NDA submission for NSCLC was expected in the second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2314803\">2314803</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In April 2019, an NDA filing was expected in 2020 in the US [<ulink linkType=\"Reference\" linkID=\"2146846\">2146846</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In June 2016, an open label single center phase I trial (NCT02812667) was expected to complete in December 2020 [<ulink linkType=\"Reference\" linkID=\"2128984\">2128984</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In September 2020, topline date from phase III trial (NCT02504489; DUBLIN-3) in patients with NSCLC were expected in the first half of 2021 [<ulink linkType=\"Reference\" linkID=\"2314803\">2314803</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In December 2019, an NDA filing for the combination of plinabulin with docetaxel for the second or third line treatment of NSCLC was expected in the first half of 2020 [<ulink linkType=\"Reference\" linkID=\"2230122\">2230122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In June 2021, data from phase III trial (NCT02504489; DUBLIN-3) in patients with NSCLC were expected in the mid of 2021 [  <ulink linkID=\"2478618\" linkType=\"Reference\">  2478618  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In March 2021, data from phase III trial (NCT02504489; DUBLIN-3) in patients with NSCLC were expected in the second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2420622\">2420622</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "04-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, the positive topline data from a phase III trial (NCT02504489; DUBLIN-3) in advanced non-small cell lung cancer were reported. The study met primary and secondary endpoints [ <ulink linkID=\"2504681\" linkType=\"Reference\">  2504681 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "04-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, the positive topline data from a phase III trial (NCT02504489; DUBLIN-3) in advanced non-small cell lung cancer were reported. The study met primary and secondary endpoints [ <ulink linkID=\"2504681\" linkType=\"Reference\">  2504681 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "in August 2021, the NDA filing for the treatment of Advanced non-small cell lung cancer was expected in the first half of 2022 [ <ulink linkID=\"2504681\" linkType=\"Reference\">  2504681 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2021, NDA submission was expected in the second half of 2022 [ <ulink linkID=\"2590492\" linkType=\"Reference\">  2590492 </ulink> ]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Feb-2008",
            "endDate": "17-Oct-2027",
            "statusDate": "01-Mar-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "8%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Feb-2008",
                "endDate": "16-Nov-2024",
                "successPercentage": "22%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "16.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Nov-2024",
                "endDate": "09-Dec-2026",
                "successPercentage": "39%",
                "predictedDateL50": "12-Mar-2024",
                "predictedDateU50": "14-May-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Dec-2026",
                "endDate": "17-Sep-2027",
                "successPercentage": "89%",
                "predictedDateL50": "16-Jan-2026",
                "predictedDateU50": "13-Apr-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Jun-2027",
                "predictedDateU50": "17-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3795",
              "name": "Febrile neutropenia"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "25-Oct-2017",
            "endDate": "07-Dec-2025",
            "statusDate": "30-Mar-2020",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Oct-2017",
                "endDate": "30-Mar-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Mar-2020",
                "endDate": "17-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Mar-2024",
                "predictedDateU50": "07-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Jan-2018",
                "milestoneExtendedDate": "",
                "notes": "In January 2018, data from the phase II/III trial (NCT03102606) for the prevention of febrile neutropenia induced by docetaxel for solid tumors were presented. Data demonstrated that grade 4 neutropenia incidence and duration of severe neutropenia was the same for 20 mg/m2 as for Neulasta [<ulink linkType=\"Reference\" linkID=\"2000342\">2000342</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-May-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, interim data from the phase II/III trial (NCT03102606) in patients with neutropenia were presented. In docetaxel + pegfilgrastim and docetaxel + plinabulin (20 mg/mm2) arms mean DSN was 0.51 and 0.54 days, respectively. Compared to pegfilgrastim, patients who had no bone pain in baseline showed less bone pain under plinabulin treatment [<ulink linkType=\"Reference\" linkID=\"2039653\">2039653</ulink>], [<ulink linkType=\"Reference\" linkID=\"2035468\">2035468</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, data reported from the phase II/III trial (NCT03102606) demonstrated patients treated with plinabulin had less bone pain while being equally protected against severe neutropenia compared to patients treated with pegfilgrastim. Patients maintained median absolute neutrophil counts within normal range, whereas pegfilgrastim caused higher than normal median absolute neutrophil counts [<ulink linkType=\"Reference\" linkID=\"2048443\">2048443</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Sep-2018",
                "milestoneExtendedDate": "",
                "notes": "In September 2018, further data from the phase III trial (NCT03102606) were presented at the 19th IASLC World Conference on Lung Cancer in Toronto, Canada. Frequency of grade 4 neutropenia (14% for plinabulin or pegfilgrastim) and duration of grade 4/severe neutropenia (0.5 days for plinabulin or pegfilgrastim) were similar for plinabulin and pegfilgrastim, at highest dose of plinabulin (20 mg/m2); however, grade 4 thrombocytopenia frequency was 50 and 36% with pegfilgrastim and plinabulin, respectively [<ulink linkType=\"Reference\" linkID=\"2075961\">2075961</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Oct-2018",
                "milestoneExtendedDate": "",
                "notes": "Later that month, further data from the phase III (NCT03102606) were presented at 2018 ESMO Congress in Munich, Germany. Mean ANC remained in normal with plinabulin whereas overshoots upper limit of normal with pegfilgrastim. Bone pain was less with plinabulin compared with pegfilgrastim. Lymphocyte count increased with both plinabulin (p < 0.002) and pegfilgrastim (p < 0.003). Neutrophil to lymphocyte ratio (NLR) was significantly increased to > 5 with pegfilgrastim while plinabulin kept postdose NLR < 5  [<ulink linkType=\"Reference\" linkID=\"2086326\">2086326</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "28-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, phase II results from breast cancer patients with chemotherapy-induced neutropenia were presented [<ulink linkType=\"Reference\" linkID=\"2199229\">2199229</ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In April 2019, an NDA filing for the combination of plinabulin with docetaxel for Chemotherapy-Induced Neutropenia was expected in fourth quarter of 2019 in China [<ulink linkType=\"Reference\" linkID=\"2146846\">2146846</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Mar-2020",
                "notes": "In September 2019, phase II/III study (NCT03102606) final data readout for CIN was expected in first quarter of 2020 [<ulink linkType=\"Reference\" linkID=\"2195078\">2195078</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Mar-2020",
                "notes": "In July 2019, an NDA filing in China for NSCLC and CIN was expected in the  fourth quarter of 2019 or first quarter of 2020 [<ulink linkType=\"Reference\" linkID=\"2172055\">2172055</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "30-Jun-2020",
                "notes": "In December 2019, final data readout from a phase III trial (NCT03102606; study-105) was expected in the first half of 2020 [<ulink linkType=\"Reference\" linkID=\"2230122\">2230122</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, the company initiated the rolling submission of NDA, for chemotherapy-induced neutropenia to China's National Medical Products Administration (NMPA) [<ulink linkType=\"Reference\" linkID=\"2260449\">2260449</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, a phase II/III trial (NCT03294577) in patients treated with TAC was expected to complete in April 2020 [<ulink linkType=\"Reference\" linkID=\"1974984\">1974984</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In June 2020, final data readout from a phase II trial (NCT04345900; PROTECTIVE-1) were expected in the second half of 2020 [<ulink linkType=\"Reference\" linkID=\"2289080\">2289080</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "03-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, the NMPA granted Breakthrough Therapy designation to the drug for treatment of febrile neutropenia in China [<ulink linkType=\"Reference\" linkID=\"2315011\">2315011</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In September 2020, final data from phase II/III (NCT03294577; Protective 2) in patients with CIN were expected in the fourth quarter of 2020 [<ulink linkType=\"Reference\" linkID=\"2314803\">2314803</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, positive top-line data were reported from phase III study (NCT03294577) [2361527].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, positive top-line data were reported from phase III study (NCT03294577) [2361527].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, final data of a phase III study (NCT03294577) in breast cancer patients with chemo-induced neutropenia were presented [ <ulink linkID=\"2469544\" linkType=\"Reference\">  2469544 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "10-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, final positive data were reported. Plinabulin demonstrated non-inferiority of single agent, margin of 0.65-day criterion versus pegfilgrastim as primary endpoint was met [ <ulink linkID=\"2473972\" linkType=\"Reference\">  2473972 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "10-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, final positive data were reported. Plinabulin demonstrated non-inferiority of single agent, margin of 0.65-day criterion versus pegfilgrastim as primary endpoint was met [ <ulink linkID=\"2473972\" linkType=\"Reference\">  2473972 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In April 2023, refiling of NDA submission to NMPA for plinabulin for the treatment of Chemotherapy-Induced Neutropenia was expected by mid-2023 [ <ulink linkID=\"2899807\" linkType=\"Reference\">  2899807 </ulink>] </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3795",
              "name": "Febrile neutropenia"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Mar-2017",
            "endDate": "",
            "statusDate": "17-Mar-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Mar-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1092086",
              "name": "BeyondSpring Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3795",
              "name": "Febrile neutropenia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy, Priority Review",
            "startDate": "17-Mar-2017",
            "endDate": "",
            "statusDate": "31-Mar-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Mar-2017",
                "endDate": "31-Mar-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Mar-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "77347",
        "displayName": "tislelizumab",
        "drugPrograms": [
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "161",
              "name": "Hodgkins disease"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Apr-2017",
            "endDate": "06-Nov-2028",
            "statusDate": "21-Apr-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "43%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Apr-2017",
                "endDate": "03-Jul-2025",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Jul-2025",
                "endDate": "02-Dec-2027",
                "successPercentage": "58%",
                "predictedDateL50": "07-Apr-2024",
                "predictedDateU50": "20-Mar-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Dec-2027",
                "endDate": "30-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "16-Nov-2026",
                "predictedDateU50": "20-Apr-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Jun-2028",
                "predictedDateU50": "06-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "17-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, a pivotal, phase II trial that assessed the efficacy and safety of tislelizumab in patients with relapsed or refractory classical Hodgkin lymphoma was completed [<ulink linkType=\"Reference\" linkID=\"1951121\">1951121</ulink>], [<ulink linkType=\"Reference\" linkID=\"2165061\">2165061</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "161",
              "name": "Hodgkins disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Aug-2020",
            "endDate": "26-Jul-2028",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "46%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Aug-2020",
                "endDate": "22-Oct-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Oct-2024",
                "endDate": "22-Aug-2027",
                "successPercentage": "53%",
                "predictedDateL50": "17-Feb-2024",
                "predictedDateU50": "20-Apr-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Aug-2027",
                "endDate": "19-Jun-2028",
                "successPercentage": "95%",
                "predictedDateL50": "15-Jun-2026",
                "predictedDateU50": "07-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Mar-2028",
                "predictedDateU50": "26-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "161",
              "name": "Hodgkins disease"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Mar-2018",
            "endDate": "30-Oct-2028",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "49%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Mar-2018",
                "endDate": "22-Oct-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Oct-2024",
                "endDate": "25-Aug-2027",
                "successPercentage": "56%",
                "predictedDateL50": "17-Feb-2024",
                "predictedDateU50": "20-Apr-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Aug-2027",
                "endDate": "10-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "18-Jun-2026",
                "predictedDateU50": "21-Mar-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-May-2028",
                "predictedDateU50": "30-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "04-Aug-2022",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "05-Jul-2026",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "73%",
            "timeToRegistration": "2.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "26-Jan-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "26-Jan-2018",
                "endDate": "23-Aug-2025",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Aug-2025",
                "endDate": "05-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "29-Mar-2024",
                "predictedDateU50": "10-Apr-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jun-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Feb-2026",
                "predictedDateU50": "05-Jul-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In February 2023, the company planned filings for first-line SCLC treatment in the US and EU in 2024 [ <ulink linkID=\"2816312\" linkType=\"Reference\"> 2816312 </ulink>], [ <ulink linkID=\"2816314\" linkType=\"Reference\"> 2816314 </ulink>], [ <ulink linkID=\"2816315\" linkType=\"Reference\"> 2816315 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "24-Dec-2027",
            "statusDate": "02-Mar-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "15-Feb-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "15-Feb-2021",
                "endDate": "03-Sep-2024",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Sep-2024",
                "endDate": "09-Jan-2027",
                "successPercentage": "39%",
                "predictedDateL50": "03-Feb-2024",
                "predictedDateU50": "27-Jan-2025",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jan-2027",
                "endDate": "09-Nov-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-Jan-2026",
                "predictedDateU50": "05-Jun-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Nov-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Aug-2027",
                "predictedDateU50": "24-Dec-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, a phase II trial (NCT04693234) for previously treated recurrent or metastatic cervical cancer was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2390226\">2390226</ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "999",
              "name": "Renal tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Feb-2023",
            "endDate": "04-Aug-2029",
            "statusDate": "20-Feb-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "5.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Feb-2023",
                "endDate": "31-Dec-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2025",
                "endDate": "07-May-2028",
                "successPercentage": "92%",
                "predictedDateL50": "05-Apr-2025",
                "predictedDateU50": "03-May-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-May-2028",
                "endDate": "07-Jun-2029",
                "successPercentage": "93%",
                "predictedDateL50": "04-May-2027",
                "predictedDateU50": "28-Sep-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jun-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jan-2029",
                "predictedDateU50": "04-Aug-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a phase II study (ChiCTR2300068589) in patients with bladder cancer, ureteral cancer and renal pelvic cancer was expected to complete in December 2025 [ <ulink linkID=\"2837627\" linkType=\"Reference\"> 2837627 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1055",
              "name": "Rectal tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2021",
            "endDate": "07-Aug-2027",
            "statusDate": "01-Jun-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "83%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "14-May-2026",
                "successPercentage": "92%",
                "predictedDateL50": "07-Aug-2023",
                "predictedDateU50": "13-Mar-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-May-2026",
                "endDate": "12-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "24-Apr-2025",
                "predictedDateU50": "30-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Feb-2027",
                "predictedDateU50": "07-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, interim data of phase II trial (NCT04911517) in 20 patients with locally advanced rectal cancer (LARC) were presented. Of 12 patients, the pathological complete response rate (pCR) was 58.3% and the objective response rate was 100%. Of patients without pCR (n = 5), three and two reached grade 1 and grade 2 tumor regression, respectively, according to AJCC standard [ <ulink linkID=\"2692025\" linkType=\"Reference\">  2692025 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Aug-2017",
            "endDate": "28-Sep-2024",
            "statusDate": "18-Oct-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "24-Aug-2017",
                "endDate": "22-Jul-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Jul-2019",
                "endDate": "18-Oct-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Oct-2023",
                "endDate": "17-Aug-2024",
                "successPercentage": "90%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Aug-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-May-2024",
                "predictedDateU50": "28-Sep-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2020",
                "milestoneExtendedDate": "31-Jul-2020",
                "notes": "In November 2019, a phase II trial (NCT03432598) with small cell lung cancer was expected to complete in July 2020 [<ulink linkType=\"Reference\" linkID=\"2043376\">2043376</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "12-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, a supplementary IND application was filed in China [<ulink linkType=\"Reference\" linkID=\"2312514\">2312514</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "15-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, an implied clinical trial approval of the drug was obtained for the drug combined with platinum and etoposide for extensive stage small cell lung cancer in China [<ulink linkType=\"Reference\" linkID=\"2338503\">2338503</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "22-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an IND was filed in China [<ulink linkType=\"Reference\" linkID=\"2400536\">2400536</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "26-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an IND was filed in China [<ulink linkType=\"Reference\" linkID=\"2400536\">2400536</ulink>]. In April 2021, an implied trial approval was granted for small cell lung cancer [<ulink linkType=\"Reference\" linkID=\"2429576\">2429576</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, a phase II study ( <ulink linkID=\"562993\" linkType=\"Protocol\">  NCT05228496 </ulink>; BGB-900-2003-IIT) was planned to begin in March 2022 in China  [ <ulink linkID=\"2615596\" linkType=\"Reference\">  2615596 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In July 2019, a phase III trial for small cell lung cancer was expected to complete in June 2022 [<ulink linkType=\"Reference\" linkID=\"2181806\">2181806</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "08-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, an implied trial approval for tislelizumab was granted for NSCLC combined with ociperlimab in China [ <ulink linkID=\"2698012\" linkType=\"Reference\">  2698012 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, final analysis data from a pivotal phase III trial (NCT04005716) of tislelizumab for the first-line treatment of previously untreated extensive-stage small cell lung cancer were expected later that year [ <ulink linkID=\"2836253\" linkType=\"Reference\"> 2836253 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, an sBLA submission was planned in China for first-line treatment of extensive stage SCLC in 2H23 [ <ulink linkID=\"2811366\" linkType=\"Reference\"> 2811366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, primary endpoint (overall survival (OS)) of a phase III RATIONALE-312 study (NCT04005716) of tislelizumab + chemotherapy in 457 patients with extensive-stage small-cell lung was met. Statistically significant benefit in OS was observed with tislelizumab (200 mg) + chemotherapy versus placebo + chemotherapy (median of 15.5 versus 13.5 months; stratified HR = 0.75; p = 0.0035) [ <ulink linkID=\"3203424\" linkType=\"Reference\"> 3203424 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, positive results of a phase III RATIONALE-312 study (NCT04005716) of tislelizumab (200 mg) in 457 patients with extensive-stage small-cell lung cancer were presented. Statistically significant benefit in overall survival was observed with tislelizumab (200 mg) + chemotherapy versus placebo + chemotherapy (median of 15.5 versus 13.5 months; stratified HR = 0.75; p = 0.0035). Significant improvement in progression-free survival with tislelizumab + chemotherapy versus placebo + chemotherapy (median of 4.8 versus 4.3 months; stratified HR = 0.63; p ˂ 0.0001) was observed [ <ulink linkID=\"3203424\" linkType=\"Reference\"> 3203424 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "18-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a sBLA was filed in China for tislelizumab combined etoposide and platinum chemotherapy for first-line extensive-stage SCLC [ <ulink linkID=\"3477065\" linkType=\"Reference\"> 3477065 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Jun-2021",
            "endDate": "01-Apr-2026",
            "statusDate": "10-Sep-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "2.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Jun-2021",
                "endDate": "19-Dec-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Dec-2024",
                "endDate": "29-Jan-2026",
                "successPercentage": "95%",
                "predictedDateL50": "19-Aug-2024",
                "predictedDateU50": "02-Apr-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Jan-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Sep-2025",
                "predictedDateU50": "01-Apr-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "01-Aug-2022",
                "notes": "In July 2022, phase II trial(ChiCTR2200062038 ), for the treatment of non small cell lung cancer was expected to start in August 2022[ <ulink linkID=\"2712251\" linkType=\"Reference\">  2712251 </ulink> ]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2024",
                "milestoneExtendedDate": "01-Aug-2024",
                "notes": "In July 2022, phase II trial(ChiCTR2200062038 ), for the treatment of non small cell lung cancer was expected to complete in August 2024 [ <ulink linkID=\"2712251\" linkType=\"Reference\">  2712251 </ulink> ]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Mar-2023",
            "endDate": "19-Nov-2028",
            "statusDate": "07-Mar-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "4.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Mar-2023",
                "endDate": "22-Mar-2025",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Mar-2025",
                "endDate": "20-Oct-2027",
                "successPercentage": "33%",
                "predictedDateL50": "22-May-2024",
                "predictedDateU50": "16-Aug-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Oct-2027",
                "endDate": "10-Oct-2028",
                "successPercentage": "95%",
                "predictedDateL50": "08-Sep-2026",
                "predictedDateU50": "10-Mar-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Oct-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jun-2028",
                "predictedDateU50": "19-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Nov-2020",
            "endDate": "07-Jun-2027",
            "statusDate": "01-Nov-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "50%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Nov-2020",
                "endDate": "10-Jun-2024",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Jun-2024",
                "endDate": "29-Jul-2026",
                "successPercentage": "67%",
                "predictedDateL50": "07-Jan-2024",
                "predictedDateU50": "08-Oct-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jul-2026",
                "endDate": "08-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Aug-2025",
                "predictedDateU50": "02-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jan-2027",
                "predictedDateU50": "07-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, a phase II trial (NCT04727996)  for biliary tract cancer was expected to complete in October 2022 [<ulink linkType=\"Reference\" linkID=\"2399728\">2399728</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "14-Jan-2028",
            "statusDate": "25-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "46%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "25-Aug-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "25-Aug-2021",
                "endDate": "11-Jul-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Jul-2024",
                "endDate": "22-Feb-2027",
                "successPercentage": "58%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Feb-2027",
                "endDate": "14-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-Jan-2026",
                "predictedDateU50": "19-Jul-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Aug-2027",
                "predictedDateU50": "14-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2016",
            "endDate": "01-Mar-2028",
            "statusDate": "17-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "80%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "29-Jun-2016",
                "endDate": "17-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "17-Dec-2021",
                "endDate": "03-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Aug-2024",
                "endDate": "24-Nov-2026",
                "successPercentage": "91%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "08-Nov-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Nov-2026",
                "endDate": "30-Dec-2027",
                "successPercentage": "92%",
                "predictedDateL50": "27-Nov-2025",
                "predictedDateU50": "09-Apr-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Aug-2027",
                "predictedDateU50": "01-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2018",
            "endDate": "17-Sep-2027",
            "statusDate": "14-Jan-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "26-May-2026",
                "successPercentage": "68%",
                "predictedDateL50": "22-Mar-2023",
                "predictedDateU50": "15-Jul-2024",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-May-2026",
                "endDate": "13-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "30-Apr-2025",
                "predictedDateU50": "13-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Mar-2027",
                "predictedDateU50": "17-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, interim results from phase II trial (NCT03493451) in patients with peripheral T-cell lymphomas were presented [<ulink linkType=\"Reference\" linkID=\"2288751\">2288751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) of a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms was met. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms were presented. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2018",
            "endDate": "20-May-2028",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "51%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2018",
                "endDate": "24-Nov-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Nov-2024",
                "endDate": "01-Jul-2027",
                "successPercentage": "64%",
                "predictedDateL50": "06-Mar-2024",
                "predictedDateU50": "30-Jun-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jul-2027",
                "endDate": "19-Apr-2028",
                "successPercentage": "95%",
                "predictedDateL50": "21-May-2026",
                "predictedDateU50": "16-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jan-2028",
                "predictedDateU50": "20-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Mar-2018",
            "endDate": "28-Sep-2027",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "63%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Mar-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "12-Aug-2026",
                "successPercentage": "70%",
                "predictedDateL50": "22-Mar-2023",
                "predictedDateU50": "15-Jul-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Aug-2026",
                "endDate": "11-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jun-2025",
                "predictedDateU50": "12-Jan-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Apr-2027",
                "predictedDateU50": "28-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, interim results from phase II trial (NCT03493451) in patients with peripheral T-cell lymphomas were presented [<ulink linkType=\"Reference\" linkID=\"2288751\">2288751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) of a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms was met. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms were presented. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1755",
              "name": "Anaplastic large cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2018",
            "endDate": "20-Sep-2027",
            "statusDate": "14-Jan-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "55%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "06-Jun-2026",
                "successPercentage": "61%",
                "predictedDateL50": "21-Mar-2023",
                "predictedDateU50": "16-Jul-2024",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jun-2026",
                "endDate": "19-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "05-May-2025",
                "predictedDateU50": "22-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Mar-2027",
                "predictedDateU50": "20-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, interim results from phase II trial (NCT03493451) in patients with anaplastic large cell lymphoma were presented [<ulink linkType=\"Reference\" linkID=\"2288751\">2288751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) of a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms was met. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms were presented. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1755",
              "name": "Anaplastic large cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2018",
            "endDate": "12-Jun-2028",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "45%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2018",
                "endDate": "04-Dec-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Dec-2024",
                "endDate": "27-Jul-2027",
                "successPercentage": "57%",
                "predictedDateL50": "15-Mar-2024",
                "predictedDateU50": "11-Jul-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Jul-2027",
                "endDate": "13-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "10-Jun-2026",
                "predictedDateU50": "21-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jan-2028",
                "predictedDateU50": "12-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1755",
              "name": "Anaplastic large cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Mar-2018",
            "endDate": "20-Sep-2027",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "54%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Mar-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "07-Aug-2026",
                "successPercentage": "60%",
                "predictedDateL50": "21-Mar-2023",
                "predictedDateU50": "16-Jul-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Aug-2026",
                "endDate": "05-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Jun-2025",
                "predictedDateU50": "01-Jan-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Apr-2027",
                "predictedDateU50": "20-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, interim results from phase II trial (NCT03493451) in patients with anaplastic large cell lymphoma were presented [<ulink linkType=\"Reference\" linkID=\"2288751\">2288751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms were presented. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) of a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms was met. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1758",
              "name": "Angioimmunoblastic T-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2018",
            "endDate": "27-Sep-2027",
            "statusDate": "14-Jan-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "15-Jun-2026",
                "successPercentage": "62%",
                "predictedDateL50": "21-Mar-2023",
                "predictedDateU50": "16-Jul-2024",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jun-2026",
                "endDate": "28-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-May-2025",
                "predictedDateU50": "29-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Mar-2027",
                "predictedDateU50": "27-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, interim results from phase II trial (NCT03493451) in patients with angioimmunoblastic T-cell lymphoma were presented [<ulink linkType=\"Reference\" linkID=\"2288751\">2288751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms were presented. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) of a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms was met. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1758",
              "name": "Angioimmunoblastic T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2018",
            "endDate": "18-Jun-2028",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "46%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2018",
                "endDate": "04-Dec-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Dec-2024",
                "endDate": "03-Aug-2027",
                "successPercentage": "58%",
                "predictedDateL50": "15-Mar-2024",
                "predictedDateU50": "11-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Aug-2027",
                "endDate": "19-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "15-Jun-2026",
                "predictedDateU50": "29-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Feb-2028",
                "predictedDateU50": "18-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1758",
              "name": "Angioimmunoblastic T-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Mar-2018",
            "endDate": "24-Sep-2027",
            "statusDate": "19-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "55%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Mar-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "12-Aug-2026",
                "successPercentage": "61%",
                "predictedDateL50": "21-Mar-2023",
                "predictedDateU50": "16-Jul-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Aug-2026",
                "endDate": "10-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jun-2025",
                "predictedDateU50": "12-Jan-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Apr-2027",
                "predictedDateU50": "24-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, interim results from phase II trial (NCT03493451) in patients with angioimmunoblastic T-cell lymphoma were presented [<ulink linkType=\"Reference\" linkID=\"2288751\">2288751</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive topline data from a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms were presented. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) of a phase II trial (NCT03493451) of tislelizumab in patients (n = 77) with relapsed/refractory mature T/NK-cell neoplasms was met. In cohorts 1, 2, and 3 (n = 22, 44, and 11, respectively), ORR was 31.8, 20.5, and 45.5%; CR rate was 18.2, 9.1, and 9.1%; median TTR was 5.75, 2.86, and 6.33 months; median DOR was not reached, 8.2, and 11.3 months; median PFS was 2.7, 2.7, and 16.8 months; median OS was 8.8, 13.3 months, and not reached, respectively. In cohorts 1, 2, and 3, proportion of patients with &gt;/=1 TEAE was 100.0, 93.2, and 90.9%; grade &gt;/= 3 TEAE was 59.1, 56.8, and 72.7%; &gt;/= 1 treatment-related TEAE was 77.3, 75.0, and 63.6%; grade &gt;/= 3 treatment-related TEAE was 31.8, 22.7, and 0.0%; immune-mediated TEAE was 27.3, 29.5, and 27.3%; grade &gt;/= 3 immune-mediated TEAE was 9.1, 4.5, and 0.0%, respectively [ <ulink linkID=\"2692210\" linkType=\"Reference\">  2692210 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Dec-2017",
            "endDate": "17-Nov-2024",
            "statusDate": "28-Dec-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Dec-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "09-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "13-Dec-2022",
                "predictedDateU50": "18-Jun-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jun-2024",
                "predictedDateU50": "17-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2022",
                "milestoneExtendedDate": "31-May-2022",
                "notes": "In December 2018, the phase III trial (NCT03412773) assessing the drug versus sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma was expected to complete in May 2022 [<ulink linkType=\"Reference\" linkID=\"2157000\">2157000</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "04-Aug-2022",
                "notes": "By August 2022, topline data from the phase III trial (NCT03412773) in HCC were expected in 3Q22 [ <ulink linkID=\"2714388\" linkType=\"Reference\"> 2714388 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, positive clinical data from phase III trial (NCT03412773) in HCC demonstrating median life expectancy of one year along with good safety profile were reported [ <ulink linkID=\"2716071\" linkType=\"Reference\"> 2716071 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "09-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, endpoints from phase III trial (NCT03412773) in HCC were met [ <ulink linkID=\"2716071\" linkType=\"Reference\"> 2716071 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, primary endpoints (OS, safety) of a phase III study (RATIONALE-301) in in patients with unresectable hepatocellular carcinoma were met. In tislelizumab versus sorafenib groups, median overall survival was 15.9 versus 14.1 months with stratified hazard ratio (sHR) was 0.85 (p = 0.0398). In tislelizumab versus sorafenib groups, the incidence of any treatment emergent adverse events (TEAEs) were 96.2 versus 100%; TEAE at &gt;/= grade 3 was 48.2 versus 65.4%; serious TEAE was 29.9 versus 28.1%; immune-mediated AEs were 17.2 versus 3.1%, immune-mediated AEs with systemic corticosteroids was 12.7 versus 3.1%; hepatitis was 5.3 versus 0.3%; hypothyroidism was 5.3 versus 0% [ <ulink linkID=\"2748359\" linkType=\"Reference\"> 2748359 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, final data from a phase III study (RATIONALE-301) in in patients with unresectable hepatocellular carcinoma were presented. In tislelizumab versus sorafenib groups, median overall survival was 15.9 versus 14.1 months with stratified hazard ratio (sHR) was 0.85 (p = 0.0398). In tislelizumab versus sorafenib groups, the incidence of any treatment emergent adverse events (TEAEs) were 96.2 versus 100%; TEAE at &gt;/= grade 3 was 48.2 versus 65.4%; serious TEAE was 29.9 versus 28.1%; immune-mediated AEs were 17.2 versus 3.1%, immune-mediated AEs with systemic corticosteroids was 12.7 versus 3.1%; hepatitis was 5.3 versus 0.3%; hypothyroidism was 5.3 versus 0% [ <ulink linkID=\"2748359\" linkType=\"Reference\"> 2748359 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "02-Jun-2015",
            "endDate": "31-Oct-2024",
            "statusDate": "28-Dec-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "28-Dec-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Dec-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "30-Sep-2024",
                "successPercentage": "95%",
                "predictedDateL50": "08-Sep-2022",
                "predictedDateU50": "06-Jun-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Jun-2024",
                "predictedDateU50": "31-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "20-Nov-2019",
                "milestoneExtendedDate": "",
                "notes": "In November 2019, the drug was granted Orphan designation for treatment of hepatocellular carcinoma [<ulink linkType=\"Reference\" linkID=\"2223029\">2223029</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "02-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "By March 2020, the FDA had granted Fast Track designation to the drug for the treatment of hepatocellular carcinoma [<ulink linkType=\"Reference\" linkID=\"2303237\">2303237</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, data from a phase II trial (NCT03419897) in patients with hepatocellular carcinoma who have received at least one systemic therapy were reported, showing that with a median follow-up time of 12.4 months, objective response rate was 13.3%, including three complete responses, disease control rate was 53.0%, median overall survival was 13.2 months and progression-free survival was 2.7 months [ <ulink linkID=\"2480952\" linkType=\"Reference\">  2480952 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2022",
                "milestoneExtendedDate": "31-May-2022",
                "notes": "In December 2018, the phase III trial (NCT03412773) assessing the drug versus sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma was expected to complete in May 2022 [<ulink linkType=\"Reference\" linkID=\"2157000\">2157000</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "04-Aug-2022",
                "notes": "By August 2022, topline data from the phase III trial (NCT03412773) in HCC were expected in 3Q22 [ <ulink linkID=\"2714388\" linkType=\"Reference\"> 2714388 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, positive clinical data from phase III trial (NCT03412773) in HCC demonstrating median life expectancy of one year along with good safety profile were reported [ <ulink linkID=\"2716071\" linkType=\"Reference\"> 2716071 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "09-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, endpoints from phase III trial (NCT03412773) in HCC were met [ <ulink linkID=\"2716071\" linkType=\"Reference\"> 2716071 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, final data from a phase III study (RATIONALE-301) in in patients with unresectable hepatocellular carcinoma were presented. In tislelizumab versus sorafenib groups, median overall survival was 15.9 versus 14.1 months with stratified hazard ratio (sHR) was 0.85 (p = 0.0398). In tislelizumab versus sorafenib groups, the incidence of any treatment emergent adverse events (TEAEs) were 96.2 versus 100%; TEAE at &gt;/= grade 3 was 48.2 versus 65.4%; serious TEAE was 29.9 versus 28.1%; immune-mediated AEs were 17.2 versus 3.1%, immune-mediated AEs with systemic corticosteroids was 12.7 versus 3.1%; hepatitis was 5.3 versus 0.3%; hypothyroidism was 5.3 versus 0% [ <ulink linkID=\"2748359\" linkType=\"Reference\"> 2748359 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, primary endpoints (OS, safety) of a phase III study (RATIONALE-301) in in patients with unresectable hepatocellular carcinoma were met. In tislelizumab versus sorafenib groups, median overall survival was 15.9 versus 14.1 months with stratified hazard ratio (sHR) was 0.85 (p = 0.0398). In tislelizumab versus sorafenib groups, the incidence of any treatment emergent adverse events (TEAEs) were 96.2 versus 100%; TEAE at &gt;/= grade 3 was 48.2 versus 65.4%; serious TEAE was 29.9 versus 28.1%; immune-mediated AEs were 17.2 versus 3.1%, immune-mediated AEs with systemic corticosteroids was 12.7 versus 3.1%; hepatitis was 5.3 versus 0.3%; hypothyroidism was 5.3 versus 0% [ <ulink linkID=\"2748359\" linkType=\"Reference\"> 2748359 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "28-Dec-2017",
            "endDate": "30-Jan-2025",
            "statusDate": "28-Dec-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "28-Dec-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "11-Dec-2024",
                "successPercentage": "94%",
                "predictedDateL50": "08-Sep-2022",
                "predictedDateU50": "06-Jun-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Aug-2024",
                "predictedDateU50": "30-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "19-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, tislelizumab was recommended for Orphan designation for treatment of HCC [<ulink linkType=\"Reference\" linkID=\"2260948\">2260948</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "22-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, the EMA granted Orphan designation to tislelizumab for the treatment of hepatocellular carcinoma [ <ulink linkID=\"2606570\" linkType=\"Reference\">  2606570 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, data from a phase II trial (NCT03419897) in patients with hepatocellular carcinoma who have received at least one systemic therapy were reported, showing that with a median follow-up time of 12.4 months, objective response rate was 13.3%, including three complete responses, disease control rate was 53.0%, median overall survival was 13.2 months and progression-free survival was 2.7 months [ <ulink linkID=\"2480952\" linkType=\"Reference\">  2480952 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2022",
                "milestoneExtendedDate": "31-May-2022",
                "notes": "In December 2018, the phase III trial (NCT03412773) assessing the drug versus sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma was expected to complete in May 2022 [<ulink linkType=\"Reference\" linkID=\"2157000\">2157000</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "04-Aug-2022",
                "notes": "By August 2022, topline data from the phase III trial (NCT03412773) in HCC were expected in 3Q22 [ <ulink linkID=\"2714388\" linkType=\"Reference\"> 2714388 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "09-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, endpoints from phase III trial (NCT03412773) in HCC were met [ <ulink linkID=\"2716071\" linkType=\"Reference\"> 2716071 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, positive clinical data from phase III trial (NCT03412773) in HCC demonstrating median life expectancy of one year along with good safety profile were reported [ <ulink linkID=\"2716071\" linkType=\"Reference\"> 2716071 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, final data from a phase III study (RATIONALE-301) in in patients with unresectable hepatocellular carcinoma were presented. In tislelizumab versus sorafenib groups, median overall survival was 15.9 versus 14.1 months with stratified hazard ratio (sHR) was 0.85 (p = 0.0398). In tislelizumab versus sorafenib groups, the incidence of any treatment emergent adverse events (TEAEs) were 96.2 versus 100%; TEAE at &gt;/= grade 3 was 48.2 versus 65.4%; serious TEAE was 29.9 versus 28.1%; immune-mediated AEs were 17.2 versus 3.1%, immune-mediated AEs with systemic corticosteroids was 12.7 versus 3.1%; hepatitis was 5.3 versus 0.3%; hypothyroidism was 5.3 versus 0% [ <ulink linkID=\"2748359\" linkType=\"Reference\"> 2748359 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "10-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, primary endpoints (OS, safety) of a phase III study (RATIONALE-301) in in patients with unresectable hepatocellular carcinoma were met. In tislelizumab versus sorafenib groups, median overall survival was 15.9 versus 14.1 months with stratified hazard ratio (sHR) was 0.85 (p = 0.0398). In tislelizumab versus sorafenib groups, the incidence of any treatment emergent adverse events (TEAEs) were 96.2 versus 100%; TEAE at &gt;/= grade 3 was 48.2 versus 65.4%; serious TEAE was 29.9 versus 28.1%; immune-mediated AEs were 17.2 versus 3.1%, immune-mediated AEs with systemic corticosteroids was 12.7 versus 3.1%; hepatitis was 5.3 versus 0.3%; hypothyroidism was 5.3 versus 0% [ <ulink linkID=\"2748359\" linkType=\"Reference\"> 2748359 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "09-Jan-2027",
            "statusDate": "27-Feb-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "55%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "16-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "16-Jun-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "22-Feb-2026",
                "successPercentage": "61%",
                "predictedDateL50": "22-Dec-2022",
                "predictedDateU50": "20-Jun-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Feb-2026",
                "endDate": "10-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "04-Mar-2025",
                "predictedDateU50": "08-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Aug-2026",
                "predictedDateU50": "09-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, top-line data from a phase II study in patients with metastatic urothelial bladder cancer were expected later that year [<ulink linkType=\"Reference\" linkID=\"2124059\">2124059</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, an independent review of data from a pivotal phase II trial demonstrated that, with a median follow-up time of 8 months at the data cut-off, the ORR in 104 efficacy-evaluable subjects was 23.1%, including 7.7% confirmed CRs and 15.4% confirmed PRs [<ulink linkType=\"Reference\" linkID=\"2157880\">2157880</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, topline data of a phase II trial were presented [<ulink linkType=\"Reference\" linkID=\"2199333\">2199333</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "30-Sep-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2019, the primary endpoint of phase II trial was met [<ulink linkType=\"Reference\" linkID=\"2199333\">2199333</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In July 2019, a phase II trial (NCT04004221) for locally advanced or metastatic urothelial bladder carcinoma was expected to complete in December 2019 [<ulink linkType=\"Reference\" linkID=\"2170048\">2170048</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Dec-2016",
            "endDate": "13-Aug-2029",
            "statusDate": "20-Feb-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "82%",
            "timeToRegistration": "5.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Dec-2016",
                "endDate": "31-Dec-2025",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2025",
                "endDate": "18-May-2028",
                "successPercentage": "93%",
                "predictedDateL50": "14-Apr-2025",
                "predictedDateU50": "25-Apr-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-May-2028",
                "endDate": "18-Jun-2029",
                "successPercentage": "94%",
                "predictedDateL50": "08-May-2027",
                "predictedDateU50": "06-Oct-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jun-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Feb-2029",
                "predictedDateU50": "13-Aug-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a phase II study (ChiCTR2300068589) in patients with bladder cancer, ureteral cancer and renal pelvic cancer was expected to complete in December 2025 [ <ulink linkID=\"2837627\" linkType=\"Reference\"> 2837627 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Dec-2016",
            "endDate": "04-Feb-2029",
            "statusDate": "07-Nov-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "43%",
            "timeToRegistration": "5.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Dec-2016",
                "endDate": "10-Feb-2025",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Feb-2025",
                "endDate": "26-Oct-2027",
                "successPercentage": "55%",
                "predictedDateL50": "02-Apr-2024",
                "predictedDateU50": "05-Sep-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Oct-2027",
                "endDate": "05-Dec-2028",
                "successPercentage": "95%",
                "predictedDateL50": "05-Sep-2026",
                "predictedDateU50": "03-Apr-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Dec-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jul-2028",
                "predictedDateU50": "04-Feb-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, data from the ongoing phase I NCT03666143 trial in solid tumors were presented, showing preliminary activity of combination with  sitravatinib in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors [<ulink linkType=\"Reference\" linkID=\"2434704\">2434704</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "11-Jan-2028",
            "statusDate": "01-Jun-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "01-Jun-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-Jun-2021",
                "endDate": "07-Jun-2024",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "07-Jun-2024",
                "endDate": "26-Jan-2027",
                "successPercentage": "33%",
                "predictedDateL50": "12-Jan-2024",
                "predictedDateU50": "17-Sep-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jan-2027",
                "endDate": "27-Nov-2027",
                "successPercentage": "91%",
                "predictedDateL50": "09-Dec-2025",
                "predictedDateU50": "22-Jun-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Nov-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Aug-2027",
                "predictedDateU50": "11-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In July 2021, the phase Ib/II trial ( <ulink linkID=\"458330\" linkType=\"Protocol\">  NCT04577963 </ulink>; 2020-013-00US3) assessing  <ulink linkID=\"69914\" linkType=\"Drug\">  fruquintinib  </ulink> in combination with tislelizumab in patients with advanced, refractory triple-negative breast cancer was expected to complete in August 2022 [ <ulink linkID=\"2522258\" linkType=\"Reference\">  2522258 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "11-Jun-2027",
            "statusDate": "19-Apr-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "19-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "19-Apr-2021",
                "endDate": "24-Jun-2024",
                "successPercentage": "79%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Jun-2024",
                "endDate": "20-Jul-2026",
                "successPercentage": "41%",
                "predictedDateL50": "17-Jan-2024",
                "predictedDateU50": "24-Oct-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jul-2026",
                "endDate": "11-May-2027",
                "successPercentage": "91%",
                "predictedDateL50": "28-Aug-2025",
                "predictedDateU50": "23-Nov-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jan-2027",
                "predictedDateU50": "11-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, a BeiGene-sponsored phase II trial (NCT04716634) of tislelizumab in combination with fruquintinib in patients with advanced or metastatic, unresectable gastric cancer, colorectal cancer or non-small cell lung cancer was expected to complete in August 2023 [ <ulink linkID=\"2455841\" linkType=\"Reference\">  2455841 </ulink>], [ <ulink linkID=\"2449409\" linkType=\"Reference\">  2449409 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Dec-2021",
            "endDate": "24-Oct-2029",
            "statusDate": "29-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "5.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Dec-2021",
                "endDate": "16-May-2026",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-May-2026",
                "endDate": "25-Dec-2028",
                "successPercentage": "30%",
                "predictedDateL50": "10-Oct-2025",
                "predictedDateU50": "28-Sep-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Dec-2028",
                "endDate": "22-Sep-2029",
                "successPercentage": "88%",
                "predictedDateL50": "08-Nov-2027",
                "predictedDateU50": "17-May-2029",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Sep-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jun-2029",
                "predictedDateU50": "24-Oct-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2026",
                "milestoneExtendedDate": "31-May-2026",
                "notes": "In December 2021, a phase II trial (NCT05189457) in patients with metastatic/stage IV prostate cancer was expected to complete in May 2026 [ <ulink linkID=\"2599221\" linkType=\"Reference\">  2599221 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2017",
            "endDate": "11-May-2024",
            "statusDate": "19-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "94%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Nov-2017",
                "endDate": "06-Apr-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Apr-2022",
                "endDate": "01-Apr-2024",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "11-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In May 2020, top-line data from a phase III trial (NCT03358875; BGB-A317-303; 2018-000245-39; CTR20171112)  in second-or third-line patients with NSCLC expected in 2020 or early 2021 [<ulink linkType=\"Reference\" linkID=\"2276464\">2276464</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Jan-2021",
                "notes": "In May 2020, top-line data from a phase III trial (NCT03358875; BGB-A317-303; 2018-000245-39; CTR20171112)  in second-or third-line patients with NSCLC expected in 2020 or early 2021 [<ulink linkType=\"Reference\" linkID=\"2276464\">2276464</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "04-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "By August 2022, the UK MHRA validated the regulatory submission of tislelizumab as first line and second line treatment in NSCLC [ <ulink linkID=\"2714388\" linkType=\"Reference\"> 2714388 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "07-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, positive primary endpoint data from a phase III trial (NCT03358875) in previously treated advanced NSCLC patients were presented. In tislelizumab versus docetaxel group, median OS (primary endpoint) was 16.9 versus 11.9 months for the ITT population (n = 535 versus 270; HR = 0.66, p &lt; 0.0001), 19.3 versus 11.5 months for PD-L1 TC &gt;/= 25% population (n = 227 versus 116, stratified HR = 0.53, p &lt; 0.0001), 24.7 versus 7.7 months for NOTCH-1 to 4 mutant population (n = 26 versus 15; HR = 0.22, p = 0.0002), and 15.7 versus 12.9 months for NOTCH-1 to 4 wild-type population (n = 218 versus 101; HR = 0.75, p = 0.0390), respectively. Almost all pre-defined subgroups showed consistent OS benefit [ <ulink linkID=\"2723164\" linkType=\"Reference\">  2723164 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "07-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, final data from a phase III trial (NCT03358875) in previously treated advanced NSCLC patients were presented. In tislelizumab versus docetaxel group, median OS was 16.9 versus 11.9 months for the ITT population (n = 535 versus 270; HR = 0.66, p &lt; 0.0001), 19.3 versus 11.5 months for PD-L1 TC &gt;/= 25% population (n = 227 versus 116, stratified HR = 0.53, p &lt; 0.0001), 24.7 versus 7.7 months for NOTCH-1 to 4 mutant population (n = 26 versus 15; HR = 0.22, p = 0.0002), and 15.7 versus 12.9 months for NOTCH-1 to 4 wild-type population (n = 218 versus 101; HR = 0.75, p = 0.0390), respectively. Almost all pre-defined subgroups showed consistent OS benefit. In tislelizumab versus docetaxel group, investigator-assessed ORR was 22.6 versus 7% (ITT) and 37.4 versus 6.9% (PD-L1 &gt;/= 25% population), and investigator assessed median DOR was 13.5 versus 6 months (ITT) and 11.9 versus 4.2 months (PD-L1 &gt;/= 25% population), respectively [ <ulink linkID=\"2723164\" linkType=\"Reference\">  2723164 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2023, the EMA approval for the drug in combination with chemotherapy for the first- and second-line treatment of metastatic NSCLC was expected in 1H24 [ <ulink linkID=\"3496582\" linkType=\"Reference\"> 3496582 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2023, the EMA approval for the drug in combination with chemotherapy for the first- and second-line treatment of metastatic NSCLC was expected in 1H24 [ <ulink linkID=\"3496582\" linkType=\"Reference\"> 3496582 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "22-May-2027",
            "statusDate": "19-Apr-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "41%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "19-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "19-Apr-2021",
                "endDate": "26-May-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "26-May-2024",
                "endDate": "05-Jul-2026",
                "successPercentage": "49%",
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "21-Aug-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Jul-2026",
                "endDate": "22-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "03-Aug-2025",
                "predictedDateU50": "07-Nov-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jan-2027",
                "predictedDateU50": "22-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, a BeiGene-sponsored phase II trial (NCT04716634) of tislelizumab in combination with fruquintinib in patients with advanced or metastatic, unresectable gastric cancer, colorectal cancer or non-small cell lung cancer was expected to complete in August 2023 [ <ulink linkID=\"2455841\" linkType=\"Reference\">  2455841 </ulink>], [ <ulink linkID=\"2449409\" linkType=\"Reference\">  2449409 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Mar-2023",
            "endDate": "20-Aug-2028",
            "statusDate": "07-Mar-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Mar-2023",
                "endDate": "14-Feb-2025",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Feb-2025",
                "endDate": "16-Jul-2027",
                "successPercentage": "44%",
                "predictedDateL50": "26-Apr-2024",
                "predictedDateU50": "20-Jun-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Jul-2027",
                "endDate": "11-Jul-2028",
                "successPercentage": "94%",
                "predictedDateL50": "26-Jun-2026",
                "predictedDateU50": "06-Dec-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Mar-2028",
                "predictedDateU50": "20-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "23-Oct-2024",
            "statusDate": "06-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "43%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "06-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-Dec-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "46%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "23-Sep-2024",
                "successPercentage": "94%",
                "predictedDateL50": "20-Jul-2023",
                "predictedDateU50": "12-May-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jun-2024",
                "predictedDateU50": "23-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "26-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, a phase III trial in newly diagnosed, stage III locally advanced, unresectable NSCLC (NCT03745222) was expected to complete in October 2023 [<ulink linkType=\"Reference\" linkID=\"2117862\">2117862</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Dec-2019",
            "endDate": "12-Dec-2025",
            "statusDate": "09-Dec-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Dec-2019",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "31-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-May-2024",
                "predictedDateU50": "12-Jun-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jul-2025",
                "predictedDateU50": "12-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, final analysis data from the pivotal phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were expected later that year [ <ulink linkID=\"2836253\" linkType=\"Reference\"> 2836253 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT03777657) of tislelizumab in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression was expected to complete in December 2024 [ <ulink linkID=\"2105178\" linkType=\"Reference\"> 2105178 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "07-Dec-2025",
            "statusDate": "17-Sep-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "17-Sep-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Sep-2017",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "30-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "29-May-2024",
                "predictedDateU50": "22-May-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jul-2025",
                "predictedDateU50": "07-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, positive data were reported for the phase IIa study (NCT04363801; DisTinGuish) of DKN-01 in combination with tislelizumab in 25 patients with advanced gastroesophageal adenocarcinoma which showed that the trial met its co-primary endpoints. In mITT population, DKK-1 high, DKK-1 low and DKK-1 unknown groups, PR was achieved by 68.2, 90, 55.6 and 33.3%, SD was observed in 27.3, 0, 44.4 and 66.7%, and objective response rate was 68.2, 90 and 55.6%, respectively; PD was not presented in any patients. DCR was 96% in mITT population. Median DOR and PFS was not achieved. Incidence rate of any serious AEs was 28%, DKN-01 related was 8%, events leading to DKN-01 discontinuation was 12%, DKN-01 related was 4%, events leading to DKN-01 dose reduction was 4%. The Wilcoxon p value for association of DKK1 expression with response was 0.075. No correlation was observed between DKK1 and PD-L1 expression [ <ulink linkID=\"2531646\" linkType=\"Reference\">  2531646 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, positive interim data from phase IIa study (NCT04363801; DisTinGuish) of DKN-01 in combination with tislelizumab in 25 patients with advanced gastroesophageal adenocarcinoma were presented. In mITT population, DKK-1 high, DKK-1 low and DKK-1 unknown groups, PR was achieved by 68.2, 90, 55.6 and 33.3%, SD was observed in 27.3, 0, 44.4 and 66.7%, and objective response rate was 68.2, 90 and 55.6%, respectively; PD was not presented in any patients. DCR was 96% in mITT population. Median DOR and PFS was not achieved. Incidence rate of any serious AEs was 28%, DKN-01 related was 8%, events leading to DKN-01 discontinuation was 12%, DKN-01 related was 4%, events leading to DKN-01 dose reduction was 4%. The Wilcoxon p value for association of DKK1 expression with response was 0.075. No correlation was observed between DKK1 and PD-L1 expression [ <ulink linkID=\"2531646\" linkType=\"Reference\">  2531646 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, data were reported from an interim analysis of the subset of patients with PD-L1 expression , showing that tislelizumab plus chemotherapy met the primary endpoint of overall survival (OS) in that group; additional follow-up was needed to assess OS in the intention-to-treat (ITT) population [ <ulink linkID=\"2602558\" linkType=\"Reference\">  2602558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In December 2018, a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (NCT03777657; BGB-A317-305) of tislelizumab began in patients (expected n = 720) in the US, China, Europe, South Korea, Puerto Rico and Taiwan with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The co-primary endpoints were PFS and OS. The study was to complete in August 2022 [<ulink linkType=\"Reference\" linkID=\"2104872\">2104872</ulink>], [<ulink linkType=\"Reference\" linkID=\"2105178\">2105178</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, final analysis data from the pivotal phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were expected later that year [ <ulink linkID=\"2836253\" linkType=\"Reference\"> 2836253 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, a BeiGene-sponsored phase II trial (NCT04716634) of tislelizumab in combination with fruquintinib in patients with advanced or metastatic, unresectable gastric cancer, colorectal cancer or non-small cell lung cancer was expected to complete in August 2023 [ <ulink linkID=\"2455841\" linkType=\"Reference\">  2455841 </ulink>], [ <ulink linkID=\"2449409\" linkType=\"Reference\">  2449409 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT03777657) of tislelizumab in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression was expected to complete in December 2024 [ <ulink linkID=\"2105178\" linkType=\"Reference\"> 2105178 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "05-Dec-2025",
            "statusDate": "17-Sep-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "17-Sep-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Sep-2017",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "29-Oct-2025",
                "successPercentage": "94%",
                "predictedDateL50": "03-Mar-2024",
                "predictedDateU50": "28-May-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jul-2025",
                "predictedDateU50": "05-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, positive interim data from phase IIa study (NCT04363801; DisTinGuish) of DKN-01 in combination with tislelizumab in 25 patients with advanced gastroesophageal adenocarcinoma were presented. In mITT population, DKK-1 high, DKK-1 low and DKK-1 unknown groups, PR was achieved by 68.2, 90, 55.6 and 33.3%, SD was observed in 27.3, 0, 44.4 and 66.7%, and objective response rate was 68.2, 90 and 55.6%, respectively; PD was not presented in any patients. DCR was 96% in mITT population. Median DOR and PFS was not achieved. Incidence rate of any serious AEs was 28%, DKN-01 related was 8%, events leading to DKN-01 discontinuation was 12%, DKN-01 related was 4%, events leading to DKN-01 dose reduction was 4%. The Wilcoxon p value for association of DKK1 expression with response was 0.075. No correlation was observed between DKK1 and PD-L1 expression [ <ulink linkID=\"2531646\" linkType=\"Reference\">  2531646 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, positive data were reported for the phase IIa study (NCT04363801; DisTinGuish) of DKN-01 in combination with tislelizumab in 25 patients with advanced gastroesophageal adenocarcinoma which showed that the trial met its co-primary endpoints. In mITT population, DKK-1 high, DKK-1 low and DKK-1 unknown groups, PR was achieved by 68.2, 90, 55.6 and 33.3%, SD was observed in 27.3, 0, 44.4 and 66.7%, and objective response rate was 68.2, 90 and 55.6%, respectively; PD was not presented in any patients. DCR was 96% in mITT population. Median DOR and PFS was not achieved. Incidence rate of any serious AEs was 28%, DKN-01 related was 8%, events leading to DKN-01 discontinuation was 12%, DKN-01 related was 4%, events leading to DKN-01 dose reduction was 4%. The Wilcoxon p value for association of DKK1 expression with response was 0.075. No correlation was observed between DKK1 and PD-L1 expression [ <ulink linkID=\"2531646\" linkType=\"Reference\">  2531646 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, data were reported from an interim analysis of the subset of patients with PD-L1 expression , showing that tislelizumab plus chemotherapy met the primary endpoint of overall survival (OS) in that group; additional follow-up was needed to assess OS in the intention-to-treat (ITT) population [ <ulink linkID=\"2602558\" linkType=\"Reference\">  2602558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In December 2018, a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (NCT03777657; BGB-A317-305) of tislelizumab began in patients (expected n = 720) in the US, China, Europe, South Korea, Puerto Rico and Taiwan with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The co-primary endpoints were PFS and OS. The study was to complete in August 2022 [<ulink linkType=\"Reference\" linkID=\"2104872\">2104872</ulink>], [<ulink linkType=\"Reference\" linkID=\"2105178\">2105178</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, final analysis data from the pivotal phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were expected later that year [ <ulink linkID=\"2836253\" linkType=\"Reference\"> 2836253 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT03777657) of tislelizumab in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression was expected to complete in December 2024 [ <ulink linkID=\"2105178\" linkType=\"Reference\"> 2105178 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Sep-2017",
            "endDate": "10-Mar-2026",
            "statusDate": "17-Sep-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "2.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Sep-2017",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "19-Jan-2026",
                "successPercentage": "94%",
                "predictedDateL50": "03-Mar-2024",
                "predictedDateU50": "28-May-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jan-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Sep-2025",
                "predictedDateU50": "10-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, data were reported from an interim analysis of the subset of patients with PD-L1 expression , showing that tislelizumab plus chemotherapy met the primary endpoint of overall survival (OS) in that group; additional follow-up was needed to assess OS in the intention-to-treat (ITT) population [ <ulink linkID=\"2602558\" linkType=\"Reference\">  2602558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In December 2018, a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (NCT03777657; BGB-A317-305) of tislelizumab began in patients (expected n = 720) in the US, China, Europe, South Korea, Puerto Rico and Taiwan with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The co-primary endpoints were PFS and OS. The study was to complete in August 2022 [<ulink linkType=\"Reference\" linkID=\"2104872\">2104872</ulink>], [<ulink linkType=\"Reference\" linkID=\"2105178\">2105178</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, final analysis data from the pivotal phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were expected later that year [ <ulink linkID=\"2836253\" linkType=\"Reference\"> 2836253 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, positive final analysis data from a phase III trial (NCT03777657) of tislelizumab for first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma revealed that the study met its primary endpoint [ <ulink linkID=\"2903735\" linkType=\"Reference\"> 2903735 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III study (NCT03777657) of tislelizumab in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression was expected to complete in December 2024 [ <ulink linkID=\"2105178\" linkType=\"Reference\"> 2105178 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jan-2018",
            "endDate": "19-Sep-2023",
            "statusDate": "04-Aug-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "23-Jan-2018",
                "endDate": "06-Apr-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Apr-2022",
                "endDate": "19-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Sep-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, positive topline data were reported from the phase III RATIONALE 302 trial in second-line esophageal cancer; tislelizumab demonstrated a  significant and clinically meaningful improvement in OS in the intention-to-treat population,  compared to chemotherapy [<ulink linkType=\"Reference\" linkID=\"2398160\">2398160</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, positive topline data were reported from the phase III RATIONALE 302 trial in second-line esophageal cancer; tislelizumab demonstrated a  significant and clinically meaningful improvement in OS in the intention-to-treat population,  compared to chemotherapy [<ulink linkType=\"Reference\" linkID=\"2398160\">2398160</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, data were reported from an interim analysis of the subset of patients with PD-L1 expression , showing that tislelizumab plus chemotherapy met the primary endpoint of overall survival (OS) in that group; additional follow-up was needed to assess OS in the intention-to-treat (ITT) population [ <ulink linkID=\"2602558\" linkType=\"Reference\">  2602558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "04-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "By August 2022, the UK MHRA validated the regulatory submission of tislelizumab as second line treatment in ESCC [ <ulink linkID=\"2714388\" linkType=\"Reference\"> 2714388 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2023, the drug was expected to grant approval in the EU for the second-line treatment of patients with ESCC in the second half of 2023 [ <ulink linkID=\"2811366\" linkType=\"Reference\"> 2811366 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jan-2018",
            "endDate": "06-Mar-2025",
            "statusDate": "23-Jan-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "23-Jan-2018",
                "endDate": "01-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Apr-2024",
                "endDate": "28-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "23-Feb-2023",
                "predictedDateU50": "16-Nov-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Oct-2024",
                "predictedDateU50": "06-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, positive topline data were reported from the phase III RATIONALE 302 trial in second-line esophageal cancer; tislelizumab demonstrated a  significant and clinically meaningful improvement in OS in the intention-to-treat population,  compared to chemotherapy [<ulink linkType=\"Reference\" linkID=\"2398160\">2398160</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, positive topline data were reported from the phase III RATIONALE 302 trial in second-line esophageal cancer; tislelizumab demonstrated a  significant and clinically meaningful improvement in OS in the intention-to-treat population,  compared to chemotherapy [<ulink linkType=\"Reference\" linkID=\"2398160\">2398160</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In January 2023, a BLA submission was planned in Japan for first- or second-line treatment of ESCC in 2H23 [ <ulink linkID=\"2811366\" linkType=\"Reference\"> 2811366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2023, regulatory submission in Japan for first- and second-line ESCC was expected in 1H24 [ <ulink linkID=\"3496582\" linkType=\"Reference\"> 3496582 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "05-Aug-2024",
            "statusDate": "19-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "23-Jan-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Jan-2018",
                "endDate": "13-Sep-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Sep-2021",
                "endDate": "02-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-May-2024",
                "predictedDateU50": "05-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, positive topline data were reported from the phase III RATIONALE 302 trial in second-line esophageal cancer; tislelizumab demonstrated a  significant and clinically meaningful improvement in OS in the intention-to-treat population,  compared to chemotherapy [<ulink linkType=\"Reference\" linkID=\"2398160\">2398160</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2021, positive topline data were reported from the phase III RATIONALE 302 trial in second-line esophageal cancer; tislelizumab demonstrated a  significant and clinically meaningful improvement in OS in the intention-to-treat population,  compared to chemotherapy [<ulink linkType=\"Reference\" linkID=\"2398160\">2398160</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "13-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, the FDA accepted a BLA filing for tislelizumab in previously treated, advanced or metastatic ESCC, based on data from the RATIONALE 302 trial. At that time,  a PDUFA date was set for July 12, 2022 [ <ulink linkID=\"2526740\" linkType=\"Reference\">  2526740 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, positive data were reported for the phase IIa study (NCT04363801; DisTinGuish) of DKN-01 in combination with tislelizumab in 25 patients with advanced gastroesophageal adenocarcinoma which showed that the trial met its co-primary endpoints. In mITT population, DKK-1 high, DKK-1 low and DKK-1 unknown groups, PR was achieved by 68.2, 90, 55.6 and 33.3%, SD was observed in 27.3, 0, 44.4 and 66.7%, and objective response rate was 68.2, 90 and 55.6%, respectively; PD was not presented in any patients. DCR was 96% in mITT population. Median DOR and PFS was not achieved. Incidence rate of any serious AEs was 28%, DKN-01 related was 8%, events leading to DKN-01 discontinuation was 12%, DKN-01 related was 4%, events leading to DKN-01 dose reduction was 4%. The Wilcoxon p value for association of DKK1 expression with response was 0.075. No correlation was observed between DKK1 and PD-L1 expression [ <ulink linkID=\"2531646\" linkType=\"Reference\">  2531646 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, positive interim data from phase IIa study (NCT04363801; DisTinGuish) of DKN-01 in combination with tislelizumab in 25 patients with advanced gastroesophageal adenocarcinoma were presented. In mITT population, DKK-1 high, DKK-1 low and DKK-1 unknown groups, PR was achieved by 68.2, 90, 55.6 and 33.3%, SD was observed in 27.3, 0, 44.4 and 66.7%, and objective response rate was 68.2, 90 and 55.6%, respectively; PD was not presented in any patients. DCR was 96% in mITT population. Median DOR and PFS was not achieved. Incidence rate of any serious AEs was 28%, DKN-01 related was 8%, events leading to DKN-01 discontinuation was 12%, DKN-01 related was 4%, events leading to DKN-01 dose reduction was 4%. The Wilcoxon p value for association of DKK1 expression with response was 0.075. No correlation was observed between DKK1 and PD-L1 expression [ <ulink linkID=\"2531646\" linkType=\"Reference\">  2531646 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, data were reported from an interim analysis of the subset of patients with PD-L1 expression , showing that tislelizumab plus chemotherapy met the primary endpoint of overall survival (OS) in that group; additional follow-up was needed to assess OS in the intention-to-treat (ITT) population [ <ulink linkID=\"2602558\" linkType=\"Reference\">  2602558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive topline interim data were reported from the RATIONALE-306 trial (NCT03783442) for the first-line treatment of advanced esophageal squamous cell carcinoma, showing that the primary endpoint of improved overall survival was met, with tislelizumabplus chemotherapy significantly improving overall survival versus chemotherapy alone [ <ulink linkID=\"2658374\" linkType=\"Reference\">  2658374 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "12-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, the FDA accepted a BLA filing for tislelizumab in previously treated, advanced or metastatic ESCC, based on data from the RATIONALE 302 trial. At that time,  a PDUFA date was set for July 12, 2022 [ <ulink linkID=\"2526740\" linkType=\"Reference\">  2526740 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Delayed",
                "milestoneDate": "13-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, the FDA had deferred the decision on approval because of COVID-19-related travel restrictions and the inability to complete inspections; at that timer, no new decision date was announced by the FDA [ <ulink linkID=\"2704279\" linkType=\"Reference\">  2704279 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "19-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the BLA for tislelizumab for first-line treatment of patients with unresectable, recurrent, locally advanced, or metastatic ESCC, based on data from RATIONALE 306 study, was accepted for review by the US FDA and was awarded a PDUFA target action date in the 2H24 [ <ulink linkID=\"3202702\" linkType=\"Reference\"> 3202702 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2023, the US approval for the treatment of adult patients with second-line ESCC was expected in 2023 or 1H24 [ <ulink linkID=\"3496582\" linkType=\"Reference\"> 3496582 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In November 2023, the US approval for the treatment of adult patients with second-line ESCC was expected in 2023 or 1H24 [ <ulink linkID=\"3496582\" linkType=\"Reference\"> 3496582 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, the BLA for tislelizumab for first-line treatment of patients with unresectable, recurrent, locally advanced, or metastatic ESCC, based on data from RATIONALE 306 study, was accepted for review by the US FDA and was awarded a PDUFA target action date in the 2H24 [ <ulink linkID=\"3202702\" linkType=\"Reference\"> 3202702 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In November 2023, the BLA for tislelizumab for first-line treatment of patients with unresectable, recurrent, locally advanced, or metastatic ESCC was awarded a PDUFA target action date set as July 2024 [ <ulink linkID=\"3496582\" linkType=\"Reference\"> 3496582 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2023",
            "endDate": "19-Sep-2030",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "44%",
            "timeToRegistration": "6.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Jul-2023",
                "endDate": "16-Jan-2027",
                "successPercentage": "80%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jan-2027",
                "endDate": "02-Jul-2029",
                "successPercentage": "58%",
                "predictedDateL50": "15-Jan-2026",
                "predictedDateU50": "08-Jun-2027",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jul-2029",
                "endDate": "26-Jul-2030",
                "successPercentage": "95%",
                "predictedDateL50": "06-Jun-2028",
                "predictedDateU50": "19-Nov-2029",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jul-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2030",
                "predictedDateU50": "19-Sep-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2027",
                "milestoneExtendedDate": "31-Jan-2027",
                "notes": "In August 2023, a phase II study (NCT05909904) in patients with head and neck squamous cell carcinoma was expected to complete in January 2027 [ <ulink linkID=\"2980014\" linkType=\"Reference\"> 2980014 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "22-Jun-2030",
            "statusDate": "21-Jul-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "32%",
            "timeToRegistration": "6.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "11-Sep-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "11-Sep-2017",
                "endDate": "16-Jan-2027",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jan-2027",
                "endDate": "22-Aug-2029",
                "successPercentage": "55%",
                "predictedDateL50": "17-Mar-2026",
                "predictedDateU50": "14-Sep-2027",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Aug-2029",
                "endDate": "23-May-2030",
                "successPercentage": "92%",
                "predictedDateL50": "12-Jul-2028",
                "predictedDateU50": "07-Jan-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-May-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Feb-2030",
                "predictedDateU50": "22-Jun-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2027",
                "milestoneExtendedDate": "31-Jan-2027",
                "notes": "In June 2023, a phase II study (NCT05909904) in patients with head and neck squamous cell carcinoma was expected to complete in January 2027 [ <ulink linkID=\"2980014\" linkType=\"Reference\"> 2980014 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Nov-2018",
            "endDate": "",
            "statusDate": "07-Nov-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-Nov-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Jun-2015",
            "endDate": "26-Jun-2028",
            "statusDate": "02-Feb-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "37%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "02-Jun-2015",
                "endDate": "11-Sep-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "11-Sep-2017",
                "endDate": "29-Dec-2024",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Dec-2024",
                "endDate": "05-Aug-2027",
                "successPercentage": "57%",
                "predictedDateL50": "08-Feb-2024",
                "predictedDateU50": "31-Aug-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2027",
                "endDate": "26-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jun-2026",
                "predictedDateU50": "21-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Feb-2028",
                "predictedDateU50": "26-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Dec-2016",
            "endDate": "14-Oct-2028",
            "statusDate": "07-Nov-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "40%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "28-Dec-2016",
                "endDate": "05-Feb-2025",
                "successPercentage": "80%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Feb-2025",
                "endDate": "29-Jun-2027",
                "successPercentage": "53%",
                "predictedDateL50": "31-Mar-2024",
                "predictedDateU50": "18-Aug-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jun-2027",
                "endDate": "11-Aug-2028",
                "successPercentage": "95%",
                "predictedDateL50": "13-Jun-2026",
                "predictedDateU50": "17-Nov-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Mar-2028",
                "predictedDateU50": "14-Oct-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "4265",
              "name": "Ureter cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Feb-2023",
            "endDate": "01-Sep-2029",
            "statusDate": "20-Feb-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "85%",
            "timeToRegistration": "5.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Feb-2023",
                "endDate": "31-Dec-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2025",
                "endDate": "09-Jun-2028",
                "successPercentage": "94%",
                "predictedDateL50": "05-Apr-2025",
                "predictedDateU50": "03-May-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jun-2028",
                "endDate": "07-Jul-2029",
                "successPercentage": "95%",
                "predictedDateL50": "21-May-2027",
                "predictedDateU50": "30-Oct-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jul-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Mar-2029",
                "predictedDateU50": "01-Sep-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a phase II study (ChiCTR2300068589) in patients with bladder cancer, ureteral cancer and renal pelvic cancer was expected to complete in December 2025 [ <ulink linkID=\"2837627\" linkType=\"Reference\"> 2837627 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "26-Feb-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "90233",
        "displayName": "odronextamab",
        "drugPrograms": [
          {
            "company": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "07-Dec-2026",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "2.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "10-May-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-May-2022",
                "endDate": "26-Jun-2025",
                "successPercentage": "64%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jun-2025",
                "endDate": "16-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "13-Oct-2024",
                "predictedDateU50": "06-Oct-2025",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Sep-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Apr-2026",
                "predictedDateU50": "07-Dec-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "03-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, an IND was field in China [<ulink linkType=\"Reference\" linkID=\"2294363\">2294363</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "07-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, an implied trial approval was granted for B-cell NHL who have relapsed or are refractory after previous systemic treatment [<ulink linkType=\"Reference\" linkID=\"2312515\">2312515</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Jan-2021",
                "notes": "By August 2020, the first Chinese patient was expected to be enrolled in a registrational global phase II trial in early 2021 in China [<ulink linkType=\"Reference\" linkID=\"2317227\">2317227</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "03-Jan-2027",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "2.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "10-May-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-May-2022",
                "endDate": "03-Aug-2025",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Aug-2025",
                "endDate": "15-Oct-2026",
                "successPercentage": "95%",
                "predictedDateL50": "05-Nov-2024",
                "predictedDateU50": "17-Nov-2025",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Oct-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-May-2026",
                "predictedDateU50": "03-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "18-Dec-2026",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "70%",
            "timeToRegistration": "2.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "10-May-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-May-2022",
                "endDate": "01-Jul-2025",
                "successPercentage": "74%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jul-2025",
                "endDate": "22-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "16-Oct-2024",
                "predictedDateU50": "12-Oct-2025",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Sep-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Apr-2026",
                "predictedDateU50": "18-Dec-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, data from phase II trial (NCT03888105) from relapsed/refractory follicular lymphoma patients were reported [ <ulink linkID=\"2996103\" linkType=\"Reference\"> 2996103 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1101935",
              "name": "Zai Lab Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "11-Dec-2026",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "2.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "10-May-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-May-2022",
                "endDate": "01-Jul-2025",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jul-2025",
                "endDate": "19-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "16-Oct-2024",
                "predictedDateU50": "12-Oct-2025",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Sep-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Apr-2026",
                "predictedDateU50": "11-Dec-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, first interim data from the DLBCL cohort (n = 140) of a phase II study (NCT03888105) were presented. According to independent central review and investigator evaluation (both, n = 130), ORR was 49.2 and 50%, complete response (CR) rate was 30.8 and 36.2%, partial response (PR) rate was 18.5 and 13.8%, stable disease (SD) rate was 3.8 and 3.1%, and progressive disease (PD) rate was 22.3 and 21.5%, respectively. In the overall safety population (n = 140), proportions of patients with any treatment-emergent adverse event (TEAE), grade &gt;/= 3 TEAE, serious AE, grade 5 TEAE, and TEAE leading to treatment discontinuation (any/treatment-related) were 99.3/87.9, 78.6/52.9, 60.7/45.7, 14.3/3.6, and 10.0/7.9%, respectively [ <ulink linkID=\"2796220\" linkType=\"Reference\">  2796220 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Jan-2016",
            "endDate": "07-Apr-2032",
            "statusDate": "11-Jan-2016",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "8.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "11-Jan-2016",
                "endDate": "19-Aug-2026",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "19-Aug-2026",
                "endDate": "30-Oct-2028",
                "successPercentage": "34%",
                "predictedDateL50": "04-Jul-2025",
                "predictedDateU50": "29-Jan-2027",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Oct-2028",
                "endDate": "27-Mar-2031",
                "successPercentage": "61%",
                "predictedDateL50": "18-Sep-2027",
                "predictedDateU50": "31-Mar-2029",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2031",
                "endDate": "27-Feb-2032",
                "successPercentage": "95%",
                "predictedDateL50": "11-Mar-2030",
                "predictedDateU50": "15-Aug-2031",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Feb-2032",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Nov-2031",
                "predictedDateU50": "07-Apr-2032",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Oct-2021",
                "notes": "In November 2019, the phase I trial in patients with lymphoma was expected to complete in October 2021 [  <ulink linkID=\"1759772\" linkType=\"Reference\">   1759772  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-Aug-2026",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, phase I trial of odronextamab in patients with lymphoma was expected to complete in August 2026 [  <ulink linkID=\"1759772\" linkType=\"Reference\">   1759772  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Jan-2016",
            "endDate": "",
            "statusDate": "11-Jan-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "11-Jan-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2015",
            "endDate": "17-Mar-2030",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "53%",
            "timeToRegistration": "6.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "13-Nov-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "18-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Aug-2026",
                "endDate": "19-Jan-2029",
                "successPercentage": "59%",
                "predictedDateL50": "06-Jan-2026",
                "predictedDateU50": "08-Feb-2027",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Jan-2029",
                "endDate": "25-Jan-2030",
                "successPercentage": "95%",
                "predictedDateL50": "01-Jan-2028",
                "predictedDateU50": "06-Jun-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Sep-2029",
                "predictedDateU50": "17-Mar-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In November 2019, data from the proof-of-concept NCT02290951 study for non-Hodgkin's lymphoma were expected for December 2019 [<ulink linkType=\"Reference\" linkID=\"2216372\">2216372</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "By January 2023, phase II data from odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma patients were presented [ <ulink linkID=\"2805569\" linkType=\"Reference\">  2805569 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2025",
                "milestoneExtendedDate": "16-Apr-2025",
                "notes": "In December 2019, the phase I trial in patients with NHL and CLL was expected to complete in April 2025 [<ulink linkType=\"Reference\" linkID=\"1614595\">1614595</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Mar-2026",
                "milestoneExtendedDate": "18-Aug-2026",
                "notes": "In August 2022, additional results from pivotal phase II study of odronextamab in patients with non-hodgkin lymphoma were expected for 2H 2022 [ <ulink linkID=\"2713874\" linkType=\"Reference\">  2713874 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Aug-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, phase II trial of odronextamab in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma was expected to complete in August 2026 [<ulink linkType=\"Reference\" linkID=\"2216433\">2216433</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "02-Nov-2028",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "53%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "30-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Aug-2025",
                "endDate": "02-Dec-2027",
                "successPercentage": "59%",
                "predictedDateL50": "18-Jan-2025",
                "predictedDateU50": "20-Feb-2026",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Dec-2027",
                "endDate": "28-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "11-Dec-2026",
                "predictedDateU50": "23-Apr-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jun-2028",
                "predictedDateU50": "02-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "27-Aug-2029",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "5.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "18-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Aug-2026",
                "endDate": "03-Oct-2028",
                "successPercentage": "68%",
                "predictedDateL50": "15-Dec-2025",
                "predictedDateU50": "27-Feb-2027",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Oct-2028",
                "endDate": "27-Jul-2029",
                "successPercentage": "95%",
                "predictedDateL50": "28-Oct-2027",
                "predictedDateU50": "05-Feb-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jul-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Apr-2029",
                "predictedDateU50": "27-Aug-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "By January 2023, phase II data from odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma patients were presented [ <ulink linkID=\"2805569\" linkType=\"Reference\">  2805569 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Mar-2026",
                "milestoneExtendedDate": "18-Aug-2026",
                "notes": "In August 2022, additional results from pivotal phase II study of odronextamab in patients with non-hodgkin lymphoma were expected for 2H 2022 [ <ulink linkID=\"2713874\" linkType=\"Reference\">  2713874 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Aug-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, phase II trial of odronextamab in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma was expected to complete in August 2026 [<ulink linkType=\"Reference\" linkID=\"2216433\">2216433</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "14-Mar-2030",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "6.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "18-Aug-2026",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Aug-2026",
                "endDate": "29-Jan-2029",
                "successPercentage": "65%",
                "predictedDateL50": "15-Dec-2025",
                "predictedDateU50": "27-Feb-2027",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jan-2029",
                "endDate": "27-Jan-2030",
                "successPercentage": "95%",
                "predictedDateL50": "06-Jan-2028",
                "predictedDateU50": "17-Jun-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jan-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Sep-2029",
                "predictedDateU50": "14-Mar-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "By January 2023, phase II data from odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma patients were presented [ <ulink linkID=\"2805569\" linkType=\"Reference\">  2805569 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Mar-2026",
                "milestoneExtendedDate": "18-Aug-2026",
                "notes": "In August 2022, additional results from pivotal phase II study of odronextamab in patients with non-hodgkin lymphoma were expected for 2H 2022 [ <ulink linkID=\"2713874\" linkType=\"Reference\">  2713874 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Aug-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, phase II trial of odronextamab in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma was expected to complete in August 2026 [<ulink linkType=\"Reference\" linkID=\"2216433\">2216433</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2015",
            "endDate": "13-Jan-2028",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "51%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "13-Nov-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "18-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Aug-2026",
                "endDate": "16-Feb-2027",
                "successPercentage": "57%",
                "predictedDateL50": "06-Jan-2026",
                "predictedDateU50": "08-Feb-2027",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Feb-2027",
                "endDate": "11-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Aug-2026",
                "predictedDateU50": "04-Jul-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Aug-2027",
                "predictedDateU50": "13-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, further results were presented from the phase I trial (NCT02290951), at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Majority of AEs reported were mild to moderate in severity (total n = 68). DLTs were not reported. Efficacy analysis included patients who received odronextamab at; /= 40 mg as of data cut-off (September 2018). ORR, CR and PR rate was 14.3, 14.3 and 0% with;  5 mg (n = 7); 100, 80 and 20% with >/= 5 to; /= 12 mg (n = 5) and 100, 80 and 20% with >/= 18 to; /= 40 mg (n = 5) according to Chenson 2007 criteria in patients with r/r follicular lymphoma grade 1 to 3a; 20, 0 and 20% with; 5 mg (n = 5); 18.2, 9.1 and 9.1% with >/= 5 to; /= 12 mg (n = 11) and 60, 20 and 40% with >/= 18 to; /= 40 mg (n = 10) according to Chenson 2007 criteria in patients with r/r diffuse large cell B cell lymphoma; and 40, 0 and 40% with; 5 mg (n = 5); 33.3, 0 and 33.3% with >/= 5 to; /= 12 mg (n = 3) and 75, 50 and 25% with >/= 18 to; /= 40 mg (n = 4) according to Chenson 2007 criteria in patients with B-NHLs-others, respectively [<ulink linkType=\"Reference\" linkID=\"2100489\">2100489</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In November 2019, data from the proof-of-concept NCT02290951 study for non-Hodgkin's lymphoma were expected for December 2019 [<ulink linkType=\"Reference\" linkID=\"2216372\">2216372</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected IND Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2020, the company expected to file a IND for odronextamab in combination with REGN-5837 for non-hodgkin lymphoma by the end of 2020 [<ulink linkType=\"Reference\" linkID=\"2375483\">2375483</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In January 2020, the company was planning to submitt a marketing application for NHL from mid-2021 to mid-2022 [<ulink linkType=\"Reference\" linkID=\"2236653\">2236653</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "By January 2023, phase II data from odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma patients were presented [ <ulink linkID=\"2805569\" linkType=\"Reference\">  2805569 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In November 2022, an NDA submission of odronextamab in b-cell non hodgkin lymphoma was expected for the second half of 2023 [ <ulink linkID=\"2765265\" linkType=\"Reference\">  2765265 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2025",
                "milestoneExtendedDate": "16-Apr-2025",
                "notes": "In December 2019, the phase I trial in patients with NHL and CLL was expected to complete in April 2025 [<ulink linkType=\"Reference\" linkID=\"1614595\">1614595</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Mar-2026",
                "milestoneExtendedDate": "18-Aug-2026",
                "notes": "In August 2022, additional results from pivotal phase II study of odronextamab in patients with non-hodgkin lymphoma were expected for 2H 2022 [ <ulink linkID=\"2713874\" linkType=\"Reference\">  2713874 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Aug-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, phase II trial of odronextamab in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma was expected to complete in August 2026 [<ulink linkType=\"Reference\" linkID=\"2216433\">2216433</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2015",
            "endDate": "12-Mar-2031",
            "statusDate": "07-Nov-2014",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "14%",
            "timeToRegistration": "7.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "02-Dec-2025",
                "successPercentage": "90%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "02-Dec-2025",
                "endDate": "01-Dec-2027",
                "successPercentage": "32%",
                "predictedDateL50": "13-Jul-2024",
                "predictedDateU50": "11-Nov-2026",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Dec-2027",
                "endDate": "26-Feb-2030",
                "successPercentage": "52%",
                "predictedDateL50": "24-Nov-2026",
                "predictedDateU50": "28-Apr-2028",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Feb-2030",
                "endDate": "01-Feb-2031",
                "successPercentage": "92%",
                "predictedDateL50": "05-Mar-2029",
                "predictedDateU50": "17-Jul-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Feb-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Oct-2030",
                "predictedDateU50": "12-Mar-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2025",
                "milestoneExtendedDate": "16-Apr-2025",
                "notes": "In December 2019, the phase I trial in patients with NHL and CLL was expected to complete in April 2025 [<ulink linkType=\"Reference\" linkID=\"1614595\">1614595</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jan-2015",
            "endDate": "19-Jan-2029",
            "statusDate": "07-Nov-2014",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "14%",
            "timeToRegistration": "5.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Dec-2023",
                "endDate": "08-Dec-2025",
                "successPercentage": "30%",
                "predictedDateL50": "20-Sep-2022",
                "predictedDateU50": "12-Jan-2025",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Dec-2025",
                "endDate": "05-Mar-2028",
                "successPercentage": "51%",
                "predictedDateL50": "01-Dec-2024",
                "predictedDateU50": "06-May-2026",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Mar-2028",
                "endDate": "20-Dec-2028",
                "successPercentage": "93%",
                "predictedDateL50": "13-Mar-2027",
                "predictedDateU50": "24-Jul-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Dec-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Sep-2028",
                "predictedDateU50": "19-Jan-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-Dec-2018",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, further results were presented from the phase I trial (NCT02290951), at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Majority of AEs reported were mild to moderate in severity (total n = 68). DLTs were not reported. Efficacy analysis included patients who received odronextamab at; /= 40 mg as of data cut-off (September 2018). ORR, CR and PR rate was 14.3, 14.3 and 0% with;  5 mg (n = 7); 100, 80 and 20% with >/= 5 to; /= 12 mg (n = 5) and 100, 80 and 20% with >/= 18 to; /= 40 mg (n = 5) according to Chenson 2007 criteria in patients with r/r follicular lymphoma grade 1 to 3a; 20, 0 and 20% with; 5 mg (n = 5); 18.2, 9.1 and 9.1% with >/= 5 to; /= 12 mg (n = 11) and 60, 20 and 40% with >/= 18 to; /= 40 mg (n = 10) according to Chenson 2007 criteria in patients with r/r diffuse large cell B cell lymphoma; and 40, 0 and 40% with; 5 mg (n = 5); 33.3, 0 and 33.3% with >/= 5 to; /= 12 mg (n = 3) and 75, 50 and 25% with >/= 18 to; /= 40 mg (n = 4) according to Chenson 2007 criteria in patients with B-NHLs-others, respectively [<ulink linkType=\"Reference\" linkID=\"2100489\">2100489</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2025",
                "milestoneExtendedDate": "16-Apr-2025",
                "notes": "In December 2019, the phase I trial in patients with NHL and CLL was expected to complete in April 2025 [<ulink linkType=\"Reference\" linkID=\"1614595\">1614595</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "09-Jan-2015",
            "endDate": "25-Sep-2024",
            "statusDate": "17-Aug-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "13-Nov-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "17-Aug-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2023",
                "endDate": "14-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Aug-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Apr-2024",
                "predictedDateU50": "25-Sep-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, preliminary data were presented at the virtual 62nd ASH Annual Meeting and Exposition. DLTs were not demonstrated during dose escalation and MTD was not reached with odronextamab doses up to 320 mg weekly [<ulink linkType=\"Reference\" linkID=\"2371088\">2371088</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, data from phase II trial (NCT03888105) from relapsed/refractory follicular lymphoma patients were reported [ <ulink linkID=\"2996103\" linkType=\"Reference\"> 2996103 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "17-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, EMA accepted an MAA for the treatment of relapsed/refractory, follicular lymphoma or R/R diffuse large B-cell lymphoma based on data from the phase I and pivotal phase II trial (ELM-1 and ELM-2) [ <ulink linkID=\"3043935\" linkType=\"Reference\"> 3043935 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "17-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "By August 2023, EMA granted orphan drug designation to the drug, for the treatment of follicle center lymphoma [ <ulink linkID=\"3043935\" linkType=\"Reference\"> 3043935 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE",
              " EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Fast Track, Priority Review",
            "startDate": "09-Jan-2015",
            "endDate": "14-May-2024",
            "statusDate": "29-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "13-Nov-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "29-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2023",
                "endDate": "14-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jan-2024",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "25-Jan-2018",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "30-Nov-2019",
                "notes": "In November 2018, a phase II trial in follicular lymphoma was expected in \"the next 12 months\" [<ulink linkType=\"Reference\" linkID=\"2099349\">2099349</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2019",
                "milestoneExtendedDate": "30-Dec-2019",
                "notes": "In May 2019, the phase II trial was planned to begin later that quarter [<ulink linkType=\"Reference\" linkID=\"2148685\">2148685</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, preliminary data were presented at the virtual 62nd ASH Annual Meeting and Exposition. DLTs were not demonstrated during dose escalation and MTD was not reached with odronextamab doses up to 320 mg weekly [<ulink linkType=\"Reference\" linkID=\"2371088\">2371088</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "04-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, the USFDA granted fast track designation for follicular lymphoma and diffuse large B-cell lymphoma [  <ulink linkID=\"2662928\" linkType=\"Reference\">  2662928  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, data from phase II trial (NCT03888105) from relapsed/refractory follicular lymphoma patients were reported [ <ulink linkID=\"2996103\" linkType=\"Reference\"> 2996103 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In November 2022, an NDA submission of odronextamab in follicular lymphoma was expected for the second half of 2023 [ <ulink linkID=\"2765265\" linkType=\"Reference\">  2765265 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "29-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted for priority review the BLA for odronextamab to treat adult patients with R/R FL or R/R DLBCL, and PDUFA action date was March 31, 2024 [ <ulink linkID=\"3279950\" linkType=\"Reference\"> 3279950 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "31-Mar-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted for priority review the BLA for odronextamab to treat adult patients with R/R FL or R/R DLBCL, and PDUFA action date was March 31, 2024 [ <ulink linkID=\"3279950\" linkType=\"Reference\"> 3279950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(EU)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "09-Jan-2015",
            "endDate": "21-Sep-2024",
            "statusDate": "17-Aug-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "13-Nov-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "17-Aug-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2023",
                "endDate": "12-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Aug-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Apr-2024",
                "predictedDateU50": "21-Sep-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, preliminary data were presented at the virtual 62nd ASH Annual Meeting and Exposition. DLTs were not demonstrated during dose escalation and MTD was not reached with odronextamab doses up to 320 mg weekly [<ulink linkType=\"Reference\" linkID=\"2371088\">2371088</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, first interim data from the DLBCL cohort (n = 140) of a phase II study (NCT03888105) were presented. According to independent central review and investigator evaluation (both, n = 130), ORR was 49.2 and 50%, complete response (CR) rate was 30.8 and 36.2%, partial response (PR) rate was 18.5 and 13.8%, stable disease (SD) rate was 3.8 and 3.1%, and progressive disease (PD) rate was 22.3 and 21.5%, respectively. In the overall safety population (n = 140), proportions of patients with any treatment-emergent adverse event (TEAE), grade &gt;/= 3 TEAE, serious AE, grade 5 TEAE, and TEAE leading to treatment discontinuation (any/treatment-related) were 99.3/87.9, 78.6/52.9, 60.7/45.7, 14.3/3.6, and 10.0/7.9%, respectively [ <ulink linkID=\"2796220\" linkType=\"Reference\">  2796220 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "17-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "By August 2023, EMA granted orphan drug designation to the drug, for the treatment of follicle center lymphoma [ <ulink linkID=\"3043935\" linkType=\"Reference\"> 3043935 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "17-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, EMA accepted an MAA for the treatment of relapsed/refractory, follicular lymphoma or R/R diffuse large B-cell lymphoma based on data from the phase I and pivotal phase II trial (ELM-1 and ELM-2) [ <ulink linkID=\"3043935\" linkType=\"Reference\"> 3043935 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "27-Feb-2027",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "11-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Dec-2023",
                "endDate": "31-Mar-2026",
                "successPercentage": "62%",
                "predictedDateL50": "09-Apr-2023",
                "predictedDateU50": "21-Jun-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Mar-2026",
                "endDate": "25-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "31-Mar-2025",
                "predictedDateU50": "15-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Oct-2026",
                "predictedDateU50": "27-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, first interim data from the DLBCL cohort (n = 140) of a phase II study (NCT03888105) were presented. According to independent central review and investigator evaluation (both, n = 130), ORR was 49.2 and 50%, complete response (CR) rate was 30.8 and 36.2%, partial response (PR) rate was 18.5 and 13.8%, stable disease (SD) rate was 3.8 and 3.1%, and progressive disease (PD) rate was 22.3 and 21.5%, respectively. In the overall safety population (n = 140), proportions of patients with any treatment-emergent adverse event (TEAE), grade &gt;/= 3 TEAE, serious AE, grade 5 TEAE, and TEAE leading to treatment discontinuation (any/treatment-related) were 99.3/87.9, 78.6/52.9, 60.7/45.7, 14.3/3.6, and 10.0/7.9%, respectively [ <ulink linkID=\"2796220\" linkType=\"Reference\">  2796220 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "14-Dec-2026",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "60%",
            "timeToRegistration": "2.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "11-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Dec-2023",
                "endDate": "19-Jan-2026",
                "successPercentage": "67%",
                "predictedDateL50": "09-Apr-2023",
                "predictedDateU50": "21-Jun-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Jan-2026",
                "endDate": "12-Nov-2026",
                "successPercentage": "95%",
                "predictedDateL50": "17-Feb-2025",
                "predictedDateU50": "25-May-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Nov-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jul-2026",
                "predictedDateU50": "14-Dec-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, first interim data from the DLBCL cohort (n = 140) of a phase II study (NCT03888105) were presented. According to independent central review and investigator evaluation (both, n = 130), ORR was 49.2 and 50%, complete response (CR) rate was 30.8 and 36.2%, partial response (PR) rate was 18.5 and 13.8%, stable disease (SD) rate was 3.8 and 3.1%, and progressive disease (PD) rate was 22.3 and 21.5%, respectively. In the overall safety population (n = 140), proportions of patients with any treatment-emergent adverse event (TEAE), grade &gt;/= 3 TEAE, serious AE, grade 5 TEAE, and TEAE leading to treatment discontinuation (any/treatment-related) were 99.3/87.9, 78.6/52.9, 60.7/45.7, 14.3/3.6, and 10.0/7.9%, respectively [ <ulink linkID=\"2796220\" linkType=\"Reference\">  2796220 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Nov-2019",
            "endDate": "30-Jun-2027",
            "statusDate": "13-Nov-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "11-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Dec-2023",
                "endDate": "17-May-2026",
                "successPercentage": "63%",
                "predictedDateL50": "09-Apr-2023",
                "predictedDateU50": "21-Jun-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-May-2026",
                "endDate": "16-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "26-Apr-2025",
                "predictedDateU50": "07-Oct-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jan-2027",
                "predictedDateU50": "30-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, first interim data from the DLBCL cohort (n = 140) of a phase II study (NCT03888105) were presented. According to independent central review and investigator evaluation (both, n = 130), ORR was 49.2 and 50%, complete response (CR) rate was 30.8 and 36.2%, partial response (PR) rate was 18.5 and 13.8%, stable disease (SD) rate was 3.8 and 3.1%, and progressive disease (PD) rate was 22.3 and 21.5%, respectively. In the overall safety population (n = 140), proportions of patients with any treatment-emergent adverse event (TEAE), grade &gt;/= 3 TEAE, serious AE, grade 5 TEAE, and TEAE leading to treatment discontinuation (any/treatment-related) were 99.3/87.9, 78.6/52.9, 60.7/45.7, 14.3/3.6, and 10.0/7.9%, respectively [ <ulink linkID=\"2796220\" linkType=\"Reference\">  2796220 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Fast Track, Priority Review",
            "startDate": "09-Jan-2015",
            "endDate": "14-May-2024",
            "statusDate": "29-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Jan-2015",
                "endDate": "13-Nov-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2019",
                "endDate": "29-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Sep-2023",
                "endDate": "14-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Jan-2024",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "06-Jun-2017",
                "milestoneExtendedDate": "",
                "notes": null,
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "30-Nov-2019",
                "notes": "In November 2018, a phase II trial in diffuse large B-cell lymphoma was expected in \"the next 12 months\" [<ulink linkType=\"Reference\" linkID=\"2099349\">2099349</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "30-Dec-2019",
                "notes": "In May 2019, the phase II trial was planned to begin later that year [<ulink linkType=\"Reference\" linkID=\"2148685\">2148685</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, preliminary data were presented at the virtual 62nd ASH Annual Meeting and Exposition. DLTs were not demonstrated during dose escalation and MTD was not reached with odronextamab doses up to 320 mg weekly [<ulink linkType=\"Reference\" linkID=\"2371088\">2371088</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "04-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, the USFDA granted fast track designation for follicular lymphoma and diffuse large B-cell lymphoma [  <ulink linkID=\"2662928\" linkType=\"Reference\">  2662928  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, first interim data from the DLBCL cohort (n = 140) of a phase II study (NCT03888105) were presented. According to independent central review and investigator evaluation (both, n = 130), ORR was 49.2 and 50%, complete response (CR) rate was 30.8 and 36.2%, partial response (PR) rate was 18.5 and 13.8%, stable disease (SD) rate was 3.8 and 3.1%, and progressive disease (PD) rate was 22.3 and 21.5%, respectively. In the overall safety population (n = 140), proportions of patients with any treatment-emergent adverse event (TEAE), grade &gt;/= 3 TEAE, serious AE, grade 5 TEAE, and TEAE leading to treatment discontinuation (any/treatment-related) were 99.3/87.9, 78.6/52.9, 60.7/45.7, 14.3/3.6, and 10.0/7.9%, respectively [ <ulink linkID=\"2796220\" linkType=\"Reference\">  2796220 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In November 2022, an NDA submission of odronextamab in diffuse large b-cell lymphoma was expected for the second half of 2023 [ <ulink linkID=\"2765265\" linkType=\"Reference\">  2765265 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "29-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted for priority review the BLA for odronextamab to treat adult patients with R/R FL or R/R DLBCL, and PDUFA action date was March 31, 2024 [ <ulink linkID=\"3279950\" linkType=\"Reference\"> 3279950 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "31-Mar-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the US FDA accepted for priority review the BLA for odronextamab to treat adult patients with R/R FL or R/R DLBCL, and PDUFA action date was March 31, 2024 [ <ulink linkID=\"3279950\" linkType=\"Reference\"> 3279950 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "93599",
        "displayName": "toripalimab",
        "drugPrograms": [
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2022",
            "endDate": "11-Nov-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "20-Nov-2024",
                "successPercentage": "33%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Nov-2024",
                "endDate": "29-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "24-Mar-2024",
                "predictedDateU50": "04-Mar-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Jun-2025",
                "predictedDateU50": "11-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2022",
            "endDate": "03-Nov-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "69%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "11-Nov-2024",
                "successPercentage": "73%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Nov-2024",
                "endDate": "21-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "21-Mar-2024",
                "predictedDateU50": "26-Feb-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jun-2025",
                "predictedDateU50": "03-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Mar-2018",
            "endDate": "12-Oct-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "49%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Mar-2018",
                "endDate": "31-Jul-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "19-Oct-2024",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Oct-2024",
                "endDate": "01-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "11-Mar-2024",
                "predictedDateU50": "28-Jan-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-May-2025",
                "predictedDateU50": "12-Oct-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "03-Mar-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2022",
            "endDate": "18-Nov-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "72%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "26-Nov-2024",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Nov-2024",
                "endDate": "03-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "27-Mar-2024",
                "predictedDateU50": "14-Mar-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jun-2025",
                "predictedDateU50": "18-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2022",
            "endDate": "26-Sep-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "62%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "19-Oct-2024",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Oct-2024",
                "endDate": "19-Aug-2025",
                "successPercentage": "93%",
                "predictedDateL50": "11-Mar-2024",
                "predictedDateU50": "28-Jan-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-May-2025",
                "predictedDateU50": "26-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Mar-2018",
            "endDate": "25-Oct-2027",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "39%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Mar-2018",
                "endDate": "31-Jul-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "31-Jul-2022",
                "endDate": "13-Aug-2024",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Aug-2024",
                "endDate": "29-Nov-2026",
                "successPercentage": "62%",
                "predictedDateL50": "17-Feb-2024",
                "predictedDateU50": "20-Nov-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Nov-2026",
                "endDate": "22-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "03-Dec-2025",
                "predictedDateU50": "13-Apr-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Jun-2027",
                "predictedDateU50": "25-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2022",
            "endDate": "17-Oct-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "19-Oct-2024",
                "successPercentage": "70%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Oct-2024",
                "endDate": "08-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "11-Mar-2024",
                "predictedDateU50": "28-Jan-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-May-2025",
                "predictedDateU50": "17-Oct-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Feb-2021",
            "endDate": "18-Feb-2025",
            "statusDate": "01-Feb-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "64%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "01-Feb-2021",
                "endDate": "16-Mar-2024",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Mar-2024",
                "endDate": "12-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "20-Dec-2023",
                "predictedDateU50": "19-May-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Sep-2024",
                "predictedDateU50": "18-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1069851",
              "name": "Coherus BioSciences Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "14-Mar-2018",
            "endDate": "05-Nov-2025",
            "statusDate": "31-Jul-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "74%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Mar-2018",
                "endDate": "31-Jul-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2022",
                "endDate": "24-Nov-2024",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Nov-2024",
                "endDate": "24-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "26-Mar-2024",
                "predictedDateU50": "07-Mar-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jun-2025",
                "predictedDateU50": "05-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "15-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, US FDA granted Orphan Drug Designation (ODD) to toripalimab for the treatment of esophageal cancer [  <ulink linkID=\"2566976\" linkType=\"Reference\">  2566976  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected sNDA/sBLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In September 2021, Coherus and Junshi Biosciences were planning to submit a BLA supplement to the US FDA for 1L ESCC in 2022 [ <ulink linkID=\"2530767\" linkType=\"Reference\">  2530767 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2016",
            "endDate": "19-Nov-2029",
            "statusDate": "10-Feb-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "5.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Dec-2016",
                "endDate": "10-Feb-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Feb-2022",
                "endDate": "31-Jul-2028",
                "successPercentage": "35%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jul-2028",
                "endDate": "16-Sep-2029",
                "successPercentage": "95%",
                "predictedDateL50": "23-Feb-2028",
                "predictedDateU50": "28-Oct-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Sep-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-May-2029",
                "predictedDateU50": "19-Nov-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Mar-2019",
                "notes": "In December 2018, phase trials for stomach cancer was expected in China in the first quarter of 2019 [ <ulink linkID=\"2103223\" linkType=\"Reference\">  2103223 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2018, the phase II trial in China in patients with Stomach tumor was expected to complete in October 2019 [ <ulink linkID=\"1884214\" linkType=\"Reference\">  1884214 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "04-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, an IND was filed in China [ <ulink linkID=\"2260928\" linkType=\"Reference\">  2260928 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, an implied clinical trial approval of the drug was obtained for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma in China [ <ulink linkID=\"2285204\" linkType=\"Reference\">  2285204 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "24-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, an implied trial approval was granted for stomach or gastroesophageal junction adenocarcinoma in China [ <ulink linkID=\"2591285\" linkType=\"Reference\">  2591285 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2028",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, a phase III study (NCT05180734) of toripalimab in combination with standard chemotherapy as the adjuvant treatment of patients after curative resection for gastric or gastroesophageal junction adenocarcinoma in China was expected to complete by July 2028 [ <ulink linkID=\"2615604\" linkType=\"Reference\">  2615604 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "203",
              "name": "Lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2016",
            "endDate": "",
            "statusDate": "12-Jul-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Aug-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2016",
            "endDate": "04-Aug-2025",
            "statusDate": "17-Feb-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2016",
                "endDate": "18-Mar-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Mar-2019",
                "endDate": "29-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-May-2024",
                "endDate": "16-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "26-Jul-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Feb-2025",
                "predictedDateU50": "04-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a phase II trial (ChiCTR2300067960) for squamous cell carcinoma was planned to initiate later that month [ <ulink linkID=\"2841807\" linkType=\"Reference\">  2841807 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "738",
              "name": "Urinary tract tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Apr-2016",
            "endDate": "",
            "statusDate": "06-Apr-2017",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "25-Apr-2016",
                "endDate": "06-Apr-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "06-Apr-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1128",
              "name": "Neuroendocrine tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Apr-2017",
            "endDate": "",
            "statusDate": "26-Dec-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "25-Apr-2017",
                "endDate": "26-Dec-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-Dec-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN",
              " CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1134",
              "name": "Thyroid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Jun-2023",
            "endDate": "02-Feb-2028",
            "statusDate": "05-Jun-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Jun-2023",
                "endDate": "30-Sep-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "30-Sep-2024",
                "endDate": "03-Nov-2026",
                "successPercentage": "95%",
                "predictedDateL50": "16-Feb-2024",
                "predictedDateU50": "25-Jan-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Nov-2026",
                "endDate": "05-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Dec-2025",
                "predictedDateU50": "08-Mar-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jul-2027",
                "predictedDateU50": "02-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jul-2019",
            "endDate": "18-Oct-2030",
            "statusDate": "23-Jul-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "6.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "23-Jul-2019",
                "endDate": "31-Jul-2029",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jul-2029",
                "endDate": "24-Aug-2030",
                "successPercentage": "95%",
                "predictedDateL50": "14-May-2029",
                "predictedDateU50": "11-Oct-2029",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Aug-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Apr-2030",
                "predictedDateU50": "18-Oct-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "27-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, an IND was filed in China [ <ulink linkID=\"2338501\" linkType=\"Reference\">  2338501 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "29-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, an implied trial approval was granted for extensive stage small cell lung cancer in China [ <ulink linkID=\"2369536\" linkType=\"Reference\">  2369536 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2019, a phase III trial for extensive stage small cell lung cancer was expected to complete in June 2022 [ <ulink linkID=\"2172610\" linkType=\"Reference\">  2172610 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the primary endpoint of the phase III trial (NCT04012606) was met [ <ulink linkID=\"3017712\" linkType=\"Reference\"> 3017712 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "19-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the NMPA accepted a sNDA for toripalimab in combination with etoposide plus platinum for the first-line treatment of patients ES-SCLC [ <ulink linkID=\"3017712\" linkType=\"Reference\"> 3017712 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "31-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the IND filing was approved by NMPA for the treatment of limited-stage small cell lung cancer in combination with tifcemalimab [ <ulink linkID=\"3061294\" linkType=\"Reference\"> 3061294 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "25-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III trial (NCT06095583) in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy was planned to initiate in October 2023 [ <ulink linkID=\"3477936\" linkType=\"Reference\"> 3477936 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2029",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III trial (NCT06095583) in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy was expected to complete in July 2029 [ <ulink linkID=\"3477936\" linkType=\"Reference\"> 3477936 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Dec-2018",
            "endDate": "",
            "statusDate": "17-Dec-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Dec-2019",
            "endDate": "07-Dec-2027",
            "statusDate": "26-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Dec-2019",
                "endDate": "21-May-2024",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-May-2024",
                "endDate": "06-Aug-2026",
                "successPercentage": "60%",
                "predictedDateL50": "08-Jan-2024",
                "predictedDateU50": "22-Aug-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Aug-2026",
                "endDate": "29-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Aug-2025",
                "predictedDateU50": "19-Dec-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-May-2027",
                "predictedDateU50": "07-Dec-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2016",
            "endDate": "",
            "statusDate": "31-May-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2016",
                "endDate": "26-Apr-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-Apr-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Mar-2019",
            "endDate": "",
            "statusDate": "12-Mar-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Nov-2022",
            "endDate": "14-Feb-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "15-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2023",
                "predictedDateU50": "14-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "26-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, marketing authorization applications was accepted by EMA [ <ulink linkID=\"2798435\" linkType=\"Reference\"> 2798435 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Breakthrough Therapy, Priority Review",
            "startDate": "14-Mar-2018",
            "endDate": "18-Jan-2024",
            "statusDate": "03-Mar-2021",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "25%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Mar-2018",
                "endDate": "03-Mar-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Mar-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Nov-2023",
                "predictedDateU50": "18-Jan-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "18-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, the US FDA granted Orphan drug designation to toripalimab for the treatment of nasopharyngeal carcinoma [ <ulink linkID=\"2287705\" linkType=\"Reference\">  2287705 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "10-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, the FDA granted Breakthrough Therapy designation to toripalimab for the treatment of nasopharyngeal carcinoma [ <ulink linkID=\"2315537\" linkType=\"Reference\">  2315537 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2021, Junshi Biosciences expected filing for the therapy in the US for nasopharyngeal carcinoma by 2021 [ <ulink linkID=\"2400045\" linkType=\"Reference\">  2400045 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "03-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, Coherus and Junshi Biosciences initiated rolling submission of the BLA for toripalimab to the US FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma [ <ulink linkID=\"2415687\" linkType=\"Reference\">  2415687 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2021",
                "milestoneExtendedDate": "12-Aug-2021",
                "notes": "In August 2021, BLA submission for nasopharyngeal carcinoma as monotherapy or in combination with other chemotherapy were expected within third quarter of year 2021 [ <ulink linkID=\"2510221\" linkType=\"Reference\">  2510221 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "12-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, the drug was granted breakthrough therapy designation by the US FDA for the first-line treatment of advanced recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin [ <ulink linkID=\"2510221\" linkType=\"Reference\">  2510221 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "31-Oct-2021",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the US FDA granted Priority Review Designation for the treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma [ <ulink linkID=\"2557787\" linkType=\"Reference\">  2557787 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "01-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, the USFDA was granted Priority Review Designation for toripalimab in combination with gemcitabine and cisplatin for the first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma and set a Prescription Drug User Fee Act (\"PDUFA\") action date for April 2022 [ <ulink linkID=\"2558059\" linkType=\"Reference\">  2558059 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "30-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the NDA was accepted by the US FDA and a PDUFA date was set for April 2022 for the first-line treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin [ <ulink linkID=\"2557787\" linkType=\"Reference\">  2557787 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "21-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, BLA resubmission for the treatment of nasopharyngeal carcinoma was accepted by the FDA and a PDUFA date was set for December 23, 2022 [ <ulink linkID=\"2706844\" linkType=\"Reference\">  2706844 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "23-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, BLA resubmission for the treatment of nasopharyngeal carcinoma was accepted by the FDA and a PDUFA date was set for December 23, 2022 [ <ulink linkID=\"2706844\" linkType=\"Reference\">  2706844 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In September 2023, approval of toripalimab by the US FDA for the treatment of NPC was expected by end of 2023 [ <ulink linkID=\"3246959\" linkType=\"Reference\"> 3246959 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In May 2023, commercial launch of the drug was expected in 3Q23 [ <ulink linkID=\"2926813\" linkType=\"Reference\"> 2926813 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In May 2023, FDA approval was expected in 3Q23 [ <ulink linkID=\"2926813\" linkType=\"Reference\"> 2926813 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2016",
            "endDate": "03-Oct-2027",
            "statusDate": "26-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Aug-2016",
                "endDate": "26-Dec-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-Dec-2019",
                "endDate": "06-May-2024",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "06-May-2024",
                "endDate": "11-Jul-2026",
                "successPercentage": "55%",
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Jul-2026",
                "endDate": "07-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jul-2025",
                "predictedDateU50": "24-Nov-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Apr-2027",
                "predictedDateU50": "03-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN",
              " CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jul-2016",
            "endDate": "03-Jul-2025",
            "statusDate": "17-Sep-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Jul-2016",
                "endDate": "17-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Sep-2019",
                "endDate": "20-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Feb-2024",
                "endDate": "20-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "02-Dec-2023",
                "predictedDateU50": "23-May-2024",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Dec-2024",
                "predictedDateU50": "03-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "10-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, an IND was filed in China [ <ulink linkID=\"2352358\" linkType=\"Reference\">  2352358 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "18-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, a clinical trial application was filed in China; in January 2021, an implied trial approval was granted for first diagnosis of stage IV or recurrent metastatic triple-negative breast cancer [ <ulink linkID=\"2386291\" linkType=\"Reference\">  2386291 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a positive interim data from phase III (NCT04085276; TORCHLIGHT) trial were reported which demonstrated primary endpoint were met [ <ulink linkID=\"2827610\" linkType=\"Reference\"> 2827610 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "20-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "n February 2023,  a positive interim data from phase III (NCT04085276; TORCHLIGHT) trial were reported which demonstrated primary endpoint were met [ <ulink linkID=\"2827610\" linkType=\"Reference\">  2827610 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "23-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the NMPA accepted a sNDA of toripalimab in combination with standard first-line chemotherapy for advanced triple-negative breast cancer [ <ulink linkID=\"2951311\" linkType=\"Reference\"> 2951311 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, a phase III trial (NCT04085276) was planned to complete in December 2024 [ <ulink linkID=\"2400791\" linkType=\"Reference\">  2400791 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-May-2019",
            "endDate": "",
            "statusDate": "13-May-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-May-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "12-Feb-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "13-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Dec-2023",
                "predictedDateU50": "12-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "26-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, marketing authorization applications was accepted by EMA [ <ulink linkID=\"2798435\" linkType=\"Reference\"> 2798435 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Dec-2016",
            "endDate": "03-Jun-2029",
            "statusDate": "07-Dec-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "70%",
            "timeToRegistration": "5.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Dec-2016",
                "endDate": "01-Feb-2026",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Feb-2026",
                "endDate": "13-Mar-2028",
                "successPercentage": "94%",
                "predictedDateL50": "07-Sep-2025",
                "predictedDateU50": "09-Jun-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Mar-2028",
                "endDate": "08-Apr-2029",
                "successPercentage": "95%",
                "predictedDateL50": "07-Apr-2027",
                "predictedDateU50": "15-Jul-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Apr-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Nov-2028",
                "predictedDateU50": "03-Jun-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In September 2018, the phase II trial in China in patients with metastatic head and neck squamous cell carcinoma was expected to complete in October 2019 [ <ulink linkID=\"1884214\" linkType=\"Reference\">  1884214 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, interim data of a phase Ib/II trial (NCT02915432) of 3 patients with head and neck squamous cell carcinoma were presented which showed that the primary endpoint (objective response rate) was met. The objective response rate/disease control rate as assessed by investigators according to RECIST v1.1 was 33.3/100%, and the median duration of response was 7.1 months [ <ulink linkID=\"2284710\" linkType=\"Reference\">  2284710 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, primary endpoint (objective response rate) of a phase Ib/II trial (NCT02915432) of 3 patients with head and neck squamous cell carcinoma was met. The objective response rate/disease control rate as assessed by investigators according to RECIST v1.1 was 33.3/100%, and the median duration of response was 7.1 months [ <ulink linkID=\"2284710\" linkType=\"Reference\">  2284710 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "11-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an implied trial approval was granted for HNSCC in China [ <ulink linkID=\"2399834\" linkType=\"Reference\">  2399834 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, interim analysis data of a phase II trial (NCT04126460) in 20 patients with recurrent, previously irradiated head and neck squamous cell carcinoma treated with salvage surgery were presented [ <ulink linkID=\"2469458\" linkType=\"Reference\">  2469458 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a phase II trial (ChiCTR2300067960) for metastatic head and neck cancer was planned to initiate later that month [ <ulink linkID=\"2841807\" linkType=\"Reference\">  2841807 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Feb-2026",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, a phase II trial (ChiCTR2300067960) for metastatic head and neck cancer was expected to complete in February 2026 [ <ulink linkID=\"2841807\" linkType=\"Reference\">  2841807 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Mar-2016",
            "endDate": "29-Apr-2027",
            "statusDate": "26-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "39%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "07-Mar-2016",
                "endDate": "26-Dec-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-Dec-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "03-Feb-2026",
                "successPercentage": "53%",
                "predictedDateL50": "09-Aug-2023",
                "predictedDateU50": "05-Mar-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Feb-2026",
                "endDate": "04-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Feb-2025",
                "predictedDateU50": "12-Jun-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Oct-2026",
                "predictedDateU50": "29-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN",
              " CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Mar-2018",
            "endDate": "27-Nov-2029",
            "statusDate": "14-Mar-2018",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Mar-2018",
                "endDate": "31-Oct-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "31-Oct-2024",
                "endDate": "18-Sep-2026",
                "successPercentage": "35%",
                "predictedDateL50": "08-Mar-2024",
                "predictedDateU50": "16-Apr-2025",
                "phaseDuration": "1.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Sep-2026",
                "endDate": "12-Dec-2028",
                "successPercentage": "54%",
                "predictedDateL50": "03-Oct-2025",
                "predictedDateU50": "04-Feb-2027",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Dec-2028",
                "endDate": "13-Oct-2029",
                "successPercentage": "95%",
                "predictedDateL50": "20-Dec-2027",
                "predictedDateU50": "26-Apr-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Oct-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jul-2029",
                "predictedDateU50": "27-Nov-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1104388",
              "name": "Shanghai Junshi Biosciences Co Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2020",
            "endDate": "11-Jul-2025",
            "statusDate": "04-Sep-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Sep-2020",
                "endDate": "05-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Apr-2024",
                "endDate": "10-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "01-Jan-2024",
                "predictedDateU50": "11-Jun-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Dec-2024",
                "predictedDateU50": "11-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "11-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the NMPA approved sNDA of toripalimab in combination with standard first-line chemotherapy for unresectable or metastatic renal cell carcinoma [ <ulink linkID=\"3007664\" linkType=\"Reference\"> 3007664 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "94819",
        "displayName": "camrelizumab",
        "drugPrograms": [
          {
            "company": {
              "id": "1003254",
              "name": "CrystalGenomics Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Apr-2019",
            "endDate": "28-Jun-2025",
            "statusDate": "20-Apr-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Apr-2019",
                "endDate": "23-Jul-2024",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Jul-2024",
                "endDate": "21-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "01-Oct-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Feb-2025",
                "predictedDateU50": "28-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "311",
              "name": "T-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "29-May-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "designation": "Breakthrough Therapy",
            "startDate": "",
            "endDate": "",
            "statusDate": "23-Jan-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "740",
              "name": "Uterus tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2020",
            "endDate": "21-Apr-2028",
            "statusDate": "14-Feb-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Feb-2020",
                "endDate": "14-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Aug-2024",
                "endDate": "22-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "09-Dec-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jan-2027",
                "endDate": "22-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-Jan-2026",
                "predictedDateU50": "14-Jun-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Oct-2027",
                "predictedDateU50": "21-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase II trial of SHR-1210 in combined with apatinib in subjects with relapsed or refractory uterine /cervical and ovarian carcinoma was expected to complete in Febraury 2023 [ <ulink linkID=\"2247395\" linkType=\"Reference\">  2247395 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Apr-2018",
            "endDate": "13-Dec-2021",
            "statusDate": "20-Apr-2018",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-2.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Apr-2018",
                "endDate": "13-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Dec-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, interim data of a phase II trial (PASSION) of camrelizumab + apatinib in patients with extensive-stage small-cell lung cancer were presented which showed that the primary endpoint (ORR) was met. In arms A, B and C, the objective response rate (ORR; primary endpoint) was 34.0, 33.3 and 33.3%; disease control rate (DCR) was 68.1, 100 and 50.0%; partial response rate was 34.0, 33.3 and 33.3%; stable disease rate was 34.0, 66.7 and 16.7%; progressive disease rate was 31.9, 0 and 50.0%; and median duration of response was 6.2, 4.2 and not reached, respectively [ <ulink linkID=\"2272979\" linkType=\"Reference\">  2272979 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, primary endpoint (ORR) of a phase II trial (PASSION) of camrelizumab + apatinib in patients with extensive-stage small-cell lung cancer was met. In arms A, B and C, the objective response rate (ORR; primary endpoint) was 34.0, 33.3 and 33.3%; disease control rate (DCR) was 68.1, 100 and 50.0%; partial response rate was 34.0, 33.3 and 33.3%; stable disease rate was 34.0, 66.7 and 16.7%; progressive disease rate was 31.9, 0 and 50.0%; and median duration of response was 6.2, 4.2 and not reached, respectively [ <ulink linkID=\"2272979\" linkType=\"Reference\">  2272979 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, a phase II clinical trial (NCT04790539) for extensive-stage (ES)-SCLC was planned to be initiated in April 2021 [ <ulink linkID=\"2695929\" linkType=\"Reference\">  2695929 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2017",
            "endDate": "11-Aug-2027",
            "statusDate": "27-Apr-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "19-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "04-Dec-2022",
                "predictedDateU50": "17-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-May-2026",
                "endDate": "15-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "29-Apr-2025",
                "predictedDateU50": "09-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Feb-2027",
                "predictedDateU50": "11-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, data from phase II trial (NCT03092895) for camrelizumab in combination with chemotherapy (FOLFOX4 or GEMOX regimen) for advanced biliary tumor were presented [ <ulink linkID=\"2329762\" linkType=\"Reference\">  2329762 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jan-2019",
            "endDate": "28-Apr-2028",
            "statusDate": "23-Jan-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Jan-2019",
                "endDate": "18-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Aug-2024",
                "endDate": "26-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "03-Feb-2024",
                "predictedDateU50": "31-Jan-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jan-2027",
                "endDate": "29-Feb-2028",
                "successPercentage": "95%",
                "predictedDateL50": "06-Jan-2026",
                "predictedDateU50": "18-Jun-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Oct-2027",
                "predictedDateU50": "28-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In February 2019, the phase II trial was expected to complete in June 2021 [ <ulink linkID=\"2118080\" linkType=\"Reference\">  2118080 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1753",
              "name": "Peripheral T-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Jun-2023",
            "endDate": "13-Mar-2029",
            "statusDate": "20-Jun-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "5.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Jun-2023",
                "endDate": "22-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Jul-2025",
                "endDate": "13-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "01-Jul-2024",
                "predictedDateU50": "21-Dec-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Dec-2027",
                "endDate": "13-Jan-2029",
                "successPercentage": "95%",
                "predictedDateL50": "01-Dec-2026",
                "predictedDateU50": "02-May-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Jan-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Sep-2028",
                "predictedDateU50": "13-Mar-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN",
              " CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Apr-2019",
            "endDate": "01-Jun-2024",
            "statusDate": "17-May-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Apr-2019",
                "endDate": "17-May-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-May-2023",
                "endDate": "02-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Mar-2024",
                "predictedDateU50": "01-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "30-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, the US FDA granted orphan drug designation for camrelizumab for the treatment of hepatocellular carcinoma [ <ulink linkID=\"2562384\" linkType=\"Reference\">  2562384 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, a phase III trial for advanced HCC was expected to complete in January 2022 in the US [ <ulink linkID=\"2110647\" linkType=\"Reference\">  2110647 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "12-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, the primary point of the trial was met with the positive results of SHR-1210-Ⅲ-310[  <ulink linkID=\"2669132\" linkType=\"Reference\">  2669132 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "17-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, an NDA was submitted to the US FDA for the combination of rivoceranib and camrelizumab as first-line treatment option for unresectable hepatocellular carcinoma [ <ulink linkID=\"2941359\" linkType=\"Reference\"> 2941359 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "31-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a BLA was submitted to the US FDA for the combination of apatinib and camrelizumab as first-line treatment option for unresectable hepatocellular carcinoma [ <ulink linkID=\"2962455\" linkType=\"Reference\"> 2962455 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive results from a phase III (NCT03764293; CARES 310) trial of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma were published [ <ulink linkID=\"3028238\" linkType=\"Reference\"> 3028238 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2024",
                "milestoneExtendedDate": "31-May-2024",
                "notes": "In August 2023, Prescription Drug User Fee Act (PDUFA) date was expected as May 2024 [ <ulink linkID=\"3033217\" linkType=\"Reference\"> 3033217 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "16-May-2024",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the FDA had set the PDUFA date for the first-line treatment option for unresectable hepatocellular carcinoma on May 16, 2024 [ <ulink linkID=\"3014030\" linkType=\"Reference\"> 3014030 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Apr-2019",
            "endDate": "13-Feb-2025",
            "statusDate": "30-Apr-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Apr-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "24-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "28-Apr-2023",
                "predictedDateU50": "30-May-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Aug-2024",
                "predictedDateU50": "13-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "12-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, the primary point of the trial was met with the positive results of SHR-1210-Ⅲ-310[  <ulink linkID=\"2669132\" linkType=\"Reference\">  2669132 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive results from a phase III (NCT03764293; CARES 310) trial of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma were published [ <ulink linkID=\"3028238\" linkType=\"Reference\"> 3028238 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jan-2019",
            "endDate": "02-Aug-2027",
            "statusDate": "23-Jan-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Jan-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "09-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "27-May-2023",
                "predictedDateU50": "26-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-May-2026",
                "endDate": "07-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Apr-2025",
                "predictedDateU50": "25-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jan-2027",
                "predictedDateU50": "02-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, primary endpoints were met for a phase II trial (NCT03827837) [ <ulink linkID=\"2283796\" linkType=\"Reference\">  2283796 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, interim results were presented from a phase II trial (NCT03827837) [ <ulink linkID=\"2283796\" linkType=\"Reference\">  2283796 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In February 2019, the phase II trial was expected to complete in June 2021 [ <ulink linkID=\"2118080\" linkType=\"Reference\">  2118080 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "1772",
              "name": "Osteosarcoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jan-2018",
            "endDate": "09-Aug-2027",
            "statusDate": "01-Jan-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jan-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "19-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "26-Jan-2023",
                "predictedDateU50": "10-Sep-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-May-2026",
                "endDate": "14-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "29-Apr-2025",
                "predictedDateU50": "09-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Feb-2027",
                "predictedDateU50": "09-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "01-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, primary endpoint of a phase II study was met [ <ulink linkID=\"2155618\" linkType=\"Reference\">  2155618 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Jul-2021",
            "endDate": "24-Nov-2027",
            "statusDate": "21-Jul-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-Jul-2021",
                "endDate": "28-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-May-2024",
                "endDate": "21-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jan-2024",
                "predictedDateU50": "05-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Sep-2026",
                "endDate": "04-Oct-2027",
                "successPercentage": "88%",
                "predictedDateL50": "24-Sep-2025",
                "predictedDateU50": "09-Feb-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jun-2027",
                "predictedDateU50": "24-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-May-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, a phase II trial (NCT04888611) was expected to complete in May 2024 in patients with recurrent glioblastoma [ <ulink linkID=\"2461584\" linkType=\"Reference\">  2461584 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3240",
              "name": "Medullary thyroid cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Oct-2019",
            "endDate": "20-Jan-2028",
            "statusDate": "26-Oct-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Oct-2019",
                "endDate": "04-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Jun-2024",
                "endDate": "26-Oct-2026",
                "successPercentage": "95%",
                "predictedDateL50": "10-Jan-2024",
                "predictedDateU50": "12-Sep-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Oct-2026",
                "endDate": "24-Nov-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Oct-2025",
                "predictedDateU50": "16-Mar-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Nov-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Jul-2027",
                "predictedDateU50": "20-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, a phase II trial famitinib combined with camrelizumab in patients with advanced thyroid was expected to complete in October 2022 [ <ulink linkID=\"2214634\" linkType=\"Reference\">  2214634 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2016",
            "endDate": "20-Sep-2025",
            "statusDate": "13-Mar-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "13-Apr-2016",
                "endDate": "13-Mar-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Mar-2019",
                "endDate": "20-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jul-2024",
                "endDate": "30-Jul-2025",
                "successPercentage": "91%",
                "predictedDateL50": "11-Feb-2024",
                "predictedDateU50": "11-Oct-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Mar-2025",
                "predictedDateU50": "20-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Nov-2018",
            "endDate": "",
            "statusDate": "29-Nov-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Nov-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3462",
              "name": "Metastatic liver cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Apr-2016",
            "endDate": "11-Aug-2027",
            "statusDate": "27-Apr-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "06-Apr-2016",
                "endDate": "27-Apr-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "19-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "04-Dec-2022",
                "predictedDateU50": "17-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-May-2026",
                "endDate": "15-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "29-Apr-2025",
                "predictedDateU50": "09-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Feb-2027",
                "predictedDateU50": "11-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, data from a phase Ib/II trial of camrelizumab plus apatinib as the second or above line treatment of advanced primary liver cancer [ <ulink linkID=\"2329762\" linkType=\"Reference\">  2329762 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Jan-2018",
            "endDate": "20-Mar-2025",
            "statusDate": "14-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Jan-2018",
                "endDate": "14-Jul-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Jul-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "18-Jan-2025",
                "successPercentage": "91%",
                "predictedDateL50": "04-Aug-2023",
                "predictedDateU50": "28-Feb-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Sep-2024",
                "predictedDateU50": "20-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "05-Nov-2019",
                "milestoneExtendedDate": "",
                "notes": "In November 2019, an IND was filed in China [ <ulink linkID=\"2212109\" linkType=\"Reference\">  2212109 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "10-Jan-2020",
                "milestoneExtendedDate": "",
                "notes": "In January 2020, an implied trial approval was granted for the drug in combination with rivoceranib mesylate plus albumin paclitaxel for locally advanced or metastatic unresectable triple negative breast cancer patients who had never received systematic antitumor therapy [ <ulink linkID=\"2232589\" linkType=\"Reference\">  2232589 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "20-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04335006) was expected to start in May 2020 for advanced breast cancer in China [ <ulink linkID=\"2267626\" linkType=\"Reference\">  2267626 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "11-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, an implied trial approval was granted for the drug in combination with chemotherapy as the neoadjuvant therapy for the triple negative breast cancer in China [ <ulink linkID=\"2294364\" linkType=\"Reference\">  2294364 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "03-Mar-2021",
                "milestoneExtendedDate": "",
                "notes": "In March 2021, an IND was filed in China [ <ulink linkID=\"2413740\" linkType=\"Reference\">  2413740 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "11-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, an implied trial approval was granted for triple negative breast cancer in China [2445076].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, results from a phase II study for combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer were reported [ <ulink linkID=\"2461073\" linkType=\"Reference\">  2461073 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "22-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, a supplementary application was filed in China [ <ulink linkID=\"2465365\" linkType=\"Reference\">  2465365 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Nov-2021",
                "milestoneExtendedDate": "30-Nov-2021",
                "notes": "In May 2021, a phase III trial (NCT05134194, CTR20212837, SHR-1210-III-327) was planned to initiate in November 2021 [ <ulink linkID=\"2576111\" linkType=\"Reference\">  2576111 </ulink>], [ <ulink linkID=\"2576112\" linkType=\"Reference\">  2576112 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Apr-2023",
                "notes": "In May 2021, a phase III trial (NCT05134194, CTR20212837, SHR-1210-III-327) was expected to complete in April 2023. [ <ulink linkID=\"2576111\" linkType=\"Reference\">  2576111 </ulink>], [ <ulink linkID=\"2576112\" linkType=\"Reference\">  2576112 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Nov-2024",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, a phase III trial (NCT04335006) was expected to complete in November 2024 for advanced breast cancer in China [ <ulink linkID=\"2267626\" linkType=\"Reference\">  2267626 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3671",
              "name": "Metastatic rectal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Jan-2021",
            "endDate": "15-Mar-2028",
            "statusDate": "17-Jan-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Jan-2021",
                "endDate": "14-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Jul-2024",
                "endDate": "22-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "24-Jan-2024",
                "predictedDateU50": "07-Nov-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Dec-2026",
                "endDate": "18-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-Dec-2025",
                "predictedDateU50": "14-May-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Sep-2027",
                "predictedDateU50": "15-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Apr-2016",
            "endDate": "27-Jun-2027",
            "statusDate": "30-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "83%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "06-Apr-2016",
                "endDate": "30-Sep-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "27-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "23-Jul-2023",
                "predictedDateU50": "26-Mar-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Apr-2026",
                "endDate": "07-May-2027",
                "successPercentage": "92%",
                "predictedDateL50": "16-Apr-2025",
                "predictedDateU50": "15-Sep-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2027",
                "predictedDateU50": "27-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "17-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, an IND was filed in China [ <ulink linkID=\"2250242\" linkType=\"Reference\">  2250242 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "31-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, an implied clinical trial approval of the drug was granted for advanced solid tumor including urinary system tumor and gynecological tumor in China [ <ulink linkID=\"2250243\" linkType=\"Reference\">  2250243 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, an implied clinical trial approval of the drug was obtained for advanced malignancies in China [ <ulink linkID=\"2274356\" linkType=\"Reference\">  2274356 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "20-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, an IND was filed in China [ <ulink linkID=\"2305762\" linkType=\"Reference\">  2305762 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, data from a phase I trial (NCT02721589) for advanced solid tumor were presented [ <ulink linkID=\"2329762\" linkType=\"Reference\">  2329762 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "24-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an implied trial approval was granted for advanced sold tumor [ <ulink linkID=\"2399834\" linkType=\"Reference\">  2399834 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "23-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, an IND was filed in China [ <ulink linkID=\"2520401\" linkType=\"Reference\">  2520401 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "30-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, an implied trial approval was granted for combined with SHR-1802 and famitinib for advanced solid tumor in China [ <ulink linkID=\"2557828\" linkType=\"Reference\">  2557828 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "21-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, a supplementary IND was filed in China [ <ulink linkID=\"2643794\" linkType=\"Reference\">  2643794 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data from a phase II study (NCT04569916) of radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib in 55 patients with advanced solid tumor were presented. All grade and grade 3 to 4 TRAEs were reported in 98.2 and 45.5% of patients, respectively. Among 42 efficacy evaluable patients, at a median follow-up of 41 weeks, ORR was 35.7%; DCR was 97.6%; the number of patients with PR, SD, and PD was 15, 26, and 1, respectively [ <ulink linkID=\"2692160\" linkType=\"Reference\">  2692160 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2023",
                "milestoneExtendedDate": "31-May-2023",
                "notes": "In September 2020, a phase II study (NCT04569916; IIT-RT-IRI-SHR1210-APA) of radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib was expected to be completed in May 2023 [ <ulink linkID=\"2722685\" linkType=\"Reference\">  2722685 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jan-2019",
            "endDate": "09-Aug-2027",
            "statusDate": "23-Jan-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Jan-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "02-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "27-May-2023",
                "predictedDateU50": "24-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-May-2026",
                "endDate": "09-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Apr-2025",
                "predictedDateU50": "20-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Jan-2027",
                "predictedDateU50": "09-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, preliminary phase II results from ovarian cancer patients were presented.Among efficacy evaluable ovarian cancer (n = 32) and cervical cancer (n = 18) patients, ORR (including unconfirmed responses) was 31.2 and 61.1%; ORR (excluding unconfirmed responses) was 28.1 and 50%; DCR was 62.5 and 83.3%, respectively. Median progression-free survival in ovarian cancer and cervical cancer patients was 4.2 and 12.3 months, respectively. Most common grade 3 or 4 treatment-emergent adverse events (TEAEs) in all patients were hypertension (35.1 versus 15.2% with ovarian cancer and cervical cancer, respectively), neutrophil count decreased (27.0 versus 15.2%, respectively) and anemia (5.4 versus 18.2%, respectively). None of the patient discontinued treatment due to treatment-related AEs [ <ulink linkID=\"2325073\" linkType=\"Reference\">  2325073 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In February 2019, the phase II trial was expected to complete in June 2021 [ <ulink linkID=\"2118080\" linkType=\"Reference\">  2118080 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase II trial of SHR-1210 in combined with apatinib in subjects with relapsed or refractory uterine /cervical and ovarian carcinoma was expected to complete in Febraury 2023 [ <ulink linkID=\"2247395\" linkType=\"Reference\">  2247395 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1033640",
              "name": "Shanghai Hengrui Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Jan-2019",
            "endDate": "08-Jul-2027",
            "statusDate": "23-Jan-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Jan-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "10-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "27-May-2023",
                "predictedDateU50": "26-May-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Apr-2026",
                "endDate": "11-May-2027",
                "successPercentage": "93%",
                "predictedDateL50": "11-Apr-2025",
                "predictedDateU50": "29-Aug-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2027",
                "predictedDateU50": "08-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, primary endpoints were met for a phase II trial (NCT03827837) [ <ulink linkID=\"2283796\" linkType=\"Reference\">  2283796 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, top-line results were presented [ <ulink linkID=\"2283796\" linkType=\"Reference\">  2283796 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "04-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, an IND was filed in China [ <ulink linkID=\"2312514\" linkType=\"Reference\">  2312514 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "10-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, an implied clinical trial approval of the drug was obtained for famitinib combined with camrelizumab for the treatment of advanced renal cell carcinoma in China [ <ulink linkID=\"2352357\" linkType=\"Reference\">  2352357 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In February 2019, the phase II trial was expected to complete in June 2021 [ <ulink linkID=\"2118080\" linkType=\"Reference\">  2118080 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "98615",
        "displayName": "trastuzumab deruxtecan",
        "drugPrograms": [
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Dec-2020",
            "endDate": "17-May-2027",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "74%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Dec-2020",
                "endDate": "26-Jun-2026",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jun-2026",
                "endDate": "16-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Feb-2026",
                "predictedDateU50": "20-Sep-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Dec-2026",
                "predictedDateU50": "17-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "26-Jun-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the phase III DESTINY-Breast11 trial (NCT05113251) of neoadjuvant trastuzumab deruxtecan monotherapy or trastuzumab deruxtecan followed by paclitaxel, trastuzumab and pertuzumab (THP) compared with standard of care regimen of doxorubicin and cyclophosphamide followed by THP in patients with high-risk HER2-positive early-stage breast cancer was expected to complete in June 2026 [ <ulink linkID=\"2588467\" linkType=\"Reference\">  2588467 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Oct-2021",
            "endDate": "09-Aug-2027",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "73%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Oct-2021",
                "endDate": "26-Jun-2026",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jun-2026",
                "endDate": "24-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "07-Jan-2026",
                "predictedDateU50": "16-Sep-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Feb-2027",
                "predictedDateU50": "09-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "26-Jun-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the phase III DESTINY-Breast11 trial (NCT05113251) of neoadjuvant trastuzumab deruxtecan monotherapy or trastuzumab deruxtecan followed by paclitaxel, trastuzumab and pertuzumab (THP) compared with standard of care regimen of doxorubicin and cyclophosphamide followed by THP in patients with high-risk HER2-positive early-stage breast cancer was expected to complete in June 2026 [ <ulink linkID=\"2588467\" linkType=\"Reference\">  2588467 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-May-2019",
            "endDate": "",
            "statusDate": "14-May-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-May-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Oct-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Oct-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "07-Mar-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Dec-2020",
            "endDate": "09-May-2027",
            "statusDate": "05-Mar-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Dec-2020",
                "endDate": "16-Jul-2024",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jul-2024",
                "endDate": "22-Jun-2026",
                "successPercentage": "28%",
                "predictedDateL50": "02-Apr-2024",
                "predictedDateU50": "15-Sep-2024",
                "phaseDuration": "1.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jun-2026",
                "endDate": "09-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "21-Aug-2025",
                "predictedDateU50": "17-Oct-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Dec-2026",
                "predictedDateU50": "09-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, first data from phase II trial of trastuzumab deruxtecan was reported at ASCO for the third-line treatment of HER2+ metastatic colorectal cancer [ <ulink linkID=\"3028827\" linkType=\"Reference\"> 3028827 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2023",
                "milestoneExtendedDate": "31-Aug-2023",
                "notes": "In March 2021, a randomized, parallel-assignment, double-blind, phase II trial (NCT04744831; DS8201-A-U207; 2020-004782-39; DESTINY-CRC02) was initiated in the US, Australia, Europe, Japan, Korea and Taiwan to assess trastuzumab deruxtecan in subjects (expected n = 120) with locally advanced, unresectable, or metastatic HER2-overexpressing colorectal cancer (CRC) of BRAF wild-type and either RAS wild-type or mutant tumor type, previously treated with standard therapy. The primary endpoint was change in confirmed objective response rate (ORR). The trial was expected to complete in August 2023 [<ulink linkType=\"Reference\" linkID=\"2432843\">2432843</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In September 2023, a phase II trial ( NCT04744831; DESTINY-CRC02) was expected to complete in July 2024 [ <ulink linkID=\"2432843\" linkType=\"Reference\"> 2432843 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": "Breakthrough Therapy",
            "startDate": "",
            "endDate": "",
            "statusDate": "07-Mar-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Feb-2018",
            "endDate": "25-Sep-2027",
            "statusDate": "07-Mar-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Feb-2018",
                "endDate": "21-May-2024",
                "successPercentage": "41%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-May-2024",
                "endDate": "13-Sep-2026",
                "successPercentage": "28%",
                "predictedDateL50": "11-Jan-2024",
                "predictedDateU50": "24-Aug-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Sep-2026",
                "endDate": "16-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Sep-2025",
                "predictedDateU50": "29-Jan-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Apr-2027",
                "predictedDateU50": "25-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Opinion",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "Source Date: 29/05/2020; Phase: C2;  In June 2021, interim results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in patients with HER2 expressing metastatic colorectal cancer were presented [2283746]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, final results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in 86 patients with HER2 expressing metastatic colorectal cancer were presented. In cohort A (HER+), cohort B (HER2 immunohistochemistry (IHC2)+/in situ hybridization (ISH)-) and cohort C (HER2 IHC+) (n = 53, 15 and 18), confirmed objective response rate (ORR) by independent central review was 45.3 (primary endpoint), 0 and 0%; complete response rate was 0% each, partial response rate was 45.3, 0 and 0%, stable disease rate was 37.7, 60.0 and 22.2%, progressive disease rate was 9.4, 33.3 and 55.6%, disease control rate was 83.0, 60.0 and 22.2%, median duration of response was 7 months and not evaluable in the other two groups, median treatment duration was 5.1, 2.1 and 1.4 months, median progression free survival was 6.9, 2.1 and 1.4 months, and median overall survival was 15.5, 7.3 and 7.7 months, respectively [ <ulink linkID=\"2469573\" linkType=\"Reference\">  2469573 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, trial top line results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in 86 patients with HER2 expressing metastatic colorectal cancer were presented. In cohort A (HER+), cohort B (HER2 immunohistochemistry (IHC2)+/in situ hybridization (ISH)-) and cohort C (HER2 IHC+) (n = 53, 15 and 18), confirmed objective response rate (ORR) by independent central review was 45.3 (primary endpoint), 0 and 0%; complete response rate was 0% each, partial response rate was 45.3, 0 and 0%, stable disease rate was 37.7, 60.0 and 22.2%, progressive disease rate was 9.4, 33.3 and 55.6%, disease control rate was 83.0, 60.0 and 22.2%, median duration of response was 7 months and not evaluable in the other two groups, median treatment duration was 5.1, 2.1 and 1.4 months, median progression free survival was 6.9, 2.1 and 1.4 months, and median overall survival was 15.5, 7.3 and 7.7 months, respectively [ <ulink linkID=\"2469573\" linkType=\"Reference\">  2469573 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, first data from phase II trial of trastuzumab deruxtecan was reported at ASCO for the third-line treatment of HER2+ metastatic colorectal cancer [ <ulink linkID=\"3028827\" linkType=\"Reference\"> 3028827 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2023",
                "milestoneExtendedDate": "31-Aug-2023",
                "notes": "In March 2021, a randomized, parallel-assignment, double-blind, phase II trial (NCT04744831; DS8201-A-U207; 2020-004782-39; DESTINY-CRC02) was initiated in the US, Australia, Europe, Japan, Korea and Taiwan to assess trastuzumab deruxtecan in subjects (expected n = 120) with locally advanced, unresectable, or metastatic HER2-overexpressing colorectal cancer (CRC) of BRAF wild-type and either RAS wild-type or mutant tumor type, previously treated with standard therapy. The primary endpoint was change in confirmed objective response rate (ORR). The trial was expected to complete in August 2023 [<ulink linkType=\"Reference\" linkID=\"2432843\">2432843</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In September 2023, a phase II trial ( NCT04744831; DESTINY-CRC02) was expected to complete in July 2024 [ <ulink linkID=\"2432843\" linkType=\"Reference\"> 2432843 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Mar-2021",
            "endDate": "11-Jun-2029",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "25%",
            "timeToRegistration": "5.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "09-Mar-2021",
                "endDate": "26-Aug-2024",
                "successPercentage": "75%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-Aug-2024",
                "endDate": "14-Apr-2026",
                "successPercentage": "75%",
                "predictedDateL50": "18-May-2024",
                "predictedDateU50": "09-Nov-2024",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Apr-2026",
                "endDate": "01-Jun-2028",
                "successPercentage": "47%",
                "predictedDateL50": "07-Jun-2025",
                "predictedDateU50": "06-Aug-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jun-2028",
                "endDate": "03-May-2029",
                "successPercentage": "95%",
                "predictedDateL50": "18-Jun-2027",
                "predictedDateU50": "05-Oct-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-May-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Jan-2029",
                "predictedDateU50": "11-Jun-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "12-Aug-2022",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Nov-2019",
            "endDate": "06-Dec-2025",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "74%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "26-Nov-2019",
                "endDate": "21-May-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-May-2021",
                "endDate": "05-Nov-2024",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Nov-2024",
                "endDate": "28-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "28-May-2024",
                "predictedDateU50": "27-Feb-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Jun-2025",
                "predictedDateU50": "06-Dec-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "03-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, the EMA validated a type II variation application for trastuzumab deruxtecan for the treatment of adults with locally advanced or metastatic HER2-positive gastric or GEJ carcinoma who have received a prior anti-HER2-based regimen, based on data from the DESTINY-Gastric01 and DESTINY-Gastric02 trials [ <ulink linkID=\"2559475\" linkType=\"Reference\">  2559475 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "10-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, the EMA's CHMP recommended approval of the drug for the treatment of adults with advanced HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen [ <ulink linkID=\"2770492\" linkType=\"Reference\">  2770492 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2015",
            "endDate": "25-Sep-2025",
            "statusDate": "08-Jul-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "73%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Sep-2015",
                "endDate": "02-Nov-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "02-Nov-2017",
                "endDate": "21-May-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-May-2021",
                "endDate": "15-Nov-2024",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Nov-2024",
                "endDate": "26-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "11-Jul-2024",
                "predictedDateU50": "22-Feb-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-May-2025",
                "predictedDateU50": "25-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": "Breakthrough Therapy",
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Dec-2020",
            "endDate": "10-Oct-2027",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "70%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Dec-2020",
                "endDate": "26-Jun-2026",
                "successPercentage": "74%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jun-2026",
                "endDate": "09-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "16-Feb-2026",
                "predictedDateU50": "27-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Mar-2027",
                "predictedDateU50": "10-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "26-Jun-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the phase III DESTINY-Breast11 trial (NCT05113251) of neoadjuvant trastuzumab deruxtecan monotherapy or trastuzumab deruxtecan followed by paclitaxel, trastuzumab and pertuzumab (THP) compared with standard of care regimen of doxorubicin and cyclophosphamide followed by THP in patients with high-risk HER2-positive early-stage breast cancer was expected to complete in June 2026 [ <ulink linkID=\"2588467\" linkType=\"Reference\">  2588467 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Dec-2020",
            "endDate": "14-May-2027",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "70%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Dec-2020",
                "endDate": "26-Jun-2026",
                "successPercentage": "74%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jun-2026",
                "endDate": "14-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "26-Mar-2026",
                "predictedDateU50": "23-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Dec-2026",
                "predictedDateU50": "14-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "26-Jun-2026",
                "milestoneExtendedDate": "",
                "notes": "In October 2021, the phase III DESTINY-Breast11 trial (NCT05113251) of neoadjuvant trastuzumab deruxtecan monotherapy or trastuzumab deruxtecan followed by paclitaxel, trastuzumab and pertuzumab (THP) compared with standard of care regimen of doxorubicin and cyclophosphamide followed by THP in patients with high-risk HER2-positive early-stage breast cancer was expected to complete in June 2026 [ <ulink linkID=\"2588467\" linkType=\"Reference\">  2588467 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Dec-2020",
            "endDate": "16-Nov-2025",
            "statusDate": "25-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "68%",
            "timeToRegistration": "1.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "04-Dec-2020",
                "endDate": "31-Dec-2024",
                "successPercentage": "72%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2024",
                "endDate": "17-Oct-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Aug-2024",
                "predictedDateU50": "14-Apr-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Oct-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Jul-2025",
                "predictedDateU50": "16-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In December 2022, phase III data from DESTINY-Breast11 trial of trastuzumab deruxtecan in high-risk HER2+ early breast cancer patients were expected for 2024 [ <ulink linkID=\"2821003\" linkType=\"Reference\"> 2821003 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In December 2022, regulatory submission based on phase III (DESTINY-Breast11) data for neoadjuvant therapy in patients with high-risk HER2 positive early-stage breast cancer was expected for 2024 [ <ulink linkID=\"2821003\" linkType=\"Reference\"> 2821003 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "20-Jan-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "01-Mar-2026",
                "successPercentage": "23%",
                "predictedDateL50": "19-Nov-2023",
                "predictedDateU50": "15-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Mar-2026",
                "endDate": "20-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "17-Apr-2025",
                "predictedDateU50": "30-Jun-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Sep-2026",
                "predictedDateU50": "20-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2015",
            "endDate": "17-May-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "17%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Sep-2015",
                "endDate": "18-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "28-Jun-2026",
                "successPercentage": "19%",
                "predictedDateL50": "04-Dec-2023",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jun-2026",
                "endDate": "17-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "30-Jun-2025",
                "predictedDateU50": "13-Nov-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jan-2027",
                "predictedDateU50": "17-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, interim data from a phase II study (NCT04482309) in 267 patients with bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer were presented. In all patients, patients with cervical, endometrial, ovarian, bilary tract, pancreatic, bladder and other cancers, the overall response rate (ORR) based on investigator assessment was 37.1, 50, 57.5, 45, 22, 4, 39 and 30%; complete response was 5.6, 5, 17.5, 10, 2.4, 0, 2.4 and 0%; partial response was 31.5, 45, 40, 35, 19.5, 4, 36.6 and 30%; stable disease was 41.6, 27.5, 30, 32.5, 56.1, 6439 and 50%, progressive disease was 15.7, 17.5, 10, 17.5, 17.1, 28, 17.1 and 7.5%, disease control rate was 68.2, 67.5, 80, 70, 65.9, 36, 70.7 and 75%; ORR based on independent central review was 36.7, 40, 52.5, 42.5, 26.8, 12, 41.5 and 32.5%, respectively [ <ulink linkID=\"3021009\" linkType=\"Reference\"> 3021009 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "19-Jul-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "28-Jun-2026",
                "successPercentage": "20%",
                "predictedDateL50": "12-Dec-2023",
                "predictedDateU50": "15-May-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jun-2026",
                "endDate": "08-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "30-Jun-2025",
                "predictedDateU50": "13-Nov-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Feb-2027",
                "predictedDateU50": "19-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "760",
              "name": "Brain tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Aug-2018",
            "endDate": "23-Jul-2025",
            "statusDate": "22-Sep-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "50%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Aug-2018",
                "endDate": "17-Sep-2024",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Sep-2024",
                "endDate": "23-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "23-Feb-2024",
                "predictedDateU50": "19-Feb-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Mar-2025",
                "predictedDateU50": "23-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "01-Feb-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "22-Mar-2026",
                "successPercentage": "32%",
                "predictedDateL50": "27-Nov-2023",
                "predictedDateU50": "28-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2026",
                "endDate": "02-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "03-May-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Sep-2026",
                "predictedDateU50": "01-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "26-Jun-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "83%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "18-Aug-2026",
                "successPercentage": "31%",
                "predictedDateL50": "27-Nov-2023",
                "predictedDateU50": "28-May-2024",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Aug-2026",
                "endDate": "27-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "24-Jul-2025",
                "predictedDateU50": "04-Jan-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Feb-2027",
                "predictedDateU50": "26-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, interim data from a phase II study (NCT04482309) in 267 patients with bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer were presented. In all patients, patients with cervical, endometrial, ovarian, bilary tract, pancreatic, bladder and other cancers, the overall response rate (ORR) based on investigator assessment was 37.1, 50, 57.5, 45, 22, 4, 39 and 30%; complete response was 5.6, 5, 17.5, 10, 2.4, 0, 2.4 and 0%; partial response was 31.5, 45, 40, 35, 19.5, 4, 36.6 and 30%; stable disease was 41.6, 27.5, 30, 32.5, 56.1, 6439 and 50%, progressive disease was 15.7, 17.5, 10, 17.5, 17.1, 28, 17.1 and 7.5%, disease control rate was 68.2, 67.5, 80, 70, 65.9, 36, 70.7 and 75%; ORR based on independent central review was 36.7, 40, 52.5, 42.5, 26.8, 12, 41.5 and 32.5%, respectively [ <ulink linkID=\"3021009\" linkType=\"Reference\"> 3021009 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "20-Aug-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "17-Aug-2026",
                "successPercentage": "33%",
                "predictedDateL50": "27-Nov-2023",
                "predictedDateU50": "28-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2026",
                "endDate": "15-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "24-Jul-2025",
                "predictedDateU50": "05-Jan-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Apr-2027",
                "predictedDateU50": "20-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "07-Feb-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "37%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "19-Mar-2026",
                "successPercentage": "41%",
                "predictedDateL50": "28-Nov-2023",
                "predictedDateU50": "13-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Mar-2026",
                "endDate": "07-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "30-Apr-2025",
                "predictedDateU50": "22-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Sep-2026",
                "predictedDateU50": "07-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2015",
            "endDate": "25-Jun-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Sep-2015",
                "endDate": "18-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "07-Aug-2026",
                "successPercentage": "39%",
                "predictedDateL50": "28-Nov-2023",
                "predictedDateU50": "13-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Aug-2026",
                "endDate": "26-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Jul-2025",
                "predictedDateU50": "23-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Feb-2027",
                "predictedDateU50": "25-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, interim data from a phase II study (NCT04482309) in 267 patients with bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer were presented. In all patients, patients with cervical, endometrial, ovarian, bilary tract, pancreatic, bladder and other cancers, the overall response rate (ORR) based on investigator assessment was 37.1, 50, 57.5, 45, 22, 4, 39 and 30%; complete response was 5.6, 5, 17.5, 10, 2.4, 0, 2.4 and 0%; partial response was 31.5, 45, 40, 35, 19.5, 4, 36.6 and 30%; stable disease was 41.6, 27.5, 30, 32.5, 56.1, 6439 and 50%, progressive disease was 15.7, 17.5, 10, 17.5, 17.1, 28, 17.1 and 7.5%, disease control rate was 68.2, 67.5, 80, 70, 65.9, 36, 70.7 and 75%; ORR based on independent central review was 36.7, 40, 52.5, 42.5, 26.8, 12, 41.5 and 32.5%, respectively [ <ulink linkID=\"3021009\" linkType=\"Reference\"> 3021009 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "19-Aug-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "31-Jul-2026",
                "successPercentage": "39%",
                "predictedDateL50": "07-Dec-2023",
                "predictedDateU50": "16-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jul-2026",
                "endDate": "09-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Jul-2025",
                "predictedDateU50": "18-Dec-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2027",
                "predictedDateU50": "19-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Oct-2018",
            "endDate": "25-Jul-2027",
            "statusDate": "28-Mar-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "34%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Oct-2018",
                "endDate": "18-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "10-Apr-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Apr-2024",
                "endDate": "15-Sep-2026",
                "successPercentage": "38%",
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "18-Jun-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Sep-2026",
                "endDate": "25-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "26-Aug-2025",
                "predictedDateU50": "06-Feb-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2027",
                "predictedDateU50": "25-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Oct-2018",
            "endDate": "08-Sep-2027",
            "statusDate": "28-Mar-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Oct-2018",
                "endDate": "18-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "29-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Mar-2024",
                "endDate": "03-Sep-2026",
                "successPercentage": "39%",
                "predictedDateL50": "03-Jan-2024",
                "predictedDateU50": "08-Jun-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Sep-2026",
                "endDate": "02-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Aug-2025",
                "predictedDateU50": "25-Jan-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Apr-2027",
                "predictedDateU50": "08-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1814",
              "name": "Neoplastic meningitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Sep-2023",
            "endDate": "19-Dec-2030",
            "statusDate": "22-Sep-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "16%",
            "timeToRegistration": "7.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Sep-2023",
                "endDate": "22-Sep-2027",
                "successPercentage": "47%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Sep-2027",
                "endDate": "11-Feb-2030",
                "successPercentage": "35%",
                "predictedDateL50": "14-Oct-2026",
                "predictedDateU50": "12-Feb-2028",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-Feb-2030",
                "endDate": "19-Nov-2030",
                "successPercentage": "95%",
                "predictedDateL50": "30-Jan-2029",
                "predictedDateU50": "01-Jul-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Nov-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Aug-2030",
                "predictedDateU50": "19-Dec-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Sep-2027",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase II trial (NCT06058988; WOnDER-BT) for the treatment of brain cancer, recurrent glioblastoma, leptomeningeal metastasis was expected to complete in September 2027 [ <ulink linkID=\"3276016\" linkType=\"Reference\"> 3276016 </ulink>].  </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2454",
              "name": "Glioblastoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Sep-2023",
            "endDate": "09-Nov-2030",
            "statusDate": "22-Sep-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "6.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Sep-2023",
                "endDate": "22-Sep-2027",
                "successPercentage": "37%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Sep-2027",
                "endDate": "15-Jan-2030",
                "successPercentage": "29%",
                "predictedDateL50": "06-Dec-2026",
                "predictedDateU50": "18-Jan-2028",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jan-2030",
                "endDate": "04-Oct-2030",
                "successPercentage": "92%",
                "predictedDateL50": "17-Jan-2029",
                "predictedDateU50": "02-Jun-2030",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Oct-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jul-2030",
                "predictedDateU50": "09-Nov-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Sep-2027",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase II trial (NCT06058988; WOnDER-BT) for the treatment of brain cancer, recurrent glioblastoma, leptomeningeal metastasis was expected to complete in September 2027 [ <ulink linkID=\"3276016\" linkType=\"Reference\"> 3276016 </ulink>].  </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "20-Jan-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "32%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "08-Mar-2026",
                "successPercentage": "36%",
                "predictedDateL50": "10-Dec-2023",
                "predictedDateU50": "15-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Mar-2026",
                "endDate": "21-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "23-Apr-2025",
                "predictedDateU50": "09-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Sep-2026",
                "predictedDateU50": "20-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "23-May-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "28%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "10-Jul-2026",
                "successPercentage": "31%",
                "predictedDateL50": "10-Dec-2023",
                "predictedDateU50": "15-May-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Jul-2026",
                "endDate": "23-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "04-Jul-2025",
                "predictedDateU50": "30-Nov-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Jan-2027",
                "predictedDateU50": "23-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, interim data from a phase II study (NCT04482309) in 267 patients with bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer were presented. In all patients, patients with cervical, endometrial, ovarian, bilary tract, pancreatic, bladder and other cancers, the overall response rate (ORR) based on investigator assessment was 37.1, 50, 57.5, 45, 22, 4, 39 and 30%; complete response was 5.6, 5, 17.5, 10, 2.4, 0, 2.4 and 0%; partial response was 31.5, 45, 40, 35, 19.5, 4, 36.6 and 30%; stable disease was 41.6, 27.5, 30, 32.5, 56.1, 6439 and 50%, progressive disease was 15.7, 17.5, 10, 17.5, 17.1, 28, 17.1 and 7.5%, disease control rate was 68.2, 67.5, 80, 70, 65.9, 36, 70.7 and 75%; ORR based on independent central review was 36.7, 40, 52.5, 42.5, 26.8, 12, 41.5 and 32.5%, respectively [ <ulink linkID=\"3021009\" linkType=\"Reference\"> 3021009 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "29-Jul-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "20-Jul-2026",
                "successPercentage": "34%",
                "predictedDateL50": "10-Dec-2023",
                "predictedDateU50": "15-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jul-2026",
                "endDate": "20-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "10-Jul-2025",
                "predictedDateU50": "09-Dec-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Mar-2027",
                "predictedDateU50": "29-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "05-Mar-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "30-Sep-2015",
            "endDate": "25-May-2027",
            "statusDate": "28-Mar-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "69%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Sep-2015",
                "endDate": "23-Feb-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "23-Feb-2018",
                "endDate": "16-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jul-2024",
                "endDate": "16-Aug-2026",
                "successPercentage": "77%",
                "predictedDateL50": "07-Mar-2024",
                "predictedDateU50": "19-Oct-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Aug-2026",
                "endDate": "17-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "17-Sep-2025",
                "predictedDateU50": "19-Dec-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jan-2027",
                "predictedDateU50": "25-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, trial top line results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in 86 patients with HER2 expressing metastatic colorectal cancer were presented. In cohort A (HER+), cohort B (HER2 immunohistochemistry (IHC2)+/in situ hybridization (ISH)-) and cohort C (HER2 IHC+) (n = 53, 15 and 18), confirmed objective response rate (ORR) by independent central review was 45.3 (primary endpoint), 0 and 0%; complete response rate was 0% each, partial response rate was 45.3, 0 and 0%, stable disease rate was 37.7, 60.0 and 22.2%, progressive disease rate was 9.4, 33.3 and 55.6%, disease control rate was 83.0, 60.0 and 22.2%, median duration of response was 7 months and not evaluable in the other two groups, median treatment duration was 5.1, 2.1 and 1.4 months, median progression free survival was 6.9, 2.1 and 1.4 months, and median overall survival was 15.5, 7.3 and 7.7 months, respectively [ <ulink linkID=\"2469573\" linkType=\"Reference\">  2469573 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, final results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in 86 patients with HER2 expressing metastatic colorectal cancer were presented. In cohort A (HER+), cohort B (HER2 immunohistochemistry (IHC2)+/in situ hybridization (ISH)-) and cohort C (HER2 IHC+) (n = 53, 15 and 18), confirmed objective response rate (ORR) by independent central review was 45.3 (primary endpoint), 0 and 0%; complete response rate was 0% each, partial response rate was 45.3, 0 and 0%, stable disease rate was 37.7, 60.0 and 22.2%, progressive disease rate was 9.4, 33.3 and 55.6%, disease control rate was 83.0, 60.0 and 22.2%, median duration of response was 7 months and not evaluable in the other two groups, median treatment duration was 5.1, 2.1 and 1.4 months, median progression free survival was 6.9, 2.1 and 1.4 months, and median overall survival was 15.5, 7.3 and 7.7 months, respectively [ <ulink linkID=\"2469573\" linkType=\"Reference\">  2469573 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, first data from phase II trial of trastuzumab deruxtecan was reported at ASCO for the third-line treatment of HER2+ metastatic colorectal cancer [ <ulink linkID=\"3028827\" linkType=\"Reference\"> 3028827 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2023",
                "milestoneExtendedDate": "31-Aug-2023",
                "notes": "In March 2021, a randomized, parallel-assignment, double-blind, phase II trial (NCT04744831; DS8201-A-U207; 2020-004782-39; DESTINY-CRC02) was initiated in the US, Australia, Europe, Japan, Korea and Taiwan to assess trastuzumab deruxtecan in subjects (expected n = 120) with locally advanced, unresectable, or metastatic HER2-overexpressing colorectal cancer (CRC) of BRAF wild-type and either RAS wild-type or mutant tumor type, previously treated with standard therapy. The primary endpoint was change in confirmed objective response rate (ORR). The trial was expected to complete in August 2023 [ <ulink linkID=\"2432843\" linkType=\"Reference\"> 2432843 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "31-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the drug was granted Breakthrough Therapy Designation in the US for the treatment of patients with HER2 positive (IHC 3+) metastatic CRC who have received two or more prior regimens based on results from DESTINY-CRC01 and DESTINY-CRC02 phase II trials [ <ulink linkID=\"3062960\" linkType=\"Reference\"> 3062960 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In September 2023, a phase II trial ( NCT04744831; DESTINY-CRC02) was expected to complete in July 2024 [ <ulink linkID=\"2432843\" linkType=\"Reference\"> 2432843 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Feb-2018",
            "endDate": "20-Nov-2027",
            "statusDate": "28-Mar-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Feb-2018",
                "endDate": "16-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jul-2024",
                "endDate": "08-Nov-2026",
                "successPercentage": "23%",
                "predictedDateL50": "07-Mar-2024",
                "predictedDateU50": "19-Oct-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Nov-2026",
                "endDate": "11-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "10-Nov-2025",
                "predictedDateU50": "26-Mar-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jun-2027",
                "predictedDateU50": "20-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, trial top line results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in 86 patients with HER2 expressing metastatic colorectal cancer were presented. In cohort A (HER+), cohort B (HER2 immunohistochemistry (IHC2)+/in situ hybridization (ISH)-) and cohort C (HER2 IHC+) (n = 53, 15 and 18), confirmed objective response rate (ORR) by independent central review was 45.3 (primary endpoint), 0 and 0%; complete response rate was 0% each, partial response rate was 45.3, 0 and 0%, stable disease rate was 37.7, 60.0 and 22.2%, progressive disease rate was 9.4, 33.3 and 55.6%, disease control rate was 83.0, 60.0 and 22.2%, median duration of response was 7 months and not evaluable in the other two groups, median treatment duration was 5.1, 2.1 and 1.4 months, median progression free survival was 6.9, 2.1 and 1.4 months, and median overall survival was 15.5, 7.3 and 7.7 months, respectively [ <ulink linkID=\"2469573\" linkType=\"Reference\">  2469573 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, final results of phase II trial (NCT03384940) of trastuzumab deruxtecan  in 86 patients with HER2 expressing metastatic colorectal cancer were presented. In cohort A (HER+), cohort B (HER2 immunohistochemistry (IHC2)+/in situ hybridization (ISH)-) and cohort C (HER2 IHC+) (n = 53, 15 and 18), confirmed objective response rate (ORR) by independent central review was 45.3 (primary endpoint), 0 and 0%; complete response rate was 0% each, partial response rate was 45.3, 0 and 0%, stable disease rate was 37.7, 60.0 and 22.2%, progressive disease rate was 9.4, 33.3 and 55.6%, disease control rate was 83.0, 60.0 and 22.2%, median duration of response was 7 months and not evaluable in the other two groups, median treatment duration was 5.1, 2.1 and 1.4 months, median progression free survival was 6.9, 2.1 and 1.4 months, and median overall survival was 15.5, 7.3 and 7.7 months, respectively [ <ulink linkID=\"2469573\" linkType=\"Reference\">  2469573 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Other Outcome",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, first data from phase II trial of trastuzumab deruxtecan was reported at ASCO for the third-line treatment of HER2+ metastatic colorectal cancer [ <ulink linkID=\"3028827\" linkType=\"Reference\"> 3028827 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2023",
                "milestoneExtendedDate": "31-Aug-2023",
                "notes": "In March 2021, a randomized, parallel-assignment, double-blind, phase II trial (NCT04744831; DS8201-A-U207; 2020-004782-39; DESTINY-CRC02) was initiated in the US, Australia, Europe, Japan, Korea and Taiwan to assess trastuzumab deruxtecan in subjects (expected n = 120) with locally advanced, unresectable, or metastatic HER2-overexpressing colorectal cancer (CRC) of BRAF wild-type and either RAS wild-type or mutant tumor type, previously treated with standard therapy. The primary endpoint was change in confirmed objective response rate (ORR). The trial was expected to complete in August 2023 [<ulink linkType=\"Reference\" linkID=\"2432843\">2432843</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In September 2023, a phase II trial ( NCT04744831; DESTINY-CRC02) was expected to complete in July 2024 [ <ulink linkID=\"2432843\" linkType=\"Reference\"> 2432843 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "19-Mar-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Mar-2021",
            "endDate": "19-Jun-2025",
            "statusDate": "28-Oct-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Mar-2021",
                "endDate": "28-Oct-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "18-Aug-2024",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Aug-2024",
                "endDate": "16-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "13-May-2024",
                "predictedDateU50": "20-Oct-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Feb-2025",
                "predictedDateU50": "19-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2022, data fromphase II DESTINY-LUNG02 trial NCT04644237) of trastuzumab deruxtecan in patients with HER2-mutated metastatic non-small cell lung cancer were expected in 2023 [  <ulink linkID=\"2612948\" linkType=\"Reference\">  2612948  </ulink> ]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Sep-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In March 2021, the phase II DESTINY-LUNG02 trial NCT04644237) of trastuzumab deruxtecan in patients with HER2-mutated metastatic non-small cell lung cancer was expected to complete in September 2023 [<ulink linkType=\"Reference\" linkID=\"2428957\">2428957</ulink>], [<ulink linkType=\"Reference\" linkID=\"2427722\">2427722</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "11-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, positive results of a phase II DESTINY-Lung01 trial (NCT04644237) of trastuzumab deruxtecan in 152 patients with HER2-mutant metastatic NSCLC were presented. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), confirmed objective response rate by blinded independent central review (BICR) was 49.0 and 56.0%, median duration of response by BICR was 16.8 month and not estimable, and median progression-free survival by BICR was 9.9 and 15.4 month, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median overall survival were 19.5 month and not estimable, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median treatment duration were 7.7 and 8.3 month, respectively [ <ulink linkID=\"3203411\" linkType=\"Reference\"> 3203411 </ulink>], [ <ulink linkID=\"3156877\" linkType=\"Reference\"> 3156877 </ulink>], [ <ulink linkID=\"3159028\" linkType=\"Reference\"> 3159028 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, positive results of a phase II DESTINY-Lung01 trial (NCT04644237) of trastuzumab deruxtecan in 152 patients with HER2-mutant metastatic NSCLC were presented. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), confirmed objective response rate by blinded independent central review (BICR) was 49.0 and 56.0%, median duration of response by BICR was 16.8 month and not estimable, and median progression-free survival by BICR was 9.9 and 15.4 month, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median overall survival were 19.5 month and not estimable, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median treatment duration were 7.7 and 8.3 month, respectively [ <ulink linkID=\"3203411\" linkType=\"Reference\"> 3203411 </ulink>], [ <ulink linkID=\"3156877\" linkType=\"Reference\"> 3156877 </ulink>], [ <ulink linkID=\"3159028\" linkType=\"Reference\"> 3159028 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-May-2018",
            "endDate": "23-Oct-2023",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "21-May-2018",
                "endDate": "28-Oct-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "28-Oct-2021",
                "endDate": "31-Dec-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2022",
                "endDate": "23-Oct-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Oct-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2020",
                "milestoneExtendedDate": "31-May-2020",
                "notes": "In May 2020, interim data from the phase II DESTINY-Lung01 trial in patients with HER2-positive metastatic NSCLC were expected later that month [<ulink linkType=\"Reference\" linkID=\"2278999\">2278999</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Sep-2021",
                "notes": "In August 2020, Daiichi expected further data in fiscal 1H21 from the phase II trial (NCT03505710; DESTINY-Lung01) assessing trastuzumab deruxtecan in HER2-mutant and HER2-positive unresectable and/or metastatic non-small cell lung cancer [<ulink linkType=\"Reference\" linkID=\"2351225\">2351225</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Skip Phase",
                "status": "Granted",
                "milestoneDate": "31-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "By December 2022, a regulatory filing was submitted in EU for trastuzumab deruxtecan for the second-line treatment of adult patients with HER2-mutant unresectable advanced or recurrent NSCLC based on phase II Destiny-Lung01 results. No phase III have been conducted for such indication in EU [ <ulink linkID=\"2821003\" linkType=\"Reference\"> 2821003 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "By December 2022, a regulatory decision was expected for trastuzumab deruxtecan in second-line treatment of patients with HER2 mutation NSCLC was expected for 2H23 [ <ulink linkID=\"2821003\" linkType=\"Reference\"> 2821003 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Sep-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In March 2021, the phase II DESTINY-LUNG02 trial NCT04644237) of trastuzumab deruxtecan in patients with HER2-mutated metastatic non-small cell lung cancer was expected to complete in September 2023 [<ulink linkType=\"Reference\" linkID=\"2428957\">2428957</ulink>], [<ulink linkType=\"Reference\" linkID=\"2427722\">2427722</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "11-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, positive results of a phase II DESTINY-Lung01 trial (NCT04644237) of trastuzumab deruxtecan in 152 patients with HER2-mutant metastatic NSCLC were presented. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), confirmed objective response rate by blinded independent central review (BICR) was 49.0 and 56.0%, median duration of response by BICR was 16.8 month and not estimable, and median progression-free survival by BICR was 9.9 and 15.4 month, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median overall survival were 19.5 month and not estimable, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median treatment duration were 7.7 and 8.3 month, respectively [ <ulink linkID=\"3203411\" linkType=\"Reference\"> 3203411 </ulink>], [ <ulink linkID=\"3156877\" linkType=\"Reference\"> 3156877 </ulink>], [ <ulink linkID=\"3159028\" linkType=\"Reference\"> 3159028 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, positive results of a phase II DESTINY-Lung01 trial (NCT04644237) of trastuzumab deruxtecan in 152 patients with HER2-mutant metastatic NSCLC were presented. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), confirmed objective response rate by blinded independent central review (BICR) was 49.0 and 56.0%, median duration of response by BICR was 16.8 month and not estimable, and median progression-free survival by BICR was 9.9 and 15.4 month, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median overall survival were 19.5 month and not estimable, respectively. In patients treated with trastuzumab deruxtecan (5.4 and 6.4 mg/kg), median treatment duration were 7.7 and 8.3 month, respectively [ <ulink linkID=\"3203411\" linkType=\"Reference\"> 3203411 </ulink>], [ <ulink linkID=\"3156877\" linkType=\"Reference\"> 3156877 </ulink>], [ <ulink linkID=\"3159028\" linkType=\"Reference\"> 3159028 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "10-May-2022",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": "1017506",
              "name": "Daiichi Sankyo Co Ltd"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "07-Feb-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "46%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "22-Mar-2026",
                "successPercentage": "51%",
                "predictedDateL50": "29-Nov-2023",
                "predictedDateU50": "13-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2026",
                "endDate": "08-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "03-May-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Sep-2026",
                "predictedDateU50": "07-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [ 2846848 ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2015",
            "endDate": "07-Jun-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "39%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Sep-2015",
                "endDate": "18-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "21-Jul-2026",
                "successPercentage": "43%",
                "predictedDateL50": "29-Nov-2023",
                "predictedDateU50": "13-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jul-2026",
                "endDate": "08-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-Jul-2025",
                "predictedDateU50": "06-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jan-2027",
                "predictedDateU50": "07-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [ 2846848 ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, interim data from a phase II study (NCT04482309) in 267 patients with bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer were presented. In all patients, patients with cervical, endometrial, ovarian, bilary tract, pancreatic, bladder and other cancers, the overall response rate (ORR) based on investigator assessment was 37.1, 50, 57.5, 45, 22, 4, 39 and 30%; complete response was 5.6, 5, 17.5, 10, 2.4, 0, 2.4 and 0%; partial response was 31.5, 45, 40, 35, 19.5, 4, 36.6 and 30%; stable disease was 41.6, 27.5, 30, 32.5, 56.1, 6439 and 50%, progressive disease was 15.7, 17.5, 10, 17.5, 17.1, 28, 17.1 and 7.5%, disease control rate was 68.2, 67.5, 80, 70, 65.9, 36, 70.7 and 75%; ORR based on independent central review was 36.7, 40, 52.5, 42.5, 26.8, 12, 41.5 and 32.5%, respectively [ <ulink linkID=\"3021009\" linkType=\"Reference\"> 3021009 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "11-Aug-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "42%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "26-Jul-2026",
                "successPercentage": "46%",
                "predictedDateL50": "10-Dec-2023",
                "predictedDateU50": "17-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jul-2026",
                "endDate": "01-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Jul-2025",
                "predictedDateU50": "10-Dec-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Mar-2027",
                "predictedDateU50": "11-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [ 2846848 ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "21-Jan-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "36%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "22-Mar-2026",
                "successPercentage": "40%",
                "predictedDateL50": "08-Dec-2023",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2026",
                "endDate": "19-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "03-May-2025",
                "predictedDateU50": "26-Jul-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Sep-2026",
                "predictedDateU50": "21-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "30-Sep-2015",
            "endDate": "14-Jan-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "3.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Sep-2015",
                "endDate": "18-Aug-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "22-Apr-2026",
                "successPercentage": "85%",
                "predictedDateL50": "08-Dec-2023",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Apr-2026",
                "endDate": "15-Dec-2026",
                "successPercentage": "95%",
                "predictedDateL50": "12-May-2025",
                "predictedDateU50": "27-Aug-2026",
                "phaseDuration": "0.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Dec-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Sep-2026",
                "predictedDateU50": "14-Jan-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Jan-2018",
                "milestoneExtendedDate": "",
                "notes": "In January 2018, updated safety and efficacy data from a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab and chemotherapy from the phase I study (NCT02564900) were presented. Updated preliminary subgroup analysis results in 44 of 45 efficacy evaluable patients showed that trastuzumab deruxtecan demonstrated an objective response rate of 45.5% and a disease control rate of 81.8%. Median duration of response was 7.0 months and median progression-free survival was 5.8 months. A total of 17 out of 44 patients were continuing to receive treatment at the time of data cut-off. A subgroup analysis of 23 patients previously treated with CPT-11 showed that DS-8201 demonstrated a confirmed an objective response rate of 43.5% and a disease control rate of 82.6%. Median duration of response was 6.9 months and median progression-free survival for this subgroup of patients was 4.1 months. Updated preliminary safety data for this subgroup of trastuzumab-treated HER2-expressing gastric cancer patients were also reported [ <ulink linkID=\"1998179\" linkType=\"Reference\"> 1998179 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-Jun-2018",
                "milestoneExtendedDate": "",
                "notes": "In June 2018, long-term results from the phase I trial (NCT02564900) in patients with advanced solid malignant tumors were presented. In part 2a, 2b, 2c and 2d subgroups, the proportion of patients with confirmed overall response rate were 54.5, 43.2, 50.0 and 38.7%, respectively; and disease control rate were 93.9, 79.5, 85.3 and 83.9%, respectively. In overall study population, the most frequent grade &gt;/= 3 TEAEs occurring &gt;/=10% were anemia and decreased platelet, neutrophils, and WBCs in 14.9, 10.4, 15.4 and 12.4%, respectively [ <ulink linkID=\"2044510\" linkType=\"Reference\"> 2044510 </ulink>] [ <ulink linkID=\"2040482\" linkType=\"Reference\"> 2040482 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "31-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the drug was granted Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors that have progressed following prior treatment and who have no alternative treatment option based on results from the DESTINY-PanTumor02 phase II trial [ <ulink linkID=\"3062960\" linkType=\"Reference\"> 3062960 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "02-Aug-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "34%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "07-Aug-2026",
                "successPercentage": "38%",
                "predictedDateL50": "15-Dec-2023",
                "predictedDateU50": "16-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Aug-2026",
                "endDate": "21-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Jul-2025",
                "predictedDateU50": "23-Dec-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Mar-2027",
                "predictedDateU50": "02-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "14-Feb-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "40%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "27-Mar-2026",
                "successPercentage": "44%",
                "predictedDateL50": "28-Nov-2023",
                "predictedDateU50": "13-May-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2026",
                "endDate": "14-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "08-May-2025",
                "predictedDateU50": "31-Jul-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Sep-2026",
                "predictedDateU50": "14-Feb-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "19-Jun-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "33%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "01-Aug-2026",
                "successPercentage": "37%",
                "predictedDateL50": "28-Nov-2023",
                "predictedDateU50": "13-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Aug-2026",
                "endDate": "20-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "13-Jul-2025",
                "predictedDateU50": "18-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Feb-2027",
                "predictedDateU50": "19-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [ <ulink linkID=\"2350936\" linkType=\"Reference\"> 2350936 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, interim data from a phase II study (NCT04482309) in 267 patients with bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer were presented. In all patients, patients with cervical, endometrial, ovarian, bilary tract, pancreatic, bladder and other cancers, the overall response rate (ORR) based on investigator assessment was 37.1, 50, 57.5, 45, 22, 4, 39 and 30%; complete response was 5.6, 5, 17.5, 10, 2.4, 0, 2.4 and 0%; partial response was 31.5, 45, 40, 35, 19.5, 4, 36.6 and 30%; stable disease was 41.6, 27.5, 30, 32.5, 56.1, 6439 and 50%, progressive disease was 15.7, 17.5, 10, 17.5, 17.1, 28, 17.1 and 7.5%, disease control rate was 68.2, 67.5, 80, 70, 65.9, 36, 70.7 and 75%; ORR based on independent central review was 36.7, 40, 52.5, 42.5, 26.8, 12, 41.5 and 32.5%, respectively [ <ulink linkID=\"3021009\" linkType=\"Reference\"> 3021009 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Aug-2020",
            "endDate": "26-Aug-2027",
            "statusDate": "18-Aug-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "36%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Aug-2020",
                "endDate": "05-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-Mar-2024",
                "endDate": "07-Aug-2026",
                "successPercentage": "40%",
                "predictedDateL50": "07-Dec-2023",
                "predictedDateU50": "16-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Aug-2026",
                "endDate": "16-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Jul-2025",
                "predictedDateU50": "23-Dec-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Mar-2027",
                "predictedDateU50": "26-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase II trial (NCT04482309) in HER2 expressing tumors demonstrating good efficacy in objective response rate (ORR) in patients with multiple HER2-expressing advanced solid tumors were reported [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase II trial (NCT04482309) in HER2 expressing tumors were met [  <ulink linkID=\"2846848\" linkType=\"Reference\">  2846848 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "20-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the phase II DESTINY-PanTumor02 trial (NCT04482309) in selected advanced/metastatic HER2-expressing tumors, including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and rare tumors was expected to complete in March 2023 [<ulink linkType=\"Reference\" linkID=\"2350936\">2350936</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "99602",
        "displayName": "lutetium (177Lu) vipivotide tetraxetan",
        "drugPrograms": [
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "276",
              "name": "Prostate tumor"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2022",
            "endDate": "05-May-2027",
            "statusDate": "31-Jan-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "85%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2022",
                "endDate": "05-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "05-May-2024",
                "endDate": "15-Jun-2026",
                "successPercentage": "94%",
                "predictedDateL50": "05-Jan-2024",
                "predictedDateU50": "18-Jul-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "15-Jun-2026",
                "endDate": "04-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jul-2025",
                "predictedDateU50": "20-Oct-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Dec-2026",
                "predictedDateU50": "05-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "designation": "Breakthrough Therapy, Priority Review",
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Mar-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "02-Nov-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "05-Aug-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2024",
                "endDate": "05-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "08-Feb-2024",
                "predictedDateU50": "14-Dec-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Apr-2025",
                "predictedDateU50": "02-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "19-Jul-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "05-Aug-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2024",
                "endDate": "05-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "11-Feb-2024",
                "predictedDateU50": "08-Dec-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Feb-2025",
                "predictedDateU50": "19-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "10-May-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "31-May-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-May-2024",
                "endDate": "31-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "30-Jan-2024",
                "predictedDateU50": "09-Sep-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Dec-2024",
                "predictedDateU50": "10-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "23-Sep-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "27-Aug-2024",
                "successPercentage": "90%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Aug-2024",
                "endDate": "13-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "14-Jan-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Apr-2025",
                "predictedDateU50": "23-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jul-2018",
            "endDate": "05-Oct-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2018",
                "endDate": "09-Jun-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "03-Sep-2024",
                "successPercentage": "90%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Sep-2024",
                "endDate": "28-Aug-2025",
                "successPercentage": "95%",
                "predictedDateL50": "17-Feb-2024",
                "predictedDateU50": "29-Jan-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Apr-2025",
                "predictedDateU50": "05-Oct-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Compassionate Use",
                "status": "Positive Opinion",
                "milestoneDate": "08-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, the UK MHRA granted positive scientific opinion for use in eligible patients with advanced prostate cancer [ <ulink linkID=\"2648400\" linkType=\"Reference\">  2648400 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jul-2018",
            "endDate": "",
            "statusDate": "01-Jul-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Jul-2017",
            "endDate": "01-Feb-2024",
            "statusDate": "31-Mar-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Jul-2017",
                "endDate": "23-May-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-May-2018",
                "endDate": "31-Mar-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Mar-2023",
                "endDate": "02-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Dec-2023",
                "predictedDateU50": "01-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2022, data readout from the PSMAfore trial in patients with mCRPC in a pre-taxane setting was expected in 2022 [ <ulink linkID=\"2705239\" linkType=\"Reference\"> 2705239 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Clinical hold",
                "status": "Negative Outcome",
                "milestoneDate": "05-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, clinical trials were kept on hold in the US [ <ulink linkID=\"2664659\" linkType=\"Reference\">  2664659 </ulink> ].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, positive topline data from a phase Ib trial (NCT03805594) of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in patients with mCRPC were presented. Among all evaluable patients (n = 43), ORR (primary endpoint) was 51% and median duration of response (DOR) was 5.6 months. In part A (n = 18), the most commonly reported grade 1 treatment-related adverse events (TRAEs) were nausea (28%), fatigue (17%), decreased appetite (17%), muscle/joint pain (22%), diarrhea (11%), dry mouth (17%), skin rash (11%), neutropenia (6%), and thrombocytopenia (6%); grade 2 TRAEs were nausea (11%), fatigue (6%), decreased appetite (6%), and muscle pain (17%); grade 3 TRAE was joint/muscle pain (6%) [ <ulink linkID=\"2748341\" linkType=\"Reference\">  2748341 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "11-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, the primary endpoint of a phase Ib trial (NCT03805594) of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in patients with mCRPC was met. Among all evaluable patients (n = 43), ORR (primary endpoint) was 51%me, with a median duration of response (DOR) of 5.6 months [ <ulink linkID=\"2748341\" linkType=\"Reference\">  2748341 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In September 2022, data from the trial in metastatic castration-resistant prostate cancer were expected in late 2022/early 2023 [  <ulink linkID=\"2737527\" linkType=\"Reference\">  2737527  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, topline results from a phase III trial (NCT04689828) in patients with metastatic castrate resistant prostate cancer were presented [ <ulink linkID=\"2784701\" linkType=\"Reference\">  2784701 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In September 2022, data from the trial in metastatic castration-resistant prostate cancer were expected in late 2022/early 2023 [ <ulink linkID=\"2737527\" linkType=\"Reference\"> 2737527 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "31-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In 1Q23, the filing has been submitted to the US FDA for expedited review, in adult patients with mCRPC pre-taxane setting [ <ulink linkID=\"2909028\" linkType=\"Reference\"> 2909028 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive data from the phase III trial (NCT03511664) in PSMA-positive mCRPC were published. Median time to first symptomatic skeletal event or death was 11.5 months in the treatment group, compared with 6.8 months for placebo [ <ulink linkID=\"3038029\" linkType=\"Reference\"> 3038029 </ulink>], [ <ulink linkID=\"3127260\" linkType=\"Reference\"> 3127260 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In April 2023, further data from the phase III trial (NCT04689828; PSMAfore) for the treatment of mCRPC in pre-taxane setting was planned to be presented in 2H23 [ <ulink linkID=\"2909066\" linkType=\"Reference\"> 2909066 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, a phase III trial (NCT03511664) in PSMA-positive mCRPC was expected to complete in December 2023 [ <ulink linkID=\"2033313\" linkType=\"Reference\"> 2033313 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "24-Aug-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "07-Jul-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Jul-2024",
                "endDate": "07-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "02-Feb-2024",
                "predictedDateU50": "03-Nov-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Mar-2025",
                "predictedDateU50": "24-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "12-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, an IND was filed in China [ <ulink linkID=\"2591284\" linkType=\"Reference\">  2591284 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "18-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, an implied trial approval was granted for the treatment of adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with standard treatment based on androgen deprivation therapy (ADT) and androgen receptor inhibitor (ARDT) in China [ <ulink linkID=\"2623580\" linkType=\"Reference\">  2623580 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "22-May-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "85%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "05-Jul-2024",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Jul-2024",
                "endDate": "21-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "31-Oct-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jan-2025",
                "predictedDateU50": "22-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "19-Mar-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "03-May-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-May-2024",
                "endDate": "16-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "19-Jan-2024",
                "predictedDateU50": "27-Jul-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Nov-2024",
                "predictedDateU50": "19-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "09-Aug-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "85%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "12-Aug-2024",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Aug-2024",
                "endDate": "30-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Feb-2024",
                "predictedDateU50": "23-Dec-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Mar-2025",
                "predictedDateU50": "09-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2021",
            "endDate": "08-Aug-2025",
            "statusDate": "09-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Jun-2021",
                "endDate": "08-Aug-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2024",
                "endDate": "04-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Feb-2024",
                "predictedDateU50": "16-Dec-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Mar-2025",
                "predictedDateU50": "08-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (NL)"
            },
            "principalCompany": {
              "id": "1017958",
              "name": "Advanced Accelerator Applications SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "01-Jul-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "26000",
              "name": "Endocyte Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "23137",
              "name": "Novartis AG"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Mar-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "100250",
        "displayName": "mavorixafor (cancer/WHIM syndrome), X4 Pharmaceuticals",
        "drugPrograms": [
          {
            "company": {
              "id": "1060643",
              "name": "X4 Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1743",
              "name": "Lymphoplasmacytic lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (GR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Apr-2000",
            "endDate": "",
            "statusDate": "30-Apr-2000",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Apr-2000",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1060643",
              "name": "X4 Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1743",
              "name": "Lymphoplasmacytic lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Dec-2019",
            "endDate": "16-Feb-2028",
            "statusDate": "30-Dec-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "51%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Dec-2019",
                "endDate": "03-Nov-2024",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Nov-2024",
                "endDate": "21-Mar-2027",
                "successPercentage": "78%",
                "predictedDateL50": "22-Feb-2024",
                "predictedDateU50": "17-May-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Mar-2027",
                "endDate": "14-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "11-Mar-2026",
                "predictedDateU50": "09-Aug-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Sep-2027",
                "predictedDateU50": "16-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-May-2021",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, first efficacy and safety data (as of cut-off date of January 22, 2021) were reported from a small initial cohort of seven patients with waldenstrom's macroglobulinemia whose tumors express mutations in MYD88 and CXCR4 in an ongoing phase Ib study (NCT04274738) of mavorixafor in combination with ibrutinib. All the patients were successfully escalated from the starting dose of 200 mg mavorixafor to 400 mg, with one patient de-escalating to 200 mg following to an observed adverse event. No observed adverse events led to study discontinuation and no serious adverse events were identified. All the four patients who were treated for &gt;/= three 28-day treatment cycles experienced rapid and clinically meaningful decreases in IgM levels, achieving a median decrease in serum IgM of 51.0% and increased peripheral WBC counts. Six patients showed a decrease in IgM after 1 cycle [ <ulink linkID=\"2452966\" linkType=\"Reference\">  2452966 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, the FDA granted Orphan Drug Designation for Waldenstrom macroglobulinemia (WM) [ <ulink linkID=\"2707690\" linkType=\"Reference\">  2707690 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In August 2021, high-dose data and clinical response outcome data were expected from the phase Ib trial in  Waldenstrom macroglobulinemia in 4Q22 [ <ulink linkID=\"2503907\" linkType=\"Reference\">  2503907 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In March 2021, a phase Ib study (NCT04274738) of mavorixafor in combination with ibrutinib in patients with Waldenstrom's macroglobulinemia whose tumors express mutations in MYD88 and CXCR4 was expected to complete in December 2022 [ <ulink linkID=\"2459310\" linkType=\"Reference\">  2459310 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1060643",
              "name": "X4 Pharmaceuticals Inc"
            },
            "indication": {
              "id": "5561",
              "name": "WHIM syndrome"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Oct-2019",
            "endDate": "08-Dec-2024",
            "statusDate": "21-Jun-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Oct-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "02-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "29-Aug-2023",
                "predictedDateU50": "26-Mar-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Jul-2024",
                "predictedDateU50": "08-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In december 2020, result from a phase III trial (<ulink linkType=\"Protocol\" linkID=\"385458\">NCT03995108</ulink>)   in patients with WHIM syndrome were expected in 2022 [<ulink linkType=\"Reference\" linkID=\"2376430\">2376430</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Oct-2022",
                "notes": "In November 2020, the phase III trial (NCT03995108) was expected to complete in October 2022  in patients with WHIM syndrome [<ulink linkType=\"Reference\" linkID=\"2168491\">2168491</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline were demonstrating that the phase III 4WHIM trial met its primary endpoint of increase in absolute neutrophil counts (ANC) above 500 cells per ml (severe neutropenia) over 24-h periods at four time points throughout the 52-week trial, with mean TAT (ANC) of 15.04 h for mavorixafor versus 2.75 h in for placebo (p &lt;0.0001) [  <ulink linkID=\"2782375\" linkType=\"Reference\">  2782375 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline were demonstrating that the phase III 4WHIM trial met its primary endpoint of increase in absolute neutrophil counts (ANC) above 500 cells per ml (severe neutropenia) over 24-h periods at four time points throughout the 52-week trial, with mean TAT (ANC) of 15.04 h for mavorixafor versus 2.75 h in for placebo (p &lt;0.0001) [  <ulink linkID=\"2782375\" linkType=\"Reference\">  2782375 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03995108) in WHIM syndrome demonstrating statistically significant reduction of approximately 60% in annualized infection rate versus placebo (p&lt;0.01) with reduction greater with time on treatment of less than one year, 7% patients with a grade 3 or higher infection and reduction of infections by more than 70%, both as compared with placebo, and 40% lower total infection score along with good safety and well tolerability were reported [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "15-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, further data from the phase III trial (NCT03995108) in WHIM syndrome were expected in June 2023 [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1060643",
              "name": "X4 Pharmaceuticals Inc"
            },
            "indication": {
              "id": "5561",
              "name": "WHIM syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy, Fast Track, Rare Pediatric Disease, Priority Review",
            "startDate": "24-Oct-2019",
            "endDate": "24-Jun-2024",
            "statusDate": "05-Sep-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Oct-2019",
                "endDate": "05-Sep-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Sep-2023",
                "endDate": "14-May-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2024",
                "predictedDateU50": "24-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "12-Nov-2019",
                "milestoneExtendedDate": "",
                "notes": "In November 2019, the FDA granted Breakthrough Therapy Designation for adult patients with WHIM syndrome [ <ulink linkID=\"2216886\" linkType=\"Reference\"> 2216886 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "31-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, the US FDA granted Fast Track designation to mavorixafor for the treatment of WHIM syndrome [ <ulink linkID=\"2355416\" linkType=\"Reference\"> 2355416 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Rare Pediatric Disease",
                "status": "Granted",
                "milestoneDate": "10-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, the US FDA granted rare paediatric disease (RPD) designation for the treatment of WHIM syndrome [ <ulink linkID=\"2376430\" linkType=\"Reference\"> 2376430 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In May 2020, the company delay to report top-line data from a phase III trial (NCT03995108; X4P-001-103; 2019-001153-10; 4WHIM; WHIM) in 2022 due to COVID-19 pandemic [ <ulink linkID=\"2275455\" linkType=\"Reference\"> 2275455 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Oct-2022",
                "notes": "In October 2019, the phase III trial (NCT03995108) was expected to complete in October 2022 [ <ulink linkID=\"2168491\" linkType=\"Reference\"> 2168491 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline were demonstrating that the phase III 4WHIM trial met its primary endpoint of increase in absolute neutrophil counts (ANC) above 500 cells per ml (severe neutropenia) over 24-h periods at four time points throughout the 52-week trial, with mean TAT (ANC) of 15.04 h for mavorixafor versus 2.75 h in for placebo (p &lt;0.0001) [  <ulink linkID=\"2782375\" linkType=\"Reference\">  2782375 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline were demonstrating that the phase III 4WHIM trial met its primary endpoint of increase in absolute neutrophil counts (ANC) above 500 cells per ml (severe neutropenia) over 24-h periods at four time points throughout the 52-week trial, with mean TAT (ANC) of 15.04 h for mavorixafor versus 2.75 h in for placebo (p &lt;0.0001) [  <ulink linkID=\"2782375\" linkType=\"Reference\">  2782375 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Dec-2022",
                "milestoneExtendedDate": "16-May-2023",
                "notes": "By May 2023, the company planned to submit filing of mavorixafor for WHIM syndrome early in 2H23 [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In October 2021, a NDA filing in the US in patients with WHIM syndrome was expected in 1Q23 [ <ulink linkID=\"2541017\" linkType=\"Reference\">  2541017 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03995108) in WHIM syndrome demonstrating statistically significant reduction of approximately 60% in annualized infection rate versus placebo (p&lt;0.01) with reduction greater with time on treatment of less than one year, 7% patients with a grade 3 or higher infection and reduction of infections by more than 70%, both as compared with placebo, and 40% lower total infection score along with good safety and well tolerability were reported [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Committee Meetings",
                "status": "Other Outcome",
                "milestoneDate": "16-May-2023",
                "milestoneExtendedDate": "",
                "notes": "By May 2023, a pre-NDA meeting was completed with the US FDA for filing of mavorixafor for WHIM syndrome [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "15-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, further data from the phase III trial (NCT03995108) in WHIM syndrome were expected in June 2023 [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, NDA filing was expected in the second half of 2023 [ <ulink linkID=\"2706502\" linkType=\"Reference\">  2706502 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "05-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, the company submitted an NDA application to US FDA for the treatment of patients with WHIM syndrome in an individuals aged 12 and older [ <ulink linkID=\"3087222\" linkType=\"Reference\"> 3087222 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "31-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, US FDA accepted and granted priority review of NDA in patients with WHIM syndrome in an individuals aged 12 and older [ <ulink linkID=\"3485258\" linkType=\"Reference\"> 3485258 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "30-Jun-2024",
                "notes": "In March 2023, the drug launch for the treatment of WHIM syndrome <i> </i>was expected in 1H24 [ <ulink linkID=\"2865997\" linkType=\"Reference\"> 2865997 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "30-Apr-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, PDUFA target action date was set on April 30, 2024 in patients with WHIM syndrome in an individuals aged 12 and older [ <ulink linkID=\"3485258\" linkType=\"Reference\"> 3485258 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1060643",
              "name": "X4 Pharmaceuticals Inc"
            },
            "indication": {
              "id": "5561",
              "name": "WHIM syndrome"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "24-Oct-2019",
            "endDate": "29-Jan-2025",
            "statusDate": "21-Jun-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Oct-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "11-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "10-May-2023",
                "predictedDateU50": "25-Apr-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Aug-2024",
                "predictedDateU50": "29-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In December 2020, result from a phase III trial (<ulink linkType=\"Protocol\" linkID=\"385458\">NCT03995108</ulink>)   in patients with WHIM syndrome were expected in 2022 [<ulink linkType=\"Reference\" linkID=\"2376430\">2376430</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Oct-2022",
                "notes": "In November 2020, the phase III trial (NCT03995108) was expected to complete in October 2022  in patients with WHIM syndrome [<ulink linkType=\"Reference\" linkID=\"2168491\">2168491</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline were demonstrating that the phase III 4WHIM trial met its primary endpoint of increase in absolute neutrophil counts (ANC) above 500 cells per ml (severe neutropenia) over 24-h periods at four time points throughout the 52-week trial, with mean TAT (ANC) of 15.04 h for mavorixafor versus 2.75 h in for placebo (p &lt;0.0001) [  <ulink linkID=\"2782375\" linkType=\"Reference\">  2782375 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline were demonstrating that the phase III 4WHIM trial met its primary endpoint of increase in absolute neutrophil counts (ANC) above 500 cells per ml (severe neutropenia) over 24-h periods at four time points throughout the 52-week trial, with mean TAT (ANC) of 15.04 h for mavorixafor versus 2.75 h in for placebo (p &lt;0.0001) [  <ulink linkID=\"2782375\" linkType=\"Reference\">  2782375 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03995108) in WHIM syndrome demonstrating statistically significant reduction of approximately 60% in annualized infection rate versus placebo (p&lt;0.01) with reduction greater with time on treatment of less than one year, 7% patients with a grade 3 or higher infection and reduction of infections by more than 70%, both as compared with placebo, and 40% lower total infection score along with good safety and well tolerability were reported [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "15-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, further data from the phase III trial (NCT03995108) in WHIM syndrome were expected in June 2023 [ <ulink linkID=\"2940012\" linkType=\"Reference\"> 2940012 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1117316",
              "name": "X4 Pharmaceuticals Inc (pre-merger)"
            },
            "indication": {
              "id": "1991",
              "name": "Neutropenia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Nov-2019",
            "endDate": "11-Feb-2028",
            "statusDate": "16-Oct-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "51%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "05-Nov-2019",
                "endDate": "16-Oct-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "16-Oct-2020",
                "endDate": "27-Nov-2024",
                "successPercentage": "68%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Nov-2024",
                "endDate": "23-Feb-2027",
                "successPercentage": "81%",
                "predictedDateL50": "23-Feb-2024",
                "predictedDateU50": "24-Jun-2025",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Feb-2027",
                "endDate": "30-Dec-2027",
                "successPercentage": "93%",
                "predictedDateL50": "02-Mar-2026",
                "predictedDateU50": "14-Jul-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Sep-2027",
                "predictedDateU50": "11-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "107814",
        "displayName": "revumenib",
        "drugPrograms": [
          {
            "company": {
              "id": "1031631",
              "name": "Syndax Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1727",
              "name": "Acute leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Breakthrough Therapy",
            "startDate": "05-Nov-2019",
            "endDate": "02-Oct-2024",
            "statusDate": "02-Nov-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Nov-2019",
                "endDate": "02-Nov-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Nov-2023",
                "endDate": "29-Aug-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Aug-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-May-2024",
                "predictedDateU50": "02-Oct-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In August 2019, initial clinical data from the phase I/II  trial (AUGMENT) were expected to report in 2020 [<ulink linkType=\"Reference\" linkID=\"2181194\">2181194</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, preliminary results from the phase I dose-escalation portion of open-label, randomized, sequentially-assigned, dose-escalaiton and dose-expansion, phase I/II trial (NCT04065399) were presented [<ulink linkType=\"Reference\" linkID=\"2272897\">2272897</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In August 2020, full clinical data from the phase I/II trial (AUGMENT) were expected in early 2021 [ <ulink linkID=\"2307301\" linkType=\"Reference\">  2307301 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In March 2021, full data from the phase I part of phase I/II   trial (NCT04065399)  were expected in the first quarter or the early second quarter of 2021 [<ulink linkType=\"Reference\" linkID=\"2418177\">2418177</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In March 2021, the phase II portion of a phase I/II trial (NCT04065399) was expected to begin  in second quarter of 2021 [<ulink linkType=\"Reference\" linkID=\"2418177\">2418177</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, updated positive data from the phase I dose-escalation portion of the phase I/II AUGMENT-101 trial (NCT04065399) were reported as of a March 12, 2021 data cutoff date. The overall response rate (ORR) was 48%, with 67% achieving minimal residual disease-negative status, with four of those patients proceeding to receive stem cell transplant. The ORR in patients harboring an MLL-rearrangement was 54%, and in patients harboring an NPM1c mutation was 29%. A recommended phase II dose (RP2D) of 226 mg every 12 h was identified for patients who are not receiving a concomitant strong CYP3A4 inhibitor, and 113 mg every 12 h for patients on a concomitant strong CYP3A4 inhibitor treatment. In the patients treated at the RP2D (n = 18) who were evaluable for efficacy, response results observed at the RP2D were consistent with the overall population. Across all patients enrolled (n = 43), SNDX-5613 was generally well-tolerated, with no discontinuations due to treatment-related adverse events observed in heavily pretreated patients [<ulink linkType=\"Reference\" linkID=\"2438871\">2438871</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "28-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, SNDX-5613 was granted US Fast Track status for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring an MLLr or NPM1 mutation [ <ulink linkID=\"2483657\" linkType=\"Reference\">  2483657 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "05-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the US FDA granted Breakthrough Therapy designation to the drug for the treatment of adult and pediatric patients with relapsed or refractory (R/R) acute leukemia [ <ulink linkID=\"2784920\" linkType=\"Reference\">  2784920 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In March 2022, topline data were expected in the first half of 2023 [ <ulink linkID=\"2624547\" linkType=\"Reference\">  2624547 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In May 2023, initial safety data from a phase I trial (NCT05326516; AUGMENT-102) for the treatment of relapsed or refractory leukemia were expected by year-end 2023 [ <ulink linkID=\"2926884\" linkType=\"Reference\"> 2926884 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In March 2022, an NDA was planned to be submitted in 2023 [ <ulink linkID=\"2624547\" linkType=\"Reference\"> 2624547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, phase I trial ( NCT05326516) was expected to complete in July 2023 [ <ulink linkID=\"2681186\" linkType=\"Reference\">  2681186 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "01-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, NDA filing under a real time oncology review was initiated for r/r KMT2Ar acute leukemia [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, positive interim data from phase II AUGMENT-101 (NCT04065399) trial were reported [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "10-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, pivotal data from phase II AUGMENT-101 (NCT04065399) trial were expected to present [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In November 2023, regulatory response for NDA filing was expected to receive in 2024 [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In November 2023, NDA filing approval was expected in 2024 [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, a phase I/II trial (NCT04065399) was to complete in January 2024 [<ulink linkType=\"Reference\" linkID=\"2186163\">2186163</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In October 2023, the drug was expected to be launched by 2024, for the treatment of acute leukemias [ <ulink linkID=\"3305547\" linkType=\"Reference\"> 3305547 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1031631",
              "name": "Syndax Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1727",
              "name": "Acute leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Sep-2019",
            "endDate": "08-May-2028",
            "statusDate": "19-Sep-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Sep-2019",
                "endDate": "01-Nov-2024",
                "successPercentage": "56%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Nov-2024",
                "endDate": "29-Mar-2027",
                "successPercentage": "54%",
                "predictedDateL50": "06-May-2024",
                "predictedDateU50": "26-Mar-2025",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Mar-2027",
                "endDate": "25-Mar-2028",
                "successPercentage": "95%",
                "predictedDateL50": "13-Mar-2026",
                "predictedDateU50": "17-Aug-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Mar-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Nov-2027",
                "predictedDateU50": "08-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, positive interim data from phase II AUGMENT-101 (NCT04065399) trial were reported [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "10-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, pivotal data from phase II AUGMENT-101 (NCT04065399) trial were expected to present [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1031631",
              "name": "Syndax Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1728",
              "name": "Acute lymphoblastic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Nov-2019",
            "endDate": "17-Mar-2026",
            "statusDate": "19-Sep-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "2.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Nov-2019",
                "endDate": "01-Oct-2024",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Oct-2024",
                "endDate": "01-Apr-2025",
                "successPercentage": "26%",
                "predictedDateL50": "08-Apr-2024",
                "predictedDateU50": "24-Jan-2025",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Apr-2025",
                "endDate": "01-Feb-2026",
                "successPercentage": "89%",
                "predictedDateL50": "02-Oct-2024",
                "predictedDateU50": "20-Aug-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Feb-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Oct-2025",
                "predictedDateU50": "17-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, initial data from phase I/II trial (NCT04065399) were expected in 2020 [<ulink linkType=\"Reference\" linkID=\"2226467\">2226467</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, preliminary results from the phase I dose-escalation portion of open-label, randomized, sequentially-assigned, dose-escalaiton and dose-expansion, phase I/II trial (NCT04065399) were presented [<ulink linkType=\"Reference\" linkID=\"2272897\">2272897</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In August 2020, full clinical data from the phase I/II  trial (AUGMENT) were expected in early 2021 [<ulink linkType=\"Reference\" linkID=\"2307301\">2307301</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In March 2021, full data from the phase I part of phase I/II   trial (NCT04065399)  were expected in the first quarter or the early second quarter of 2021 [<ulink linkType=\"Reference\" linkID=\"2418177\">2418177</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In March 2021, the phase II portion of a phase I/II trial (NCT04065399) was expected to begin  in second quarter of 2021 [<ulink linkType=\"Reference\" linkID=\"2418177\">2418177</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, updated positive data from the phase I dose-escalation portion of the phase I/II AUGMENT-101 trial (NCT04065399) were reported as of a March 12, 2021 data cutoff date. The overall response rate (ORR) was 48%, with 67% achieving minimal residual disease-negative status, with four of those patients proceeding to receive stem cell transplant. The ORR in patients harboring an MLL-rearrangement was 54%, and in patients harboring an NPM1c mutation was 29%. A recommended phase II dose (RP2D) of 226 mg every 12 h was identified for patients who are not receiving a concomitant strong CYP3A4 inhibitor, and 113 mg every 12 h for patients on a concomitant strong CYP3A4 inhibitor treatment. In the patients treated at the RP2D (n = 18) who were evaluable for efficacy, response results observed at the RP2D were consistent with the overall population. Across all patients enrolled (n = 43), SNDX-5613 was generally well-tolerated, with no discontinuations due to treatment-related adverse events observed in heavily pretreated patients [<ulink linkType=\"Reference\" linkID=\"2438871\">2438871</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In August 2021, updated clinical data from the phase I/II trial (AUGMENT-101) were expected in 4Q21 [ <ulink linkID=\"2507882\" linkType=\"Reference\">  2507882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, updated interim positive data for phase I part of phase I/II trial (NCT04065399) were to be presented at American Society of Hematology Annual Meeting [  <ulink linkID=\"2765083\" linkType=\"Reference\">  2765083 </ulink> ] [  <ulink linkID=\"2764598\" linkType=\"Reference\">  2764598 </ulink> ]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In March 2022, an NDA was planned to be submitted in 2023 [ <ulink linkID=\"2624547\" linkType=\"Reference\">  2624547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In May 2023, initial safety data from a phase I trial (NCT05326516; AUGMENT-102) for the treatment of relapsed or refractory leukemia were expected by year-end 2023 [ <ulink linkID=\"2926884\" linkType=\"Reference\"> 2926884 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In March 2022, topline data were expected in the first half of 2023 [ <ulink linkID=\"2624547\" linkType=\"Reference\">  2624547 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, phase I trial ( NCT05326516) was expected to complete in July 2023 [ <ulink linkID=\"2681186\" linkType=\"Reference\">  2681186 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, positive interim data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial in adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia were reported. Data showed that the trial endpoints were met [ <ulink linkID=\"3305547\" linkType=\"Reference\"> 3305547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, positive interim data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial in adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia were reported [ <ulink linkID=\"3305547\" linkType=\"Reference\"> 3305547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, positive interim data from phase II AUGMENT-101 (NCT04065399) trial were reported [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "10-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, pivotal data from phase II AUGMENT-101 (NCT04065399) trial were expected to present [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, a phase I/II trial (NCT04065399) was to complete in January 2024 [<ulink linkType=\"Reference\" linkID=\"2186163\">2186163</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1031631",
              "name": "Syndax Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1728",
              "name": "Acute lymphoblastic leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Sep-2019",
            "endDate": "15-Mar-2028",
            "statusDate": "19-Sep-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "14%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Sep-2019",
                "endDate": "01-Nov-2024",
                "successPercentage": "57%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Nov-2024",
                "endDate": "28-Jan-2027",
                "successPercentage": "27%",
                "predictedDateL50": "09-May-2024",
                "predictedDateU50": "24-Feb-2025",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jan-2027",
                "endDate": "27-Jan-2028",
                "successPercentage": "88%",
                "predictedDateL50": "04-Feb-2026",
                "predictedDateU50": "18-Jun-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Sep-2027",
                "predictedDateU50": "15-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, positive interim data from phase II AUGMENT-101 (NCT04065399) trial were reported [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "10-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, pivotal data from phase II AUGMENT-101 (NCT04065399) trial were expected to present [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1031631",
              "name": "Syndax Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "05-Nov-2019",
            "endDate": "07-Apr-2026",
            "statusDate": "19-Sep-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "30%",
            "timeToRegistration": "2.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Nov-2019",
                "endDate": "01-Nov-2024",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Nov-2024",
                "endDate": "02-May-2025",
                "successPercentage": "37%",
                "predictedDateL50": "09-May-2024",
                "predictedDateU50": "24-Feb-2025",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-May-2025",
                "endDate": "01-Mar-2026",
                "successPercentage": "89%",
                "predictedDateL50": "02-Nov-2024",
                "predictedDateU50": "20-Sep-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Mar-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Nov-2025",
                "predictedDateU50": "07-Apr-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In December 2019, initial data from phase I/II trial (NCT04065399) were expected in 2020 [ <ulink linkID=\"2226467\" linkType=\"Reference\">  2226467 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "20-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, the US FDA granted Orphan status for the treatment of acute myeloid leukemia [<ulink linkType=\"Reference\" linkID=\"2273475\">2273475</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Apr-2020",
                "milestoneExtendedDate": "",
                "notes": "In April 2020, preliminary results from the phase I dose-escalation portion of open-label, randomized, sequentially-assigned, dose-escalaiton and dose-expansion, phase I/II trial (NCT04065399) were presented [<ulink linkType=\"Reference\" linkID=\"2272897\">2272897</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In August 2020, full clinical data from the phase I/II  trial (AUGMENT) were expected in early 2021 [<ulink linkType=\"Reference\" linkID=\"2307301\">2307301</ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In March 2021, full data from the phase I part of phase I/II   trial (NCT04065399)  were expected in the first quarter or the early second quarter of 2021 [<ulink linkType=\"Reference\" linkID=\"2418177\">2418177</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In March 2021, the phase II portion of a phase I/II trial (NCT04065399) was expected to begin in second quarter of 2021 [ <ulink linkID=\"2418177\" linkType=\"Reference\">  2418177 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, updated positive data from the phase I dose-escalation portion of the phase I/II AUGMENT-101 trial (NCT04065399) were reported as of a March 12, 2021 data cutoff date. The overall response rate (ORR) was 48%, with 67% achieving minimal residual disease-negative status, with four of those patients proceeding to receive stem cell transplant. The ORR in patients harboring an MLL-rearrangement was 54%, and in patients harboring an NPM1c mutation was 29%. A recommended phase II dose (RP2D) of 226 mg every 12 h was identified for patients who are not receiving a concomitant strong CYP3A4 inhibitor, and 113 mg every 12 h for patients on a concomitant strong CYP3A4 inhibitor treatment. In the patients treated at the RP2D (n = 18) who were evaluable for efficacy, response results observed at the RP2D were consistent with the overall population. Across all patients enrolled (n = 43), SNDX-5613 was generally well-tolerated, with no discontinuations due to treatment-related adverse events observed in heavily pretreated patients [<ulink linkType=\"Reference\" linkID=\"2438871\">2438871</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "03-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, updated interim positive data for phase I part of phase I/II trial (NCT04065399) were to be presented at American Society of Hematology Annual Meeting [  <ulink linkID=\"2765083\" linkType=\"Reference\">  2765083 </ulink> ] [  <ulink linkID=\"2764598\" linkType=\"Reference\">  2764598 </ulink> ]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In March 2022, an NDA was planned to be submitted in 2023 [ <ulink linkID=\"2624547\" linkType=\"Reference\">  2624547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In March 2022, topline data were expected in the first half of 2023 [ <ulink linkID=\"2624547\" linkType=\"Reference\">  2624547 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In May 2023, initial safety data from a phase I/II trial (NCT03013998; Beat-AML) for the treatment of acute myeloid leukemia were expected by year-end 2023 [ <ulink linkID=\"2926884\" linkType=\"Reference\"> 2926884 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, positive interim data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial in adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia were reported [ <ulink linkID=\"3305547\" linkType=\"Reference\"> 3305547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, positive interim data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial in adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia were reported. Data showed that the trial endpoints were met [ <ulink linkID=\"3305547\" linkType=\"Reference\"> 3305547 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, positive interim data from phase II AUGMENT-101 (NCT04065399) trial were reported [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In June 2021, an open-label, non-randomized, phase Ib/II trial ( <ulink linkID=\"284608\" linkType=\"Protocol\"> NCT03013998 </ulink>; BAML-16-001; Beat AML Master Clinical Trial) was expected to complete in December 2023. The trial was to assess the drug in combination with <ulink linkID=\"70895\" linkType=\"Drug\"> venetoclax </ulink> and <ulink linkID=\"37370\" linkType=\"Drug\"> azacitidine </ulink>for front-line treatment of acute myeloid leukemia [ <ulink linkID=\"2512541\" linkType=\"Reference\"> 2512541 </ulink>], [ <ulink linkID=\"2507882\" linkType=\"Reference\"> 2507882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "09-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, initial data from trial NCT05360160 were to be presented in December 2023 [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "10-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, pivotal data from phase II AUGMENT-101 (NCT04065399) trial were expected to present [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, a phase I/II trial (NCT04065399) was to complete in January 2024 [<ulink linkType=\"Reference\" linkID=\"2186163\">2186163</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In November 2023, topline data from phase II AUGMENT-101 (NCT04065399) trial were expected to report in 4Q24 [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, phase I/II SAVE(NCT05360160) study was expected to complete in December 2024 [ <ulink linkID=\"3493014\" linkType=\"Reference\"> 3493014 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1031631",
              "name": "Syndax Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe(X5)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "19-Sep-2019",
            "endDate": "02-Mar-2028",
            "statusDate": "22-Dec-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Sep-2019",
                "endDate": "01-Nov-2024",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Nov-2024",
                "endDate": "28-Jan-2027",
                "successPercentage": "38%",
                "predictedDateL50": "09-May-2024",
                "predictedDateU50": "24-Feb-2025",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jan-2027",
                "endDate": "23-Jan-2028",
                "successPercentage": "88%",
                "predictedDateL50": "04-Feb-2026",
                "predictedDateU50": "18-Jun-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Sep-2027",
                "predictedDateU50": "02-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "22-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, Orphan Drug Designation granted to SNDX-5613 by European Commission for the treatment of acute myeloid leukemia [  <ulink linkID=\"2588210\" linkType=\"Reference\">  2588210  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "02-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, positive interim data from phase II AUGMENT-101 (NCT04065399) trial were reported [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "10-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In November 2023, pivotal data from phase II AUGMENT-101 (NCT04065399) trial were expected to present [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In November 2023, topline data from phase II AUGMENT-101 (NCT04065399) trial were expected to report in 4Q24 [ <ulink linkID=\"3488756\" linkType=\"Reference\"> 3488756 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      }
    ]
  }